[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2009233858A1 - Method for preparing 3-trifluoromethyl chalcones - Google Patents

Method for preparing 3-trifluoromethyl chalcones Download PDF

Info

Publication number
AU2009233858A1
AU2009233858A1 AU2009233858A AU2009233858A AU2009233858A1 AU 2009233858 A1 AU2009233858 A1 AU 2009233858A1 AU 2009233858 A AU2009233858 A AU 2009233858A AU 2009233858 A AU2009233858 A AU 2009233858A AU 2009233858 A1 AU2009233858 A1 AU 2009233858A1
Authority
AU
Australia
Prior art keywords
formula
compound
alkyl
halogen
ocf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2009233858A
Other versions
AU2009233858B2 (en
Inventor
Gary David Annis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corteva Agriscience LLC
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Publication of AU2009233858A1 publication Critical patent/AU2009233858A1/en
Application granted granted Critical
Publication of AU2009233858B2 publication Critical patent/AU2009233858B2/en
Priority to AU2015202910A priority Critical patent/AU2015202910B2/en
Priority to AU2015202911A priority patent/AU2015202911B2/en
Priority to AU2017235974A priority patent/AU2017235974B2/en
Assigned to CORTEVA AGRISCIENCE LLC reassignment CORTEVA AGRISCIENCE LLC Request for Assignment Assignors: E. I. DU PONT DE NEMOURS AND COMPANY
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/35—Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or of halogen atoms in the reaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/74—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/02—Monocyclic aromatic halogenated hydrocarbons
    • C07C25/13—Monocyclic aromatic halogenated hydrocarbons containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/455—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation with carboxylic acids or their derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/38—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

WO 2009/126668 PCT/US2009/039832 1 TITLE METHOD FOR PREPARING 3-TRIFLUOROMETHYL CHALCONES FIELD OF THE INVENTION This invention pertains to a method for preparing 3-trifluoromethyl chalcones and 5 trifluoroacetyl intermediates. The present invention also relates to novel trifluoroacetyl and halo compounds useful as starting materials and intermediates for the aforedescribed method. SUMMARY OF THE INVENTION The present invention provides a method for preparing a compound of Formula 1 0
F
3 C 10 1 wherein Z is optionally substituted phenyl; and Q is phenyl or 1 -naphthalenyl, each optionally substituted; comprising distilling water from a mixture comprising a compound of Formula 2
F
3 C >-O zj~ 2 15 a compound of Formula 3 0
H
3 C <Q 3 a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4
M(OH)
2 4 wherein M is Ca, Sr or Ba, 20 alkali metal carbonates of Formula 4a (M ) 2 CO3 4a wherein M 1 is Li, Na or K, WO 2009/126668 PCT/US2009/039832 2 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water. This invention also provides a method for preparing a compound of Formula 2 wherein Z is optionally substituted phenyl, comprising 5 (1) forming a reaction mixture comprising a Grignard reagent derived from a compound of Formula 5 z-X 5 wherein X is Cl, Br or I, by contacting the compound of Formula 5 with (a) magnesium metal, or 10 (b) an alkylmagnesium halide in the presence of an ethereal solvent; and then (2) contacting the reaction mixture with a compound of Formula 6 O Y
CF
3 6 wherein Y is OR 11 or NR 12
R
13 ; 15 R 11 is Ci-C 5 alkyl; and
R
12 and R 13 are independently C 1
-C
2 alkyl; or R 1 2 and R 13 are taken together as
-CH
2
CH
2 0CH 2
CH
2
-
This invention also provides a method for preparing a compound of Formula 2 wherein Z is phenyl optionally substituted with up to 5 substituents independently selected from R 2 ; 20 and each R 2 is independently F, Cl, Br, C 1
-C
6 alkyl, C 1
-C
6 fluoroalkyl, C 1
-C
6 alkoxy, C 1 C 6 fluoroalkoxy, C 1
-C
6 alkylthio or C 1
-C
6 fluoroalkylthio, comprising (1) forming a reaction mixture comprising a Grignard reagent derived from a compound of Formula 5 z-X 5 wherein X is I, 25 by contacting the compound of Formula 5 with (a) magnesium metal, or (b) an alkylmagnesium halide in the presence of an ethereal solvent; and then (2) contacting the reaction mixture with a compound of Formula 6 WO 2009/126668 PCT/US2009/039832 3 0 Y
CF
3 6 wherein Y is OR 11 or NR 12
R
13 .
R
11 is C 1
-C
5 alkyl; and
R
12 and R 13 are independently Ci-C 2 alkyl; or R 1 2 and R 13 are taken together as 5 -CH 2
CH
2 0CH 2
CH
2
-
This invention also relates to the method disclosed above for preparing a compound of Formula 1 from a compound of Formula 2 and a compound of Formula 3 wherein the method is further characterized by preparing the compound of Formula 2 from the compounds of Formulae 5 and 6 by the method disclosed above. 10 The invention also relates to a method for preparing a compound of Formula 7
F
3 C 0 Z>KQ 7 wherein Z is optionally substituted phenyl; and Q is phenyl or 1 -naphthalenyl, each optionally substituted; 15 using a compound of Formula 1. The method is characterized by (a) preparing the compound of Formula 1 by the method disclosed above, or (b) using as said compound of Formula 1 a compound of Formula 1 prepared by the method disclosed above. The present invention also relates to novel compounds of Formulae 2 and 5, useful as starting materials for the aforedescribed methods. 20 DETAILS OF THE INVENTION As used herein, the terms "comprises," "comprising," "includes," "including," "has," "having," "contains" or "containing," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, a mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements 25 but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus. Further, unless expressly stated to the contrary, "or" refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
WO 2009/126668 PCT/US2009/039832 4 Also, the indefinite articles "a" and "an" preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore "a" or "an" should be read to include one or at least one, and the singular word form of the element or component also includes the 5 plural unless the number is obviously meant to be singular. In the above recitations, the term "alkyl", used either alone or in compound words such as "alkylthio" or "haloalkyl" includes straight chain or branched alkyl, such as, methyl, ethyl, n-propyl, i-propyl, or the different butyl, pentyl or hexyl isomers. "Alkoxy" includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the 10 different butoxy, pentoxy and hexyloxy isomers. "Alkylthio" includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers. "Alkylsulfinyl" includes both enantiomers of an alkylsulfinyl group. Examples of "alkylsulfinyl" include CH 3 S(O)-, CH 3
CH
2 S(O)-,
CH
3
CH
2
CH
2 S(O)-, (CH 3
)
2 CHS(O)- and the different butylsulfinyl, pentylsulfinyl and 15 hexylsulfinyl isomers. Examples of "alkylsulfonyl" include CH 3
S(O)
2 -, CH 3
CH
2
S(O)
2 -,
CH
3
CH
2
CH
2
S(O)
2 -, (CH 3
)
2
CHS(O)
2 -, and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers. "Alkylamino", "dialkylamino" and the like, are defined analogously to the above examples. "Cycloalkyl" includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and 20 cyclohexyl. The term "alkylcycloalkyl" denotes alkyl substitution on a cycloalkyl moiety and includes, for example, ethylcyclopropyl, i-propylcyclobutyl, 3-methylcyclopentyl and 4-methylcyclohexyl. The term "cycloalkylalkyl" denotes cycloalkyl substitution on an alkyl moiety. Examples of "cycloalkylalkyl" include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups. 25 The term "halogen", either alone or in compound words such as "haloalkyl", or when used in descriptions such as "alkyl substituted with halogen" includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as "haloalkyl", or when used in descriptions such as "alkyl substituted with halogen" said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Similarly, 30 "fluoroalkyl" means said alkyl may be partially or fully substituted with fluorine atoms. Examples of "haloalkyl" or "alkyl substituted with halogen" include F 3 C-, ClCH 2 -,
CF
3
CH
2 - and CF 3 CCl 2 -. The terms "halocycloalkyl", "haloalkoxy", "haloalkylthio", "haloalkylsulfinyl", "haloalkylsulfonyl", and the like, are defined analogously to the term "haloalkyl". Examples of "haloalkoxy" include CF 3 0-, CCl 3
CH
2 0-, HCF 2
CH
2
CH
2 0- and 35 CF 3
CH
2 0-. Examples of "haloalkylthio" include CCl 3 S-, CF 3 S-, CCl 3
CH
2 S- and ClCH 2
CH
2
CH
2 S-- Examples of "haloalkylsulfinyl" include CF 3 S(O)-, CCl3S(O)-,
CF
3
CH
2 S(O)- and CF 3
CF
2 S(O)-. Examples of "haloalkylsulfonyl" include CF 3 S(0) 2 -, CCl 3 S(0) 2 -, CF 3
CH
2 S(0) 2 - and CF 3
CF
2 S(0) 2 -. The term "halodialkylamino" denotes WO 2009/126668 PCT/US2009/039832 5 dialkylamino wherein at least one of the amino components is substituted with at least one halogen. Examples of "halodialkylamino" include CH 2 ClCH 2
N(CH
3 )- and (CF 3
CH
2
)
2 N-. "Alkylcarbonyl" denotes a straight-chain or branched alkyl moieties bonded to a C(=O) moiety. Examples of "alkylcarbonyl" include CH 3 C(=O)-, CH 3
CH
2
CH
2 C(=O)- and 5 (CH 3
)
2 CHC(=O)-. Examples of "alkoxycarbonyl" include CH 3 0C(=O)-, CH 3
CH
2 0C(=O)-,
CH
3
CH
2
CH
2 0C(=O)-, (CH 3
)
2 CHOC(=O)- and the different butoxy or pentoxycarbonyl isomers. In the present disclosure and claims, the radicals "SO 2 " and S(O)2" mean sulfonyl, "-CN" means cyano, "-NO 2 " means nitro, and "-OH" means hydroxy. 10 The total number of carbon atoms in a substituent group is indicated by the "Cj-Cj" prefix where i and j are numbers from 1 to 9. For example, Ci-C 4 alkylsulfonyl designates methylsulfonyl through butylsulfonyl, including possible isomers. C 2 alkoxycarbonyl designates CH 3 0C(O)-; C 3 alkoxycarbonyl designates CH 3
CH
2 C(O)-; and C 4 alkoxycarbonyl includes (CH 3
)
2 CHC(O)- and CH 3
CH
2
CH
2 C(O)-. 15 When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents, e.g., for (Rv), in U-1 of Exhibit 1, r is 1, 2, 3, 4 or 5. When a group contains a substituent which can be hydrogen (e.g., -NR 4
R
5 in the definition of R 3 wherein R 4 or R5 may be hydrogen in Embodiment 2), 20 then when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted. When a variable group is shown to be optionally attached to a position, for example (Rv), in U-41 of Exhibit 1 wherein r may be 0, then hydrogen may be at the position even if not recited in the variable group definition. When one or more positions on a group are said to be "not substituted" or "unsubstituted", then hydrogen atoms 25 are attached to take up any free valency. The terms "heterocyclic ring" or "heterocycle" denote a ring or ring in which at least one atom forming the ring backbone is not carbon, e.g., nitrogen, oxygen or sulfur. Typically a heterocyclic ring contains no more than 4 nitrogens, no more than 2 oxygens and no more than 2 sulfurs. The term "ring member" refers to an atom or other moiety (e.g., C(0), 30 C(=S), S(O) or S(0)2) forming the backbone of a ring. Unless otherwise indicated, a heterocyclic ring can be a saturated, partially unsaturated or fully unsaturated ring, and furthermore, an unsaturated heterocyclic ring can be partially unsaturated or fully unsaturated. Therefore recitation of "heterocyclic ring" without indicating whether it is saturated or unsaturated is synonymous with recitation of "saturated or unsaturated 35 heterocyclic ring". When a fully unsaturated heterocyclic ring satisfies Hickel's rule, then said ring is also called a "heteroaromatic ring" or "aromatic heterocyclic ring". "Aromatic" indicates that each of the ring atoms is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and that (4n + 2) 7r electrons, where n is a positive integer, WO 2009/126668 PCT/US2009/039832 6 are associated with the ring to comply with Hickel's rule. Unless otherwise indicated, heterocyclic rings and ring systems can be attached through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen. The term "optionally substituted" in connection with phenyl or 1-naphthalenyl in the 5 definitions of Z and Q refers to groups which are unsubstituted or have at least one non hydrogen substituent. As Z and Q are peripheral to the portions of the molecules undergoing reaction in the present methods, a very broad range of both number and type of substituents is compatible with the present methods. As used herein, the following definitions shall apply unless otherwise indicated. The term "optionally substituted" is used interchangeably with 10 the phrase "substituted or unsubstituted" or with the term "(un)substituted." Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other. When R 3 or Q 1 is a 5- or 6-membered nitrogen-containing heterocyclic ring, it may be attached to the remainder of Formula 1 though any available carbon or nitrogen ring atom, 15 unless otherwise described. As noted in Embodiment 1B, R 3 or Q1 can be (among others) phenyl optionally substituted with one or more substituents selected from a group of substituents as defined in Embodiment 1B. An example of phenyl optionally substituted with one to five substituents is the ring illustrated as U-1 in Exhibit 1, wherein Rv is as defined in Embodiment 1B for R 3 or Q 1 and r is an integer from 0 to 5. 20 As noted above, R 3 or Q1 can be (among others) 5- or 6-membered heterocyclic ring, which may be saturated or unsaturated, optionally substituted with one or more substituents selected from a group of substituents as defined in Embodiment 2. Examples of a 5- or 6-membered unsaturated aromatic heterocyclic ring optionally substituted with from one or more substituents include the rings U-2 through U-61 illustrated in Exhibit 1 wherein Rv is 25 any substituent as defined in Embodiment 2 for R 3 or Q 1 and r is an integer from 0 to 4, limited by the number of available positions on each U group. As U-29, U-30, U-36, U-37, U-38, U-39, U-40, U-41, U-42 and U-43 have only one available position, for these U groups r is limited to the integers 0 or 1, and r being 0 means that the U group is unsubstituted and a hydrogen is present at the position indicated by (Rv),. 30 Exhibit 1 ()r3 ()r4 (R )r 3 (R )r 4 (R )r U-1 4 U3 U- 4 U 5 S 2 0 25 U-1 U-2 U-3 U-4 U-5 WO 2009/126668 PCT/US2009/039832 7 (R)r (R )r (R)r N (R4) N (R)r N N 5 4 2 U-6 U-7 U-8 U-9 U-10 4 (R )r N (R )r (R )r 4 (R )r (R )r / N/ 2 94 4 2 5 N N N 07 2 s5 5 s S-J 2, U-11 U-12 U-13 U-14 U-15 (R )r (R )r (R )r 4 (R)r 3 (R )r Nl 5N N N N N-O 5 U-16 U-17 U-18 U-19 U-20 4 (R )r 4 (R )r 3 (R )r 4 (R )r (R )r 3 5 N 3 N 0-N N-S 5 S S-N N U-21 U-22 U-23 U-24 U-25 4 (R )r 3 (R )r 4 (R )r 5 N 3 N-N 5N N-N (R )r (R )r U-26 U-27 U-28 U-29 U-30 (R )r (R )r (R )r R )r (R )r N N N N./ N N-N N-N N-N N U-31 U-32 U-33 U-34 U-35 0N N S N (R V)r (R )r )r (r (R)r (R )r U-36 U-37 U-38 U-39 U-40 N S N (R )r (R )r 0 , Nj S \ (R )r(R)r (R )r N N=N U-41 U-42 U-43 U-44 U-45 WO 2009/126668 PCT/US2009/039832 8 4 (R)5 (Rv)r (Rv)r (Rv)r (Rv)r 3 r44 6 5N N-N N-N N N 2 U-46 U-47 U-48 U-49 U-50 6 (Rv)r (RV)r (Rv)r (RV)r 6 (Rv)r 2 N 3 ~ 0 NNN U-51 U-52 U-53 U-54 U-55 NR) (R )r N(R)r RN )r (R)r 6Ny N and N 6N N> 4 U-56 U-57 U-58 U-59 U-60 4 (R )r N N
AN
6 U-61 Note that when R 3 or Q 1 is a 5- or 6-membered saturated or unsaturated non-aromatic heterocyclic ring optionally substituted with one or more substituents selected from the group of substituents as defined in Embodiment 2 for R 3 or Q1, one or two carbon ring members of the heterocycle can optionally be in the oxidized form of a carbonyl moiety. 5 Examples of a 5- or 6-membered saturated or non-aromatic unsaturated heterocyclic ring include the rings G-1 through G-35 as illustrated in Exhibit 2. Note that when the attachment point on the G group is illustrated as floating, the G group can be attached to the remainder of Formula 1 through any available carbon or nitrogen of the G group by replacement of a hydrogen atom. The optional substituents corresponding to Rv can be 10 attached to any available carbon or nitrogen by replacing a hydrogen atom. For these G rings, r is typically an integer from 0 to 4, limited by the number of available positions on each G group. Note that when R 3 or Q 1 comprises a ring selected from G-28 through G-35, G 2 is selected from 0, S or N. Note that when G 2 is N, the nitrogen atom can complete its valence 15 by substitution with either H or the substituents corresponding to Rv as defined in Embodiment 1B.
WO 2009/126668 PCT/US2009/039832 9 Exhibit 2 (Rv)r (Rv)r (Rv)r (R )r (R)r G-1 G-2 G-3 G-4 G-5 (Rv)r (Rv)r (Rv)r (R )r (Rv)r X7 G-6 G-7 G-8 G-9 G-10 0 (R )r (R )r (RV)r Rv)r v)r 0 r 1-05S 10? G-11 G-12 G-13 G-14 G-15 (RR)r (R )r -(R ) R)r (R )r S N ON 2< N N N 2 N G-16 G-17 G-18 G-19 G-20 (R )r (R )r (R )r (R )r (R )r N_ N_ U0/ N_ 2 S 20 G-21 G-22 G-23 G-24 G-25 (R )r (R )r (RV) 0 (RV)r 0 (R )r 0 N rs r 0KZ 22 G-26 G-27 G-28 G-29 G-30 (R )r (R )r (R )r 0 (R )r (R )r G2 N .G2 , /G2 ' G2 and 62 G-31 G-32 G-33 G-34 G-35 Note that when Rv is H when attached to an atom, this is the same as if said atom is unsubstituted. The nitrogen atoms that require substitution to fill their valence are 5 substituted with H or Rv. Note that when the attachment point between (Rv)r and the U group is illustrated as floating, (Rv)r can be attached to any available carbon atom or nitrogen atom of the U group. Note that when the attachment point on the U group is WO 2009/126668 PCT/US2009/039832 10 illustrated as floating, the U group can be attached to the remainder of Formula 1 through any available carbon or nitrogen of the U group by replacement of a hydrogen atom. Note that some U groups can only be substituted with less than 4 Rv groups (e.g., U-2 through U 5, U-7 through U-48, and U-52 through U-61). 5 A wide variety of synthetic methods are known in the art to enable preparation of aromatic and nonaromatic heterocyclic rings; for extensive reviews see the eight volume set of Comprehensive Heterocyclic Chemistry, A. R. Katritzky and C. W. Rees editors-in-chief, Pergamon Press, Oxford, 1984 and the twelve volume set of Comprehensive Heterocyclic Chemistry II, A. R. Katritzky, C. W. Rees and E. F. V. Scriven editors-in-chief, Pergamon 10 Press, Oxford, 1996. In some instances herein ratios are recited as single numbers, which are relative to the number 1; for example, a ratio of 4 means 4 : 1. In the context of the present invention, "decanter" refers to a device capable of separately removing an upper (i.e. less dense) liquid phase and/or a lower (i.e. more dense) 15 liquid phase from a liquid (e.g., azeotrope condensate) comprising two liquid phases. A Dean-Stark trap is an example of one type of decanter. Embodiments of the present invention include: Embodiment 1. The method described in the Summary of the Invention for preparing the compound of Formula 1 comprising distilling water from the mixture 20 comprising the compound of Formula 2, the compound of Formula 3, the base, and the aprotic solvent capable of forming a low-boiling azeotrope with water. Embodiment 1A. The method of Embodiment 1 wherein the base is an alkaline earth metal hydroxide of Formula 4 and the mixture further comprises a polar aprotic solvent. 25 Embodiment 1B. The method of Embodiment 1 wherein the base comprises an alkali metal carbonate of Formula 4a. Embodiment IC. The method of Embodiment 1 wherein the base comprises 1,5 diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene or a mixture thereof. 30 Embodiment ID. The method described in the Summary of the Invention for preparing a compound of Formula 7 using a compound of Formula 1, the method characterized by preparing the compound of Formula 1 by the method of Embodiment 1. Embodiment 1E. The method described in the Summary of the Invention for preparing 35 a compound of Formula 7 using a compound of Formula 1, the method characterized by preparing the compound of Formula 1 by the method of Embodiment 1A.
WO 2009/126668 PCT/US2009/039832 11 Embodiment IF. The method described in the Summary of the Invention for preparing a compound of Formula 7 using a compound of Formula 1, the method characterized by preparing the compound of Formula 1 by the method of Embodiment 1B. 5 Embodiment 1G. The method described in the Summary of the Invention for preparing a compound of Formula 7 using a compound of Formula 1, the method characterized by preparing the compound of Formula 1 by the method of Embodiment IC. Embodiment 2. The method of any one of Embodiments 1 through IG wherein 10 Q is phenyl or 1 -naphthalenyl, each optionally substituted with up to four substituents independently selected from R 3 ; each R 3 is independently halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 2
-C
6 alkenyl,
C
2
-C
6 haloalkenyl, C 2
-C
6 alkynyl, C 3
-C
6 haloalkynyl, C 3
-C
6 cycloalkyl, C 3 C 6 halocycloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, C 2
-C
7 15 alkylcarbonyl, C 2
-C
7 haloalkylcarbonyl, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, -N(R 4
)R
5 , -C(=W)N(R 4
)R
5 , -C(=W)OR 5 , -CN, -OR 11 or
-NO
2 ; or a phenyl ring or a 5- or 6-membered saturated or unsaturated heterocyclic ring, each ring optionally substituted with one or more substituents 20 independently selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 3
-C
6 cycloalkyl, C 3
-C
6 halocycloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, -CN, -NO 2 , -N(R 4
)R
5 ,
-C(=W)N(R
4
)R
5 , -C(=O)OR 5 and R 7 ; 25 each R 4 is independently H, Ci-C 6 alkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3
-C
6 cycloalkyl, C 4
-C
7 alkylcycloalkyl, C 4
-C
7 cycloalkylalkyl, C 2
-C
7 alkylcarbonyl or C 2
-C
7 alkoxycarbonyl; each R 5 is independently H; or Ci-C 6 alkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3
-C
6 cycloalkyl, C 4
-C
7 alkylcycloalkyl or C 4
-C
7 cycloalkylalkyl, each optionally 30 substituted with one or more substituents independently selected from R 6 ; each R 6 is independently halogen, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 alkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 alkylamino, C 2
-C
8 dialkylamino, C 3
-C
6 cycloalkylamino, C 2
-C
7 alkylcarbonyl, C 2
-C
7 alkoxycarbonyl, C 2
-C
7 alkylaminocarbonyl, C 3
-C
9 dialkylaminocarbonyl, 35 C 2
-C
7 haloalkylcarbonyl, C 2
-C
7 haloalkoxycarbonyl, C 2
-C
7 haloalkylaminocarbonyl, C 3
-C
9 halodialkylaminocarbonyl, -OH, -NH 2 , -CN or
-NO
2 ; or Q1- WO 2009/126668 PCT/US2009/039832 12 each R 7 is independently a phenyl ring or a pyridinyl ring, each ring optionally substituted with one or more substituents independently selected from R 8 ; each R 8 is independently halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, 5 Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, Ci-C 6 alkylamino, C 2
-C
6 dialkylamino, C 2
-C
4 alkylcarbonyl, C 2
-C
4 alkoxycarbonyl,
C
2
-C
7 alkylaminocarbonyl, C 3
-C
7 dialkylaminocarbonyl, -OH, -NH 2 , -C(=O)OH, -CN or -NO 2 ; each Q 1 is independently a phenyl ring or a 5- or 6-membered saturated or unsaturated 10 heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 3
-C
6 cycloalkyl, C 3
-C
6 halocycloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, Ci-C 6 alkylamino, C 2
-C
6 15 dialkylamino, -CN, -NO 2 , -C(=W)N(R 9
)R
10 and -C(=O)OR 1 0 ; each R 9 is independently H, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3
-C
6 cycloalkyl, C 4
-C
7 alkylcycloalkyl, C 4
-C
7 cycloalkylalkyl,
C
2
-C
7 alkylcarbonyl or C 2
-C
7 alkoxycarbonyl; each R 10 is independently H; or Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 20 alkynyl, C 3
-C
6 cycloalkyl, C 4
-C
7 alkylcycloalkyl or C 4
-C
7 cycloalkylalkyl; each R 11 is independently H; or C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3
-C
6 cycloalkyl,
C
4
-C
7 alkylcycloalkyl, C4-C 7 cycloalkylalkyl, C 2
-C
7 alkylcarbonyl, C 2
-C
7 alkoxycarbonyl, Ci-C 6 alkylsulfonyl or Ci-C 6 haloalkylsulfonyl; and each W is independently 0 or S. 25 Embodiment 2A. The method of Embodiment 2 wherein Q is phenyl optionally substituted with up to four substituents independently selected from R 3 . Embodiment 2B. The method of Embodiment 2 wherein Q is 1-naphthalenyl optionally substituted with up to four substituents independently selected from R 3 . Embodiment 2C. The method of Embodiment 2 wherein each R 3 is independently 30 halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -C(W)N(R 4
)R
5 , -C(W)OR 5 or -CN; or a phenyl ring or a 5- or 6-membered saturated or unsaturated heterocyclic ring, each ring optionally substituted with substituents independently selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -CN, -C(W)N(R 4
)R
5 and -C(O)OR 5 . Embodiment 2D. The method of Embodiment 2 wherein each R4 is independently H or 35 Ci-C 6 alkyl. Embodiment 2E. The method of Embodiment 2 wherein each R 5 is independently H; or Ci-C 6 alkyl optionally substituted with substituents independently selected from
R
6
.
WO 2009/126668 PCT/US2009/039832 13 Embodiment 2F. The method of Embodiment 2 wherein each R 6 is independently halogen, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 alkylthio, C 2
-C
7 alkoxycarbonyl,
C
2
-C
7 alkylaminocarbonyl, C 3
-C
9 dialkylaminocarbonyl, C 2
-C
7 haloalkylaminocarbonyl, C 3
-C
9 halodialkylaminocarbonyl or -CN; or Q 1 . 5 Embodiment 2G. The method of Embodiment 2 wherein each Q 1 is independently a pyridinyl ring optionally substituted with up to four halogen. Embodiment 2H. The method of Embodiment 2B wherein Q is and 3 R
R
3 is C(O)N(R 4
)R
5 or C(O)OR 5 . Embodiment 21. The method of Embodiment 2H wherein 10 R4 is H, C 2
-C
7 alkylcarbonyl or C 2
-C
7 alkoxycarbonyl. Embodiment 2J. The method of Embodiment 21 wherein R4 is H. Embodiment 2K. The method of any one of Embodiments 2H through 2J wherein
R
3 is C(O)N(R 4
)R
5 or C(O)OR 5 a;
R
5 is C 1
-C
6 alkyl or C 1
-C
6 haloalkyl, each substituted with one substituent 15 independently selected from hydroxy, Ci-C 6 alkoxy, Ci-C 6 alkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 alkylsulfonyl, C 2
-C
7 alkylaminocarbonyl, C 3
-C
9 dialkylaminocarbonyl, C 2
-C
7 haloalkylaminocarbonyl and C 3
-C
9 halodialkylaminocarbonyl; and
R
5 a is Ci-C 6 alkyl, C 2
-C
6 alkenyl or C 2
-C
6 alkynyl, each optionally substituted with 20 one or more substituents independently selected from halogen, Ci-C 2 alkoxy and phenyl optionally substituted with up to 5 substituents selected from halogen and Ci-C 3 alkyl. Embodiment 2L. The method of any one of Embodiments 2H through 2K wherein
R
5 a is Ci-C 6 alkyl optionally substituted with phenyl. 25 Embodiment 2M. The method of any one of Embodiments 2H through 2L wherein
R
3 is C(O)N(R 4
)R
5 . Embodiment 2N. The method of any one of Embodiments 2H through 2J wherein
R
3 is C(O)OR 5 . Embodiment 20. The method of any one of Embodiments 2K through 2L wherein 30 R 3 is C(O)OR 5 a. Embodiment 3. The method of any one of Embodiments 1 through 20 wherein Z is phenyl optionally substituted with up to 5 substituents independently selected from R 2 (i.e.
WO 2009/126668 PCT/US2009/039832 14 3 2 (R2 5 6 wherein n is 0, 1, 2, 3, 4 or 5); and each R 2 is independently halogen, C 1
-C
6 alkyl, C 1
-C
6 haloalkyl, C 1
-C
6 alkoxy, C 1 C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylamino, C 2
-C
6 5 dialkylamino, -CN or -NO 2 Embodiment 3A. The method of Embodiment 3 wherein Z is a phenyl ring substituted with up to 3 substituents independently selected from R2, said substituents attached at the 3, 4 or 5 positions of the phenyl ring. Embodiment 3B. The method of Embodiment 3 or 3A wherein each R 2 is 10 independently F, Cl, Br, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, Ci-C 6 alkoxy, Ci-C 6 fluoroalkoxy, Ci-C 6 alkylthio or Ci-C 6 fluoroalkylthio. Embodiment 3C. The method of Embodiment 3 or 3A wherein each R 2 is independently halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl or -CN. Embodiment 3D. The method of Embodiment 3C wherein each R 2 is independently 15 halogen or Ci-C 6 haloalkyl. Embodiment 3E. The method of Embodiment 3D wherein each R 2 is independently halogen or CF 3 Embodiment 3F. The method of Embodiment 3E wherein each R 2 is independently F, Cl or CF 3 20 Embodiment 3G. The method of Embodiment 3A wherein Z is
R
2 a R2b /\
R
2 c
R
2 a is halogen, C 1
-C
2 haloalkyl or C 1
-C
2 haloalkoxy; R2b is H, halogen or cyano; and R 2 c is H, halogen or CF 3 Embodiment 3H. The method of Embodiment 3G wherein R 2 a is CF 3 or halogen; and
R
2 c is H, CF 3 or halogen. 25 Embodiment 31. The method of Embodiment 3H wherein R 2 a is CF 3 Embodiment 3J. The method of any one of Embodiments 3G through 31 wherein R2b is H. Embodiment 3K. The method of any one of Embodiments 3G through 3J wherein R 2 c is CF 3 or halogen. 30 Embodiment 3L. The method of Embodiment 3K wherein R 2 c is CF 3 , F, Cl or Br.
WO 2009/126668 PCT/US2009/039832 15 Embodiment 3M. The method of Embodiment 3L wherein R 2 c is F, Cl or Br. Embodiment 3N. The method of Embodiment 3L wherein R 2 c is CF 3 , Cl or Br. Embodiment 30. The method of Embodiment 3N wherein R 2 c is Cl or Br. Embodiment 3P. The method of Embodiment 30 wherein R2b is H and R 2 c is Cl. 5 Embodiment 3Q. The method of Embodiment 30 wherein R2b is H and R 2 c is Br. Embodiment 4. The method described in the Summary of the Invention for preparing a compound of Formula 2, comprising (1) forming a reaction mixture comprising a Grignard reagent derived from a compound of Formula 5 by contacting the compound of Formula 5 with (a) magnesium metal, or (b) an alkylmagnesium 10 halide in the presence of an ethereal solvent; and then (2) contacting the reaction mixture with a compound of Formula 6. Embodiment 4A. The method of any one of Embodiments 1 through 20 and 3 through 3Q further characterized by preparing the compound of Formula 2 by the method of Embodiment 4. 15 Embodiment 4B. The method of Embodiment 4 or 4A wherein X is Cl or I. Embodiment 4C. The method of Embodiment 4 or 4A wherein X is Br or I. Embodiment 4D. The method of Embodiment 4 or 4A wherein X is Cl or Br. Embodiment 4E. The method of Embodiment 4 or 4A wherein X is Cl. Embodiment 4F. The method of Embodiment 4 or 4A wherein X is Br. 20 Embodiment 4G. The method of Embodiment 4 or 4A wherein X is I. Embodiment 4H. The method of any one of Embodiments 4 through 4G wherein Z is phenyl optionally substituted with up to 5 substituents independently selected from R 2 (i.e. 3 2 (2 5 6 25 wherein n is 0, 1, 2, 3, 4 or 5); and each R 2 is independently F, Cl, Br, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, Ci-C 6 alkoxy, Ci-C 6 fluoroalkoxy, Ci-C 6 alkylthio or Ci-C 6 fluoroalkylthio; provided that when X is Cl then each R 2 is independently F, Cl, C 1
-C
6 alkyl, C 1
-C
6 fluoroalkyl, Ci-C 6 alkoxy, Ci-C 6 fluoroalkoxy, Ci-C 6 alkylthio or Ci-C6 30 fluoroalkylthio. Embodiment 41. The method of Embodiment 4H wherein when X is Br then each R2 is independently F, Cl, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, Ci-C 6 alkoxy, Ci-C 6 fluoroalkoxy, C 1
-C
6 alkylthio or C 1
-C
6 fluoroalkylthio; and when X is Cl then each R 2 is independently F, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, Ci-C 6 alkoxy, Ci 35 C 6 fluoroalkoxy, Ci-C 6 alkylthio or Ci-C 6 fluoroalkylthio.
WO 2009/126668 PCT/US2009/039832 16 Embodiment 4J. The method of any one of Embodiments 3, 4H and 41 wherein Z is a phenyl ring substituted with up to 3 substituents independently selected from R2, said substituents attached at the 3, 4 or 5 positions of the phenyl ring. Embodiment 4K. The method of any one of Embodiments 4H, 41 and 4J wherein each 5 R 2 is independently F, Cl, Br, Ci-C 6 alkyl or Ci-C 6 fluoroalkyl. Embodiment 4L. The method of Embodiment 4K wherein each R 2 is independently F, Cl, Br or Ci-C 6 fluoroalkyl. Embodiment 4M. The method of Embodiment 4L wherein each R2 is independently F, Cl, Br or CF 3 10 Embodiment 4N. The method of any one of Embodiments 4H through 4M wherein Z is a phenyl ring substituted with 2 substituents independently selected from R2, said substituents attached at the 3 and 5 positions of the phenyl ring. Embodiment 40. The method of Embodiment 4N wherein each R2 is independently F, Cl, Br or CF 3 15 Embodiment 4P. The method of Embodiment 40 wherein at least one R2 is CF 3 . Embodiment 4Q. The method of Embodiment 4P wherein one R 2 is CF 3 and the other R2 is Cl or Br. Embodiment 4R. The method of Embodiment 4Q wherein one R2 is CF 3 and the other R2 is Cl. 20 Embodiment 4S. The method of Embodiment 3A or 3H wherein Z is
R
2 a R2b /\
R
2 c
R
2 a is F, Cl, Br, Ci-C 2 fluoroalkyl or Ci-C 2 fluoroalkoxy; R2b is H, F, Cl or Br; and
R
2 c is H, F, Cl, Br or CF 3 Embodiment 4T. The method of Embodiment 4S wherein R 2 a is CF 3 , F, Cl or Br; and
R
2 c is H, CF 3 , F, Cl or Br. 25 Embodiment 4U. The method of Embodiment 4T wherein R 2 a is CF 3 . Embodiment 4V. The method of any one of Embodiments 4S through 4U wherein R2b is H. Embodiment 4W. The method of any one of Embodiments 4S through 4V wherein R 2 c is CF 3 , F, Cl or Br. 30 Embodiment 4X. The method of Embodiment 4W wherein R 2 c is F, Cl or Br. Embodiment 4Y. The method of Embodiment 4W wherein R 2 c is CF 3 , Cl or Br. Embodiment 4Z. The method of Embodiment 4Y wherein R 2 c is Cl or Br. Embodiment 4ZA. The method of Embodiment 4Z wherein R2b is H and R 2 c is Cl.
WO 2009/126668 PCT/US2009/039832 17 Embodiment 4ZB. The method of Embodiment 4Z wherein R2b is H and R 2 c is Br. Embodiment 4ZC. The method of any one of Embodiments 4S through 4ZB wherein X is I. Embodiment 5. A compound of Formula 2 as described in the Summary of the 5 Invention wherein Z is
R
2 a R2b /\
R
2 c
R
2 a is CF 3 ; R2b is H or halogen; and R 2 c is halogen. Embodiment 5A. A compound of Embodiment 5 wherein R2b is H. Embodiment 5B. A compound of Embodiment 5 or 5A wherein R 2 c is F, Cl or Br. 10 Embodiment 5C. A compound of Embodiment 5B wherein R 2 c is Cl or Br. Embodiment 5D. A compound of Embodiment 5C selected from the group consisting of: 1-[3-chloro-5-(trifluoromethyl)]-2,2,2-trifluoroethanone; and 1-[3-bromo-5-(trifluoromethyl)]-2,2,2-trifluoroethanone. 15 Embodiment 5E. A compound of Formula 5 as described in the Summary of the Invention which is 1 -chloro-3 -iodo-5 -(trifluoromethyl)benzene. Embodiment 6. The method of Embodiment 1A or 1E wherein M is Ca (i.e. the alkaline earth metal hydroxide is calcium hydroxide). Embodiment 6A. The method of Embodiment 1A, 1E or 6 wherein the molar ratio of the 20 alkaline earth metal hydroxide to the compound of Formula 2 is at least about 0.1. Embodiment 6A1. The method of Embodiment 6A wherein the molar ratio of the alkaline earth metal hydroxide to the compound of Formula 2 is at least about 0.5. 25 Embodiment 6B. The method of Embodiment 6A1 wherein the molar ratio of the alkaline earth metal hydroxide to the compound of Formula 2 is at least about 0.8. Embodiment 6C. The method of any one of Embodiments 1A, 1E or 6 through 6B wherein the molar ratio of the alkaline earth metal hydroxide to the compound of 30 Formula 2 is no more than about 1. Embodiment 6D. The method of Embodiment 1B or IF wherein M 1 is K (i.e. the alkali metal carbonate is potassium carbonate).
WO 2009/126668 PCT/US2009/039832 18 Embodiment 6E. The method of Embodiment IB, IF or 6D wherein the molar ratio of the alkali metal carbonate to the compound of Formula 2 is at least about 0.01. Embodiment 6F. The method of Embodiment 6E wherein the molar ratio of the alkali metal carbonate to the compound of Formula 2 is at least about 0.03. 5 Embodiment 6G. The method of any one of Embodiments IB, IF or 6D through 6F wherein the molar ratio of the alkali metal carbonate to the compound of Formula 2 is no more than about 0.2. Embodiment 6H. The method of Embodiment IC or IG wherein the molar ratio of the 1,5-diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene or a 10 mixture therof to the compound of Formula 2 is at least about 0.01. Embodiment 61. The method of Embodiment 6H wherein the molar ratio of the 1,5 diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene or a mixture thereof to the compound of Formula 2 is at least about 0.03. Embodiment 6J. The method of any one of Embodiments 1 C, 1 G, 6H or 61 wherein the 15 molar ratio of the 1,5-diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo [5.4.0]undec-7-ene or a mixture thereof to the compound of Formula 2 is no more than about 0.2. Embodiment 7. The method of Embodiment 1A or 1E wherein the polar aprotic solvent comprises an amide or sulfoxide (including mixtures thereof). 20 Embodiment 7A. The method of Embodiment 7 wherein the polar aprotic solvent comprises one or more of NN-dimethylformamide, NN-dimethylacetamide, N-methylpyrrolidinone and methyl sulfoxide. Embodiment 7B. The method of Embodiment 7 wherein the polar aprotic solvent comprises an amide. 25 Embodiment 7C. The method of Embodiment 7B wherein the polar aprotic solvent comprises one or more of NN-dimethylformamide, NN-dimethylacetamide, N-methylpyrrolidinone. Embodiment 7D. The method of Embodiment 7C wherein the polar aprotic solvent comprises NN-dimethylformamide. 30 Embodiment 8. The method of Embodiment 1A or 1E wherein the aprotic solvent capable of forming a low-boiling azeotrope with water comprises an ether. Embodiment 8A. The method of Embodiment 8 wherein the aprotic solvent capable of forming a low-boiling azeotrope with water comprises tert-butyl methyl ether. Embodiment 8B. The method of any one of Embodiments IB, IC, IF, IG or 6D 35 through 6J wherein the aprotic solvent capable of forming a low-boiling azeotrope with water comprises acetonitrile. Embodiment 8C. The method of Embodiment 8A wherein the polar aprotic solvent comprises NN-dimethylformamide.
WO 2009/126668 PCT/US2009/039832 19 Embodiment 8D. The method of Embodiment 8C wherein the tert-butyl methyl ether and the NN-dimethylformamide are in a weight ratio in a range from about 0.5 to about 2. Embodiment 9. The method of Embodiment 1A or 1E wherein the mixture is at a 5 temperature of at least about 65 'C. Embodiment 9A. The method of Embodiment 9 wherein the mixture is at a temperature of at least about 70 'C. Embodiment 9B. The method of Embodiment 9A wherein the mixture is at a temperature of at least about 75 'C. 10 Embodiment 9C. The method of Embodiment IB, IC, IF or IG wherein the mixture is at a temperature of at least about 65 'C. Embodiment 9D. The method of Embodiment 9C wherein the mixture is at a temperature of at least about 80 'C. Embodiment 9E. The method of Embodiment 9D wherein the mixture is at a 15 temperature of at least about 85 'C. Embodiment 9F. The method of any one of Embodiments 9 through 9E wherein the mixture is at a temperature of no more than about 110 'C. Embodiment 9G. The method of Embodiment 9F wherein the mixture is at a temperature of no more than about 100 'C. 20 Embodiment 9H. The method of Embodiment 9G wherein the mixture is at a temperature of no more than about 90 'C. Embodiment 10. The method of Embodiment 4 or 4A wherein the compound of Formula 5 is contacted with magnesium metal. Embodiment 10 A. The method of Embodiment 10 wherein the molar ratio of 25 magnesium metal to the compound of Formula 5 is at least about 1. Embodiment 1OB. The method of Embodiment I0A wherein the molar ratio of magnesium metal to the compound of Formula 5 is at least about 1.02. Embodiment 10C. The method of Embodiment 1OB wherein the molar ratio of magnesium metal to the compound of Formula 5 is at least about 1.05. 30 Embodiment 1OD. The method of any one of Embodiments 10 through 1OC wherein the molar ratio of magnesium metal to the compound of Formula 5 is no more than about 1.2. Embodiment 10E. The method of Embodiment 1OD wherein the molar ratio of magnesium metal to the compound of Formula 5 is no more than about 1.1. 35 Embodiment 1OF. The method of Embodiment 4 or 4A wherein the compound of Formula 5 is contacted with an alkylmagnesium halide. Embodiment lOG. The method of Embodiment 1OF wherein the alkylmagnesium halide is a Ci-C 4 alkylmagnesium halide.
WO 2009/126668 PCT/US2009/039832 20 Embodiment I0H. The method of Embodiment 1OF or 1OG wherein the alkylmagnesium halide is a secondary alkylmagnesium halide. Embodiment 101. The method of Embodiment I0H wherein the alkylmagnesium halide is an isopropylmagnesium halide. 5 Embodiment 1OJ. The method of Embodiment 101 wherein the alkylmagnesium halide is isopropylmagnesium chloride. Embodiment 10K. The method of any one of Embodiments 1 OF through 1 OJ wherein the molar ratio of the alkylmagnesium halide to the compound of Formula 5 is at least about 1. 10 Embodiment 1OL. The method of Embodiment 10K wherein the molar ratio of the alkylmagnesium halide to the compound of Formula 5 is at least about 1.05. Embodiment 10M. The method of any one of Embodiments 1OF through 1OL wherein the molar ratio of the alkylmagnesium halide to the compound of Formula 5 is no more than about 1.2. 15 Embodiment ION. The method of Embodiment 10M wherein the molar ratio of the alkylmagnesium halide to the compound of Formula 5 is no more than about 1.15. Embodiment 100. The method of Embodiment 4 or 4A wherein the compound of Formula 6 is methyl trifluoroacetate or ethyl trifluoroacetate. 20 Embodiment 11. The method of Embodiment 4 or 4A wherein the ethereal solvent comprises one or more of ethyl ether, 1,4-dioxane, tetrahydrofuran and 1,2 dimethoxyethane. Embodiment 11 A. The method of Embodiment 11 wherein the ethereal solvent comprises ethyl ether or tetrahydrofuran. 25 Embodiment 11B. The method of Embodiment 11 A wherein the ethereal solvent comprises tetrahydrofuran. Embodiment 1 IC. The method of any one of Embodiments 4, 4A or 11 through 11 B wherein the compound of Formula 5 is contacted with (a) magnesium metal, or (b) an alkylmagnesium halide in the presence of an aromatic hydrocarbon 30 solvent in addition to the ethereal solvent. Embodiment 1 ID. The method of Embodiment 1 IC wherein the aromatic hydrocarbon solvent comprises one or more of benzene, toluene and xylene. Embodiment 11 E. The method of Embodiment 1 ID wherein the aromatic hydrocarbon solvent comprises toluene. 35 Embodiments of this invention, including Embodiments 1-i1E above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the aforedescribed methods for preparing WO 2009/126668 PCT/US2009/039832 21 compounds of Formulae 1, 2 and 7 but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formulae 1, 2 and 7 by these methods. Combinations of Embodiments 1-1iE are illustrated by: Embodiment A. The method described in the Summary of the Invention for preparing 5 the compound of Formula 1 comprising distilling water from the mixture comprising the compound of Formula 2, the compound of Formula 3, the base, and the aprotic solvent capable of forming a low-boiling azeotrope with water, wherein Z is phenyl optionally substituted with up to 5 substituents independently selected 10 from R 2 ; Q is phenyl or 1 -naphthalenyl, each optionally substituted with up to four substituents independently selected from R 3 ; each R 2 is independently halogen, C 1
-C
6 alkyl, C 1
-C
6 haloalkyl, C 1
-C
6 alkoxy, C 1 C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylamino, C 2
-C
6 15 dialkylamino, -CN or -NO 2 ; each R 3 is independently halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 2
-C
6 alkenyl,
C
2
-C
6 haloalkenyl, C 2
-C
6 alkynyl, C 3
-C
6 haloalkynyl, C 3
-C
6 cycloalkyl, C 3 C 6 halocycloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, C 2
-C
7 alkylcarbonyl, C 2
-C
7 haloalkylcarbonyl, Ci-C 6 haloalkylthio, Ci-C 6 20 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, -N(R 4
)R
5 , -C(=W)N(R 4
)R
5 , -C(=W)OR 5 , -CN, -OR 11 or
-NO
2 ; or a phenyl ring or a 5- or 6-membered saturated or unsaturated heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 3
-C
6 25 cycloalkyl, C 3
-C
6 halocycloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, -CN, -NO 2 , -N(R 4
)R
5 ,
-C(=W)N(R
4
)R
5 , -C(=O)OR 5 and R 7 ; each R 4 is independently H, Ci-C 6 alkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3
-C
6 30 cycloalkyl, C 4
-C
7 alkylcycloalkyl, C 4
-C
7 cycloalkylalkyl, C 2
-C
7 alkylcarbonyl or C 2
-C
7 alkoxycarbonyl; each R 5 is independently H; or Ci-C 6 alkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3
-C
6 cycloalkyl, C 4
-C
7 alkylcycloalkyl or C 4
-C
7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R 6 ; 35 each R 6 is independently halogen, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 alkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 alkylamino, C 2
-C
8 dialkylamino, C 3
-C
6 cycloalkylamino, C 2
-C
7 alkylcarbonyl, C 2
-C
7 alkoxycarbonyl, C 2
-C
7 alkylaminocarbonyl, C 3
-C
9 dialkylaminocarbonyl, WO 2009/126668 PCT/US2009/039832 22
C
2
-C
7 haloalkylcarbonyl, C 2
-C
7 haloalkoxycarbonyl, C 2
-C
7 haloalkylaminocarbonyl, C 3
-C
9 halodialkylaminocarbonyl, -OH, -NH 2 , -CN or
-NO
2 ; or Q1 each R 7 is independently a phenyl ring or a pyridinyl ring, each ring optionally 5 substituted with one or more substituents independently selected from R 8 ; each R 8 is independently halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, Ci-C 6 alkylamino, C 2
-C
6 dialkylamino, C 2
-C
4 alkylcarbonyl, C 2
-C
4 alkoxycarbonyl, 10 C 2
-C
7 alkylaminocarbonyl, C 3
-C
7 dialkylaminocarbonyl, -OH, -NH 2 , -C(=O)OH, -CN or -NO 2 ; each Q 1 is independently a phenyl ring or a 5- or 6-membered saturated or unsaturated heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 3
-C
6 15 cycloalkyl, C 3
-C
6 halocycloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, Ci-C 6 alkylamino, C 2
-C
6 dialkylamino, -CN, -NO 2 , -C(=W)N(R 9
)R
10 and -C(=O)OR 1 0 ; each R 9 is independently H, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 20 alkynyl, C 3
-C
6 cycloalkyl, C 4
-C
7 alkylcycloalkyl, C 4
-C
7 cycloalkylalkyl,
C
2
-C
7 alkylcarbonyl or C 2
-C
7 alkoxycarbonyl; each R 10 is independently H; or Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3
-C
6 cycloalkyl, C 4
-C
7 alkylcycloalkyl or C 4
-C
7 cycloalkylalkyl; each R 11 is independently H; or C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, C 3
-C
6 cycloalkyl, 25 C 4
-C
7 alkylcycloalkyl, C 4
-C
7 cycloalkylalkyl, C 2
-C
7 alkylcarbonyl, C 2
-C
7 alkoxycarbonyl, Ci-C 6 alkylsulfonyl or Ci-C 6 haloalkylsulfonyl; and each W is independently 0 or S. Embodiment Al. The method of Embodiment A wherein the base is an alkaline earth metal hydroxide of Formula 4 and the mixture further comprises a polar aprotic 30 solvent. Embodiment A2. The method of Embodiment A or Al wherein Q is phenyl optionally substituted with up to four substituents independently selected from R 3 . Embodiment A3. The method of Embodiment A or Al wherein Q is 1-naphthalenyl optionally substituted with up to four substituents independently selected from 35 R3. Embodiment A4. The method of Embodiment A, Al or A2 wherein each R 2 is independently halogen or Ci-C 6 haloalkyl; WO 2009/126668 PCT/US2009/039832 23 each R 3 is independently halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -C(W)N(R 4
)R
5 ,
-C(W)OR
5 or -CN; or a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -CN, -C(W)N(R 4
)R
5 and 5 -C(O)OR 5 ; each R4 is independently H or Ci-C 6 alkyl; each R 5 is independently H; or Ci-C 6 alkyl optionally substituted with one or more substituents independently selected from R 6 ; each R 6 is independently halogen, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 alkylthio, C 2 10 C 7 alkoxycarbonyl, C 2
-C
7 alkylaminocarbonyl, C 3
-C
9 dialkylaminocarbonyl,
C
2
-C
7 haloalkylaminocarbonyl, C 3
-C
9 halodialkylaminocarbonyl or -CN; or Ql and each Q 1 is independently a pyridinyl ring optionally substituted with up to 4 halogen. Embodiment A5. The method of Embodiment A3 wherein
R
2 a Zis R 2 b /Q is
R
2 c R 15 R 2 a is halogen, Ci-C 2 haloalkyl or Ci-C 2 haloalkoxy; R2b is H, halogen or cyano;
R
2 c is H, halogen or CF 3 ;
R
3 is C(O)N(R 4
)R
5 or C(O)OR 5 a; R4 is H, C 2
-C
7 alkylcarbonyl or C 2
-C
7 alkoxycarbonyl; and 20 R 5 is C 1
-C
6 alkyl or C 1
-C
6 haloalkyl, each substituted with one substituent independently selected from hydroxy, Ci-C 6 alkoxy, Ci-C 6 alkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 alkylsulfonyl, C 2
-C
7 alkylaminocarbonyl, C 3
-C
9 dialkylaminocarbonyl,
C
2
-C
7 haloalkylaminocarbonyl and C 3
-C
9 halodialkylaminocarbonyl; and 25 R 5 a is Ci-C 6 alkyl, C 2
-C
6 alkenyl or C 2
-C
6 alkynyl, each optionally substituted with one or more substituents independently selected from halogen, Ci-C 2 alkoxy and phenyl optionally substituted with up to 5 substituents selected from halogen and Ci-C 3 alkyl. Embodiment A6. The method of Embodiment A5 wherein R 3 is C(O)N(R 4
)R
5 . 30 Embodiment A7. The method of Embodiment A5 wherein R 3 is C(O)OR 5 a. Embodiment B. The method described in the Summary of the Invention for preparing the compound of Formula 1 comprising distilling water from the mixture comprising the compound of Formula 2, the compound of Formula 3, the base, WO 2009/126668 PCT/US2009/039832 24 and the aprotic solvent capable of forming a low-boiling azeotrope with water, wherein Z is phenyl optionally substituted with up to 5 substituents independently selected from R 2 (i.e. 5 (R 2) wherein n is 0, 1, 2, 3, 4 or 5); and each R 2 is independently F, Cl, Br, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, Ci-C 6 alkoxy, Ci-C 6 fluoroalkoxy, Ci-C 6 alkylthio or Ci-C 6 fluoroalkylthio; further comprising preparing the compound of Formula 2 by 10 (1) forming a reaction mixture comprising a Grignard reagent derived from a compound of Formula 5 z-X 5 wherein X is Cl, Br or I, by contacting the compound of Formula 5 with (a) magnesium metal, or 15 (b) an alkylmagnesium halide in the presence of an ethereal solvent; and then (2) contacting the reaction mixture with a compound of Formula 6 O Y
CF
3 6 wherein Y is OR 11 or NR 12
R
13 . 20 R 11 is C 1
-C
5 alkyl; and
R
12 and R 13 are independently Ci-C 2 alkyl; or R 12 and R 13 are taken together as
-CH
2
CH
2 0CH 2
CH
2
-
Embodiment B 1. The method of Embodiment B wherein the base is an alkaline earth metal hydroxide of Formula 4 and the mixture further comprises a polar aprotic 25 solvent.
WO 2009/126668 PCT/US2009/039832 25 Embodiment B2. The method of Embodiment B or BI wherein Z is
R
2 a R2b /\
R
2 c
R
2 a is F, Cl, Br, C 1
-C
2 fluoroalkyl or C 1
-C
2 fluoroalkoxy; R2b is H, F, Cl or Br; and
R
2 c is H, F, Cl, Br or CF 3 5 Embodiment C. The method described in the Summary of the Invention for preparing a compound of Formula 2, comprising (1) forming a reaction mixture comprising a Grignard reagent derived from a compound of Formula 5 by contacting the compound of Formula 5 with (a) magnesium metal, or (b) an alkylmagnesium halide in the presence of an ethereal solvent; and then (2) contacting the reaction 10 mixture with a compound of Formula 6, wherein X is I; Z is phenyl optionally substituted with up to 5 substituents independently selected from R 2 (i.e. (R 2) 15 wherein n is 0, 1, 2, 3, 4 or 5); and each R 2 is independently F, Cl, Br, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, Ci-C 6 alkoxy, Ci-C 6 fluoroalkoxy, Ci-C 6 alkylthio or Ci-C 6 fluoroalkylthio. Embodiment C1. The method of Embodiment C wherein Z is
R
2 a R2b /\
R
2 c
R
2 a is F, Cl, Br, C 1
-C
2 fluoroalkyl or C 1
-C
2 fluoroalkoxy; 20 R2b is H, F, Cl or Br; and
R
2 c is H, F, Cl, Br or CF 3
-
WO 2009/126668 PCT/US2009/039832 26 Embodiment D. A method for preparing a compound of Formula 7
F
3 C 0 7 wherein Z is optionally substituted phenyl; and 5 Q is phenyl or 1 -naphthalenyl, each optionally substituted; using a compound of Formula 1 0 F3C z I characterized by: preparing said compound of Formula 1 by the method described in the Summary of the Invention for preparing the compound of Formula 1 comprising 10 distilling water from the mixture comprising the compound of Formula 2, the compound of Formula 3, the base, and the aprotic solvent capable of forming a low-boiling azeotrope with water. Embodiment D1. The method of Embodiment D wherein the base is an alkaline earth metal hydroxide of Formula 4 and the mixture further comprises a polar aprotic 15 solvent. Embodiment D2. The method of Embodiment D or D1 wherein
R
2 a Zis R 2 b; Q is R 4
R
2 C R5 0
R
2 a is halogen, C 1
-C
2 haloalkyl or C 1
-C
2 haloalkoxy; R2b is H, halogen or cyano;
R
2 c is H, halogen or CF 3 ; 20 R 4 is H, C 2
-C
7 alkylcarbonyl or C 2
-C
7 alkoxycarbonyl; and
R
5 is Ci-C 6 alkyl or C 1
-C
6 haloalkyl, each substituted with one substituent independently selected from hydroxy, C 1
-C
6 alkoxy, C 1
-C
6 alkylthio, C 1
-C
6 alkylsulfinyl, C 1
-C
6 alkylsulfonyl, C 2
-C
7 alkylaminocarbonyl, C 3
-C
9 dialkylaminocarbonyl,
C
2
-C
7 haloalkylaminocarbonyl and C 3
-C
9 25 halodialkylaminocarbonyl.
WO 2009/126668 PCT/US2009/039832 27 Embodiment E. A method for preparing a compound of Formula 7
F
3 C 0 7 wherein Z is optionally substituted phenyl; and 5 Q is phenyl or 1 -naphthalenyl, each optionally substituted; using a compound of Formula 1 0 F3C z I characterized by: using as said compound of Formula 1 a compound of Formula 1 prepared by the method described in the Summary of the Invention for preparing 10 the compound of Formula 1 comprising distilling water from the mixture comprising the compound of Formula 2, the compound of Formula 3, the base, and the aprotic solvent capable of forming a low-boiling azeotrope with water. Embodiment E l. The method of Embodiment E wherein the base is an alkaline earth metal hydroxide of Formula 4 and the mixture further comprises a polar aprotic 15 solvent. Embodiment E2. The method of Embodiment E or El wherein
R
2 a Zis R 2 b; Q is R 4
R
2 C R5 0
R
2 a is halogen, C 1
-C
2 haloalkyl or C 1
-C
2 haloalkoxy; R2b is H, halogen or cyano;
R
2 c is H, halogen or CF 3 ; 20 R 4 is H, C 2
-C
7 alkylcarbonyl or C 2
-C
7 alkoxycarbonyl; and
R
5 is Ci-C 6 alkyl or C 1
-C
6 haloalkyl, each substituted with one substituent independently selected from hydroxy, C 1
-C
6 alkoxy, C 1
-C
6 alkylthio, C 1
-C
6 alkylsulfinyl, C 1
-C
6 alkylsulfonyl, C 2
-C
7 alkylaminocarbonyl, C 3
-C
9 dialkylaminocarbonyl,
C
2
-C
7 haloalkylaminocarbonyl and C 3
-C
9 25 halodialkylaminocarbonyl.
WO 2009/126668 PCT/US2009/039832 28 In the following Schemes 1-10 the definitions of Z, Q, R2, R 3 , R4, R5, R 6 , R7, R 8 , R9,
R
10 , R 11 , R 12 , R 13 and W in the compounds of Formulae 1 through 7 and 11 through 15 are as defined above in the Summary of the Invention and description of Embodiments unless otherwise indicated. Formula la is a subset of Formula 1. Formula 5a is a subset of 5 Formula 5. Formulae 7a, 7b, 7c, 7d, 7e and 7f are subsets of Formula 7. Formula 13a is a subset of Formula 13. In the method of the invention illustrated in Scheme 1, a compound of Formula 1 is prepared by distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, an alkaline earth metal hydroxide base of Formula 4, a polar 10 aprotic solvent, and an aprotic solvent capable of forming a low-boiling azeotrope with water. Scheme 1
F
3 C O M(OH) 2
F
3 C O M(OH) 2 F + H 3 C 4 Q Z Azeotropic z 2 3 water removal 1 wherein M is Ca, Sr or Ba. 15 The first step of this reaction involves an aldol condensation to form a compound of Formula 11. The compound of Formula 11 is not isolated, but instead under the reaction conditions is converted to the compound of Formula 1. The stoichiometry of this reaction involves equimolar amounts of the compounds of Formula 2 and Formula 3, and using equimolar amounts typically is most cost-effective. 20 However, small molar excesses of one of the reactants are not deleterious to the reaction, and if one of the reactants is much less expensive or more preparatively accessible, using it in a slight excess (e.g., 1.05 molar equivalents) may be desirable to ensure complete conversion of the more expensive or less preparatively accessible reactant. Alkaline earth metal hydroxides of Formula 4 and compounds capable of forming said 25 alkaline earth metal hydroxides on contact with water have been discovered to be particularly efficacious in providing high yields of compounds of Formula 1. These alkaline earth metal hydroxide bases include calcium, strontium or barium hydroxides, with calcium hydroxide preferred for its low cost. The alkaline earth metal hydroxides of Formula 4 can be formed in situ from compounds capable of forming alkaline earth metal hydroxides on 30 contact with water (identified herein as "alkaline earth metal hydroxide precursors") such as alkaline earth metal hydrides. Alkaline earth metal hydroxide precursors can react with water present in the reaction mixture, including water formed by the reaction, to form the corresponding alkaline earth metal hydroxides. Alkaline earth metal hydrides are preferred WO 2009/126668 PCT/US2009/039832 29 as precursors, as their reaction to form alkaline earth metal hydroxides removes water formed by the reaction without distillation. Calcium hydride is particularly preferred as an alkaline earth metal hydroxide precursor because of its commercial availability and relatively low cost. Although calcium hydride is advantageous for directly removing water, 5 adding calcium hydroxide to form the reaction mixture is preferred for the method of Scheme 1, in which water is removed by azeotropic distillation, because calcium hydroxide does not form hydrogen gas and is easier to scale up, and inherently safer to use than a metal hydride on a large scale. The alkaline earth metal hydroxide is added to form the reaction mixture such that the 10 molar ratio of alkaline earth metal hydroxide to the compound of Formula 3 is typically in the range of about 0.1 to about 1. Typically a ratio in the range of about 0.5 to about 1 provides a rapid rate of reaction and high product yields. In the present method the reaction mixture comprises both a polar aprotic solvent and an aprotic solvent capable of forming a low-boiling azeotrope with water. The polar aprotic 15 solvent can comprise a mixture of polar aprotic solvent compounds, but typically is a single polar aprotic solvent compound. As is generally understood in the art, aprotic solvent means a liquid compound that does not have -OH or -NH moieties in its molecular structure. Also as is generally understood in the art, polar solvent means a liquid compound that has a dielectric constant greater than 15. For the present method, polar aprotic solvents of 20 particular note are sufficiently polar to be miscible with water in all proportions at room temperature (e.g., about 20 to 25 C). The polar aprotic solvent most preferably has a boiling point higher than the boiling point of the low-boiling azeotrope, so that the polar aprotic solvent is not removed from the reaction mixture. These properties are best provided by amide and sulfoxide solvents, which are commercially available at relatively low cost. 25 By amide solvents is meant solvent compounds containing a carboxamide molecular moiety. Common examples of amide solvents are NN-dimethylformamide, NN-dimethylacetamide and N-methylpyrrolidinone. Sulfoxide solvents comprise a sulfoxide molecular moiety; common examples include dimethyl sulfoxide (also known as methyl sulfoxide) and sulfolane. NN-dimethylformamide is most preferred, as it provides excellent results, has a 30 boiling point substantially greater than water but still can be readily removed by distillation, and is commercially available at relatively low cost. In the present method, inclusion of an aprotic solvent capable of forming a low-boiling azeotrope with water facilitates removal by distillation of water formed as a byproduct. The aprotic solvent is ordinarily a single solvent compound, but can also be a mixture of 35 solvent compounds (e.g., xylene isomers). By low-boiling azeotrope is meant an azeotrope having a boiling point less than both the boiling point of water and the boiling point of the aprotic solvent. By definition, low-boiling azeotropes containing water have normal boiling points of less than 100 'C (i.e. the normal boiling point of water). Thus the boiling point of WO 2009/126668 PCT/US2009/039832 30 the low-boiling azeotrope will be substantially less than the boiling points of the compounds of Formulae 1, 2 and 3, and these compounds will remain in the reaction mixture during distillation. As already mentioned, preferably the polar aprotic solvent and the aprotic solvent capable of forming a low-boiling azeotrope are selected so that the polar aprotic 5 solvent has a boiling point higher than the azeotrope so that the polar aprotic solvent is not removed during the distillation. Aprotic solvents forming azeotropes with water are well known in the art, and compendia have been published listing their boiling points (see, for example, Azeotropic Data, Number 6 in the Advances in Chemistry Series, American Chemical Society, Washington, D.C., 1952, particularly pages 6-12). Examples of suitable 10 aprotic solvents forming low-boiling azeotropes with water include esters such as ethyl acetate, aromatic hydrocarbons such as benzene and toluene, and ethers such as tert-butyl methyl ether, tetrahydrofuran and 1,4-dioxane. Preferably, the azeotrope formed by the aprotic solvent and water contains a higher percentage of water than is soluble in the aprotic solvent at room temperature (e.g., 15-35 'C), thus facilitating large-scale separation of water 15 from the condensed azeotrope in a decanter trap, and recycling the water-depleted aprotic solvent to the middle of the distillation column. Therefore water-immiscible aprotic solvents such as ethyl acetate, benzene, toluene and tert-butyl methyl ether are preferred over tetrahydrofuran and 1,4 dioxane, which are miscible with water. Tert-butyl methyl ether has been discovered to be particularly useful as an aprotic 20 solvent in the present method. Tert-butyl methyl ether forms a water azeotrope boiling at 52.6 'C and containing 4% water and 96% tert-butyl methyl ether, and therefore is able to rapidly transfer water by distillation from the reaction mixture. Furthermore, water is soluble in tert-butyl methyl ether to the extent of only about 1%. Therefore in large-scale preparations wherein the amount of tert-butyl methyl ether in the decanter trap is not 25 sufficient to dissolve all the water formed by the reaction, the condensate in the trap will separate into an upper layer comprising tert-butyl methyl ether containing only about 1% water, which can be returned to the middle of the distillation column, and a lower layer comprising predominately water, which can be removed. In addition, the relatively low boiling points of tert-butyl methyl ether and its azeotrope with water accommodate selecting 30 a wide range of reaction temperatures by adjusting the proportion of tert-butyl methyl ether combined with a polar aprotic solvent having a boiling point above 100 'C, particularly above 120 'C (e.g., NN-dimethylformamide). For example, reaction mixtures comprising much more tert-butyl methyl ether than NN-dimethylformamide (DMF) can boil at pot temperatures not much above 55 'C, while a reaction mixtures comprising little tert-butyl 35 methyl ether relative to DMF can boil at a pot temperatures above 100 'C. Typically the tert-butyl methyl ether and NN-dimethylformamide are in a weight ratio in a range from about 0.5 to about 2.
WO 2009/126668 PCT/US2009/039832 31 The reaction of the method of Scheme 1 can be conducted over a wide range of temperatures. Typically the reaction temperature is at least about 65 'C. Although the reaction proceeds at lower temperatures, the rates are slower, and aprotic solvent-water azeotropes boiling below 50 'C typically comprise relatively little water (e.g., 5 dichloromethane forms azeotrope containing 1.5% water), which slows water removal. More typically the reaction temperature is at least about 70 'C and most typically at least about 75 'C. Although high temperatures increase the reaction rate, they can also cause side reactions decreasing product purity and yield. Therefore typically the reaction temperature is not more than about 110 'C, more typically not more than about 100 'C, and most 10 typically not more than about 90 'C. The compounds of Formulae 2 and 3, alkaline earth metal hydroxide of Formula 4 (or a precursor such as an alkaline earth metal hydride), polar aprotic solvent and aprotic solvent capable of forming a low-boiling azeotrope can be combined in any convenient order to form the reaction mixture. 15 Reaction progress can be monitored by conventional methods such as thin layer chromatography, HPLC and 1 H NMR analyses of aliquots. After completion of the reaction, the mixture is typically cooled to room temperature and the product isolated by conventional methods, such as filtration, extraction, distillation and crystallization. For example, alkali metal hydroxides and other solids can be mostly removed by filtration. Water can be added 20 to the filtrate, followed by a strong acid (such as hydrochloric acid) to neutralize any remaining base and help remove polar solvents such as DMF. Separation of the organic phase, further washing with water to remove polar solvents such as DMF, drying over desiccants such as magnesium sulfate or molecular sieves, and then evaporation of the solvent leaves the product, often as a crystalline solid, which can be recrystallized from 25 solvents such as hexanes. For large-scale preparations in which drying with desiccants is impractical, the separated organic phase can be dried and concentrated by removing by distillation both water and the aprotic solvent capable of forming an azeotrope with water (subsequently referred to herein as the "Reaction Azeotrope Solvent"). The residue can then be diluted 30 with a nonpolar solvent having a boiling point higher than the Reaction Azeotrope Solvent (e.g., hexanes fraction having a 65-70 'C normal boiling point when the Reaction Azeotrope Solvent is tert-butyl methyl ether) and distillation continued to remove the residual Reaction Azeotrope Solvent and optionally some of the nonpolar solvent. Often cooling the mixture comprising product and the nonpolar solvent causes crystallization of the product. 35 Alternatively, the nonpolar solvent can be removed by further distillation or evaporation to leave the product. Instead of isolating the product, transferring the product to a solvent useful for a subsequent reaction (e.g., the method of Scheme 6) may be more convenient. After WO 2009/126668 PCT/US2009/039832 32 removing by distillation both water and the Reaction Azeotrope Solvent, the residue can be diluted with a solvent useful in the subsequent reaction (referred to herein as the "Replacement Reaction Solvent"). Minor amounts of residual Reaction Azeotrope Solvent may be acceptable in the subsequent reaction. Alternatively, if the Replacement Reaction 5 Solvent has a boiling point higher than the Reaction Azeotrope Solvent (e.g., tetrahydrofuran as Replacement Reaction Solvent when the Reaction Azeotrope Solvent is tert-butyl methyl ether), the residual Reaction Azeotrope Solvent can be easily removed by distillation. The method of Scheme 1 typically provides the compound of Formula 1 as a mixture of E and Z geometric isomers (denoted by the wavy line in Formula 1), in which one isomer 10 may predominate. Purification methods such as recrystallization often provide purified products containing mostly or exclusively a single geometric isomer. In an alternative method for preparing compounds of Formula 1, compounds of Formulae 2 and 3 are contacted with an alkaline earth metal hydride such as calcium hydride in the presence of a polar aprotic solvent such as DMF without needing to include an aprotic 15 solvent capable of forming a low-boiling azeotrope with water or distilling water from the mixture. In this method the alkaline earth metal hydride serves both as a source of base to catalyze the condensation and a drying agent to remove water formed as a byproduct. As the alkaline metal hydride serves as the primary drying agent, stoichiometry requires a molar ratio of at least 0.5 relative to the compounds of Formulae 2 and 3. Typically a ratio of 20 about 1.3 provides a rapid rate of reaction and high product yields. Alkaline earth metal hydrides generally have little solubility in solvents inert to them, so small particle size improves mass transfer and the availability of these reagents to react (e.g., with water). Although typically a molar ratio of alkaline metal hydride to the compound of Formula 3 of not more than about 2 is needed for best results (i.e. high conversion and product yields), 25 large particle size of alkaline earth metal hydrides may require a molar ratio of hydride to the compound of Formula 3 of more than 2 for best results. This method is typically conducted at a temperature of at least about 45 'C, more typically at least about 55 'C, and typically not more than about 100 'C, more typically not more than about 80 'C. In the method of the invention illustrated in Scheme la, a compound of Formula 1 is 30 prepared by distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, an alkali metal carbonate base of Formula 4a, and an aprotic solvent capable of forming a low-boiling azeotrope with water.
WO 2009/126668 PCT/US2009/039832 33 Scheme la F3C O (MI) 2
CO
3
F
3 C\ O (M I) 2 CO3 O + H 3 C >Q 4a F 4a F3 Z Azeotropic Z 2 3 11 water removal 1 wherein M 1 is Li, Na or K. The first step of this reaction involves an aldol condensation to form a compound of 5 Formula 11. The compound of Formula 11 is not isolated, but instead under the reaction conditions is converted to the compound of Formula 1. The stoichiometry of this reaction involves equimolar amounts of the compounds of Formula 2 and Formula 3 as described for Scheme 1. Alkali metal carbonates of Formula 4a have been discovered to be particularly 10 efficacious in providing high yields of compounds of Formula 1. These alkali metal carbonate bases include lithium, sodium or potassium carbonate, with potassium carbonate preferred for its low cost. The alkali metal carbonate is added to form the reaction mixture such that the molar ratio of alkali metal carbonate to the compound of Formula 3 is typically in the range of 15 about 0.01 to about 0.2. Typically a ratio in the range of about 0.03 to about 0.05 provides complete conversion of compounds of Formula 3 to compounds of Formula 1. The alkali metal carbonate can be added to the reaction mixture in small portions so that the rate of reaction can be controlled, and the rate of generation of water in the reaction vessel can be matched to the rate of water removal by distillation of the solvent/water azeotrope. 20 In the method of Scheme la, acetonitrile has been discovered to be particularly useful as an aprotic solvent in the present method. Acetonitrile forms a water azeotrope boiling at 76.5 'C and containing about 16.3% water and about 83.7% acetonitrile by weight, and therefore is able to rapidly transfer water by distillation from the reaction mixture. The reaction of the method of Scheme la can be conducted over a wide range of 25 temperatures. Typically the reaction temperature is at least about 65 'C. Although the reaction proceeds at lower temperatures, the rates are slower, and aprotic solvent-water azeotropes boiling below 50 'C typically comprise relatively little water (e.g., dichloromethane forms azeotrope containing 1.5% water), which slows water removal. More typically the reaction temperature is at least about 80 'C and most typically at least 30 about 85 'C. Although high temperatures increase the reaction rate, they can also cause side reactions decreasing product purity and yield. Therefore typically the reaction temperature is not more than about 110 'C, more typically not more than about 100 'C, and most typically not more than about 90 'C.
WO 2009/126668 PCT/US2009/039832 34 In the method of the invention illustrated in Scheme 1b, a compound of Formula 1 is prepared by distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, a base selected from 1,5-diazabicyclo[4.3.0]non-5-ene, 1,8 diazabicyclo[5.4.0]undec-7-ene, and mixtures thereof, and an aprotic solvent capable of 5 forming a low-boiling azeotrope with water. Scheme lb F+ O base F 3 C base F3C z H 3 C Q -- C Q - zJQ Z Azeotropic z 2 3 water removal 1 wherein base is 1,5-diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene or a mixture thereof. 10 The first step of this reaction involves an aldol condensation to form a compound of Formula 11. The compound of Formula 11 is not isolated, but instead under the reaction conditions is converted to the compound of Formula 1. The stoichiometry of this reaction involves equimolar amounts of the compounds of Formula 2 and Formula 3 as described for Scheme 1. 15 1,5-Diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene or mixtures thereof have been discovered to be particularly efficacious in providing high yields of compounds of Formula 1. Both 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo [5.4.0]undec-7-ene are liquids at 25 'C. On a large (i.e. commercial) scale, liquids can be added to a reaction mixture more accurately and with less material loss than solids. 20 1,5-Diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene or a mixture thereof is added to form the reaction mixture such that the molar ratio of 1,5 diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene or a mixture thereof to the compound of Formula 3 is typically in the range of about 0.01 to about 0.2. Typically a ratio in the range of about 0.03 to about 0.05 provides a rapid rate of reaction and high product 25 yields. The 1,5-diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene or mixture thereof can be added to the reaction mixture in small portions so that the rate of reaction can be controlled, and the rate of generation of water in the reaction vessel can be matched to the rate of water removal by distillation of the solvent/water azeotrope. In the method of Scheme 1b, acetonitrile has been discovered to be particularly useful 30 as an aprotic solvent in the present method. Acetonitrile forms a water azeotrope boiling at 76.5 'C and containing 16.3% water and 83.7% acetonitrile by weight, and therefore is able to rapidly transfer water by distillation from the reaction mixture.
WO 2009/126668 PCT/US2009/039832 35 The reaction of the method of Scheme lb can be conducted over a wide range of temperatures. Typically the reaction temperature is at least about 65 'C. Although the reaction proceeds at lower temperatures, the rates are slower, and aprotic solvent-water azeotropes boiling below 50 'C typically comprise relatively little water (e.g., 5 dichloromethane forms azeotrope containing 1.5% water), which slows water removal. More typically the reaction temperature is at least about 80 'C and most typically at least about 85 'C. Although high temperatures increase the reaction rate, they can also cause side reactions decreasing product purity and yield. Therefore typically the reaction temperature is not more than about 110 'C, more typically not more than about 100 'C, and most 10 typically not more than about 90 'C. Regarding the methods of Schemes 1, la and 1b, and the above-described alternative method for preparing compounds of Formula 1, in their broadest definitions Z in Formulae 1 and 2 is optionally substituted phenyl, and Q in Formulae 1 and 3 is phenyl or 1 naphthalenyl, each optionally substituted. Q and Z are appendages not directly involved in 15 the aldol condensation and dehydration providing compounds of Formula 1. The reaction conditions for the present methods are relatively mild and thus accommodate a wide range of optional substituents on phenyl and 1-naphthalenyl. Only functionalities most reactive to hydroxide bases are susceptible to being affected. Therefore the particular substituents on the phenyl and 1-naphthalenyl moieties of Q and Z described in the Embodiments (e.g., 1 20 through IG, 2 through 20, A through A7) and elsewhere in the present disclosure should be regarded as merely illustrative, as the scope of utility of the present methods is more general. In the method of the present invention illustrated in Scheme 2, a compound of Formula 2 is prepared from a corresponding compound of Formula 5 by forming a Grignard reagent intermediate (depicted as Formula 12), and then reacting the Grignard reagent with a 25 compound of Formula 6. Scheme 2 0 Y )
CF
3 [Mg] ZMX1] 6
F
3 C 5 12 z 2 In one embodiment of this method, a compound of Formula 5 is contacted with magnesium metal in the presence of an ethereal solvent to form a Grignard reagent. In the 30 context of the present disclosure and claims, an ethereal solvent contains one or more organic compounds consisting of atoms selected hydrogen, carbon and oxygen and having at least one ether linkage (i.e. C-O-C) but no other functionality. Common examples of ethers WO 2009/126668 PCT/US2009/039832 36 include diethyl ether, tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane, but other ethers such as butyl diglyme (1,1'-[oxybis(2,1-ethanediyloxy)]bisbutane) are also employed to prepare and use Grignard reagents. Typically in this embodiment, the ethereal solvent comprises diethyl ether or tetrahydrofuran. More typically the ethereal solvent comprises 5 tetrahydrofuran. When the Grignard reagent is prepared using magnesium metal, X 1 in Scheme 2 is the same as X if no other anionic species are added to the reaction mixture. For preparing Grignard reagents from magnesium metal, the metal is typically in the form of turnings, shavings or powder to provide high surface area for reaction. Typically the magnesium metal is contacted with the compound of Formula 5 at a temperature of at least 10 about 0 'C, more typically at least about 20 'C, and most typically at least about 25 'C. Typically the temperature is no more than about 65 'C, more typically no more than about 40 'C, and most typically no more than about 35 'C. As stoichiometry requires at least equimolar amounts of magnesium metal relative to the compound of Formula 5 for complete conversion, the molar ratio of magnesium metal to the compound of Formula 5 is typically at 15 least about 1, more typically at least about 1.02 and most typically at least about 1.05. Although larger excesses of magnesium metal can be used, they provide no advantage and increase solid residues. Typically the molar ratio of magnesium metal to the compound of Formula 5 is no more than about 1.2, and more typically no more than about 1.1. Alternatively in another embodiment of this method, the Grignard reagent is prepared 20 by contacting the compound of Formula 5 with an alkylmagnesium halide. For an example of this general method of forming Grignard reagents, see J. L. Leazer and R. Cvetovich, Org. Syn. 2005, 82, 115-119. The alkylmagnesium halide is typically a secondary alkylmagnesium halide, which is more reactive than a primary alkylmagnesium halide. Typically the alkylmagnesium halide is a Ci-C 4 alkylmagnesium halide. Of note is the 25 alkylmagnesium halide being an isopropylmagnesium halide, particularly isopropylmagnesium chloride. In this embodiment of the present method, X 1 in Scheme 2 represents a mixture of anions provided both by X in the compound of Formula 5 and the halide of the alkylmagnesium halide. For example, if X is I and the alkylmagnesium halide is isopropylmagnesium chloride, then X 1 represents a mixture of Cl and I (present as 30 anions). In this embodiment, the compound of Formula 5 is contacted with the alkylmagnesium halide in the presence of an ethereal solvent. Typically the compound of Formula 5 is contacted with the alkylmagnesium halide at a temperature of at least -30 'C, more typically at least -20 'C and most typically at least about -10 'C. Typically the temperature is no more than about 40 'C, more typically no more than about 20 'C, and most 35 typically no more than about 10 'C. Typically in this embodiment, the ethereal solvent comprises diethyl ether, tetrahydrofuran or a mixture thereof, and more typically the ethereal solvent comprises tetrahydrofuran. As stoichiometry requires at least equimolar amounts of alkylmagnesium halide relative to the compound of Formula 5 for complete conversion, the WO 2009/126668 PCT/US2009/039832 37 molar ratio of the alkyl magnesium halide to the compound of Formula 5 is typically at least about 1, and more typically at least about 1.05. Although larger excesses of alkylmagnesium halide can be used, they can subsequently react with the compound of Formula 6, so that more compound of Formula 6 is required and more byproduct is produced. Typically the 5 molar ratio of the alkyl magnesium halide to the compound of Formula 5 is no more than about 1.2, and more typically no more than about 1.15. However, larger amounts of alkylmagnesium halide can be desirable to compensate for water impurities in the reaction solvent. As is well known in the art, Grignard reagents react very rapidly with solvents 10 containing hydroxy groups, including water, and thus solvents for preparing and using Grignard reagents should contain as little impurity water as feasible, i.e. be anhydrous. Also, as Grignard reagents react with oxygen, the reaction mixtures are preferably protected from oxygen, e.g., by being blanketed by nitrogen or argon gas. For both embodiments of this method, and particularly the embodiment forming the 15 Grignard reagent using an alkylmagnesium halide, the method can be conducted in the presence of an aromatic hydrocarbon solvent in addition to the ethereal solvent. The term "aromatic hydrocarbon solvent" in this method denotes a solvent comprising one or more aromatic hydrocarbon compounds. Aromatic hydrocarbon compounds contain only carbon and hydrogen atoms and for aromaticity comprise at least one benzene ring, which can be 20 substituted with hydrocarbon moieties such as alkyl groups. Aromatic hydrocarbon solvents commonly comprise one or more of benzene, toluene and xylene (which is typically present as a mixture of isomers). Because aromatic hydrocarbon solvents are higher boiling than common ethereal solvents such as diethyl ether and tetrahydrofuran, including aromatic hydrocarbon solvents in the reaction mixture forming the Grignard reagent improves the 25 margin of safety in large-scale production. The formation of Grignard reagents is generally exothermic, and in the event of loss of cooling and subsequent loss of the lower boiling ethereal solvent, the presence of the higher boiling aromatic hydrocarbon solvent will curtail the reaction. For the present method, toluene is particularly preferred as the aromatic hydrocarbon solvent, because of its low cost, relatively low toxicity, low freezing point and 30 moderately high boiling point. According to this method, the reaction mixture containing the Grignard reagent formed from the compound of Formula 5 is then contacted with a compound of Formula 6 to give a compound of Formula 2. The compound of Formula 6 is typically contacted with the reaction mixture containing the Grignard reagent at a temperature of at least about -80 'C, 35 more typically at least about -25 'C, and most typically at least about -5 'C. The temperature is typically no more than about 0 'C. Typically the compound of Formula 6 is added to the reaction mixture containing the Grignard reagent in solution, and an excess of compound of Formula 6 relative to the Grignard reagent formed from the compound of WO 2009/126668 PCT/US2009/039832 38 Formula 5 is used. Alternatively, the reaction mixture containing the Grignard reagent formed from the compound of Formula 5 can be added to an excess of the compound of Formula 6. When the Grignard reagent is prepared from magnesium metal, the molar ratio of compound of Formula 6 relative to the compound of Formula 5 is typically at least about 5 1.05 and more typically at least about 1.1, and typically no more than about 1.3 and more typically no more than about 1.2. When the Grignard reagent is prepared from an alkylmagnesium halide, the amount of alkylmagnesium halide used is more relevant than the amount of the compound of Formula 5 relative to the compound of Formula 6, because excess alkylmagnesium halide can also react with the compound of Formula 6. In this 10 embodiment the ratio of the compound of Formula 6 to the alkylmagnesium halide used is typically at least about 1.05 and more typically at least about 1.1, and typically no more than about 1.3 and more typically no more than about 1.2. The reaction mixture is typically worked up by addition of an aqueous mineral acid such as hydrochloric acid, and extracting the product into moderately polar, water 15 immiscible organic solvent such as diethyl ether, dichloromethane or toluene. Usually the compound of Formula 2 is obtained in a mixture with its hydrate derivative and its alkyl hemi-ketal derivative (from alkanol byproduct formed from the compound of Formula 6 when Y is OR 1 1). Either or both of these derivatives of the compound of Formula 2 can be conveniently converted to the compound of Formula 2 by treatment (i.e. contact) with a 20 strong acid such as an organic sulfonic acid, e.g., p-toluenesulfonic acid, in the presence of an aprotic organic solvent, and removing the water and/or alkanol formed by distillation. Preferably the aprotic organic solvent is immiscible with water. Typically the aprotic organic solvent comprises one or more solvents selected from hydrocarbons such as heptane or toluene and halogenated hydrocarbons such as 1,2-dichloroethane. During the distillation, 25 the reaction mixture in the pot is typically heated to at least about 45 'C, more typically at least about 80 'C, typically no more than about 120 'C, more typically no more than about 110 'C, and most typically no more than about 100 'C. Solvents such as heptane, toluene and 1,2-dichloroethane and their azeotropes with water and alkanols have normal boiling points accommodating these reaction temperatures. Solvents such as toluene that form low 30 boiling azeotropes with water and alkanols are preferred. After removal of water and alkanols, the distillation can be continued to remove the solvent, and continued at reduced pressure to isolate the product compound of Formula 2. The method of Scheme 2 is particularly useful when X is I (i.e. iodo), because this facilitates preparation of compounds of Formula 2 wherein Z is a phenyl ring optionally 35 substituted with up to 5 substituents selected from not just F, alkyl, fluoroalkyl, alkoxy, fluoroalkoxy, alkylthio and fluoroalkylthio, but also Cl and Br, which would be more likely to react with magnesium metal or alkylmagnesium halides if X were Cl or Br. Although Grignard reagents are more often prepared from chloro- or bromophenyl compounds, WO 2009/126668 PCT/US2009/039832 39 iodophenyl compounds (i.e. X is I) are discovered to work well in forming Grignard reagents, and moreover when X is I the phenyl ring can be substituted with halogens at other positions, particularly the 3- and 5- positions (relative to X), which is especially useful for forming insecticidal 4,5-dihydroisoxazole compounds. 5 Of note is the method of Scheme 2 wherein X is I and Z is phenyl substituted at the 3 and 5-positions relative to X with substituents independently selected from F, Cl, Br and
CF
3 , particularly wherein one substituent is CF 3 and the other substituent is CF 3 , Cl or Br, more particularly wherein one substituent is CF 3 and the other substituent is Cl or Br, and most particularly wherein one substituent is CF 3 and the other substituent is Cl. 10 Compounds of Formulae 5 and 6 can be prepared by a wide variety of methods known in the art. Many of these compounds are known, and a substantial number are commercially available. The above noted embodiment of the method of Scheme 2 involves compounds of Formula 5 wherein X is I (e.g., 1-chloro-3-iodo-5-(trifluoromethyl)benzene). These compounds can be prepared by the method illustrated in Scheme 3. In this method a 15 compound of Formula 13 is diazotized to form a diazonium salt intermediate, which is then reduced to form the compound of Formula 5a (i.e. Formula 5 wherein X is I). Scheme 3
NH
2 a 1. Diazotization a (R )n 2. Reduction 13 5a wherein Ra are substituents such as R2 as defined in Embodiment 3H. 20 In this method, a compound of Formula 13 is contacted with sodium nitrite in the presence of a mineral acid such as hydrochloric acid or sulfuric acid. Usually for best results two or more molar equivalents of the mineral acid are required relative to the number of moles of the compound of Formula 5a used in the reaction. The reaction is typically conducted in a suitable solvent such as aqueous hydrochloric acid or acetic acid. A 25 temperature in the range from about -5 to about 5 'C is usually employed for the preparation of the diazonium salt. The diazonium salt of a compound of Formula 13 is then contacted with a reducing agent such as hypophosphorous acid or ethanol to provide a compound of Formula 5a. The reduction reaction is usually conducted in the same solvent as was used for the diazonium salt formation at a temperature from about 5 to about 20 'C. The product of 30 Formula 5a can be isolated by standard techniques such as crystallization, extraction, and distillation. The diazotization and reduction of anilines by this general method is well known and has been reviewed; see, for example, N. Kornblum, Org. Reactions 1944, 2, 262 340.
WO 2009/126668 PCT/US2009/039832 40 2-Chloro-6-iodo-4-(trifluoromethyl)benzenamine, 4-chloro-2-iodo-6-(trifluoromethyl) benzenamine and 2-chloro-4-iodo-6-(trifluoromethyl)benzenamine are of particular note as compounds of Formula 13 for preparing 1-chloro-3-iodo-5-(trifluoromethyl)benzene as the compound of Formula 5a by this method. 5 Compounds of Formula 13 can be prepared from compounds of Formula 14 by iodination as shown in Scheme 4. Scheme 4
NH
2 NH 2 (R8)n_____ Iodination (RJ (Ra~n li (R)n | 14 13 10 wherein Ra are substituents such as R 2 as defined in Embodiment 3H. In this method a compound of Formula 14 is contacted with an iodination reagent such as iodine monochloride in a suitable solvent such as water or acetic acid. Optionally hydrochloric acid can be included in the reaction mixture to increase the solubility of the compound of Formula 14 and the iodine monochloride in the reaction medium. Usually only 15 about one molar equivalent of iodine monochloride is needed to completely convert the compound of Formula 14 to the compound of Formula 13. Larger molar excesses of iodine monochloride can be used to shorten the reaction time, but with increased process cost. The reaction can be conducted in a temperature range from about 0 to about 100 'C, typically at temperature of about 50 'C. The product of Formula 13 can be isolated by conventional 20 means, such as filtration, extraction and distillation. As illustrated in Scheme 5, compounds of Formula 13a containing at least one chlorine or bromine moiety can also be prepared by contacting corresponding compounds of Formula 13 with a suitable chlorinating or brominating agent such as chlorine, hydrochloric acid/hydrogen peroxide, or hydrobromic acid/hydrogen peroxide. 25 Scheme 5
NH
2 NH 2 Chlorination (Ra)n0 (R)p or Bromination () 13 13a wherein Ra are substituents such as R 2 as defined in Embodiment 3H; at least one Rb is Cl (from chlorination) or Br (from bromination) and the other instances of Rb are Ra WO 2009/126668 PCT/US2009/039832 41 substituents of Formula 13; and p = n + number of chlorine or bromine atoms from chlorination or bromination, respectively. The reaction is conducted in a solvent such as water or acetic acid. The temperature range can be from 0 to 100 'C with a temperature range between 25 and 50 'C preferred. 5 In another aspect of the present invention, compounds of Formula 1 prepared by the method of Scheme 1, are useful for preparing compounds of Formula 7.
F
3 C 0 7 A variety of routes are possible for the preparation of compounds of Formula 7 from compounds of Formula 1. In one method as shown in Scheme 6, a compound of Formula 1 10 is contacted with hydroxylamine and a base to form a 5-(trifluoromethyl)-4,5 dihydroisoxazole compound of Formula 7. Scheme 6
HONH
2
F
3 C Base
F
3 C Q z ~Solvent 1 7 15 Hydroxylamine can be generated from a mineral acid salt such as hydroxylamine sulfate or hydroxylamine chloride by treatment with a base in a suitable solvent, or can be obtained commercially as 50% aqueous solution. In this method before contact with an enone of Formula 1, hydroxylamine or a mineral acid salt thereof is typically contacted with a base. When a mineral acid salt of hydroxylamine is used, the base is contacted in an 20 amount in excess of the amount needed to convert the hydroxylamine mineral acid salt to hydroxylamine. Base is not consumed in the reaction of Scheme 6, and appears to act as a catalyst for the desired cyclization. Deprotonation of the hydroxylamine with a base prior to contact with an enone of Formula 1 is necessary to obtain good yields, because in the absence of base the reaction of hydroxylamine with enones can afford products other than 25 compounds of Formula 1. Therefore although often about one molar equivalent of base (in addition to any base used to convert a hydroxylamine mineral acid salt to hydroxylamine) is used relative to hydroxylamine, less than one molar equivalent of base can give excellent results. More than one molar equivalent (e.g., up to about 5 molar equivalents) of base relative to hydroxylamine can be used, provided that the excess base does not react with the 30 enone of Formula 1 or the isoxazole of Formula 7.
WO 2009/126668 PCT/US2009/039832 42 A molar excess of one to three equivalents of hydroxylamine relative to the enone of Formula 1 can be used. To ensure the cost-effective, complete, and expeditious conversion of the enone of Formula 1 to the isoxazole of Formula 7, in a manner suitable for large-scale production, between about one and about two molar equivalents of hydroxylamine relative to 5 the enone of Formula 1 are typically found to be most suitable. Suitable bases can include, but are not limited to, alkali metal alkoxides such as sodium methoxide, alkali metal carbonates such as sodium carbonate or potassium carbonate, alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, and organic bases. Preferred organic bases are amine bases having at least one pair of free 10 electrons available for protonation such as pyridine, triethylamine or NN diisopropylethylamine. Weaker bases such as pyridine can be used, but stronger bases which efficiently deprotonate hydroxylamine, such as an alkali metal alkoxide or an alkali metal hydroxide, typically provide better results. Because water is an especially useful solvent for deprotonating hydroxylamine, as well as forming hydroxylamine from its salts, 15 bases compatible with water are of particular note. Examples of strong bases that are soluble and compatible with water are alkali metal hydroxides. Sodium hydroxide is preferred, because it is inexpensive and works well for deprotonating hydroxylamine, thereby forming the sodium salt of hydroxylamine in aqueous solution. Alkali metal alkoxides are frequently used in solution in a lower alkanol, often the alkanol corresponding to the alkoxide. 20 The method of Scheme 6 is conducted in the presence of a suitable solvent. For best results the solvent should be inert to the base and hydroxylamine, and should be capable of dissolving the enone of Formula 1. Suitable organic solvents include alcohols, ethers, nitriles or aromatic hydrocarbons. Water-miscible solvents such as alcohols (e.g., methanol, isopropanol), ethers (e.g., tetrahydrofuran) or nitriles (e.g., acetonitrile) work well with alkali 25 metal hydroxide bases. Solvents which are non-nucleophilic (e.g., ethers and nitriles) often provide the best results. Particularly when a single solvent is used, the most preferred solvents are tetrahydrofuran and acetonitrile. Alternatively it may be more desirable to conduct the reaction using a mixture of two solvents formed by contacting a solution of the enone of Formula 1 in a solvent such as 30 tetrahydrofuran or acetonitrile with a solution of hydroxylamine and a base such as sodium hydroxide in a second solvent, which acts as the co-solvent in the solvent mixture. Water is particularly useful as a co-solvent, because mineral acid salts of hydroxylamine and alkali metal hydroxide bases such as sodium hydroxide are particularly soluble in water. The rapid generation of hydroxylamine from its mineral acid salt and subsequent deprotonation of 35 hydroxylamine facilitated by water, and the solubility and stability of the deprotonated species in water are especially desirable. In large-scale production, solutions rather than slurries are preferred, because they are easier to handle and transfer in process equipment.
WO 2009/126668 PCT/US2009/039832 43 When water is the co-solvent, the other solvent is typically a water-miscible solvent such as tetrahydrofuran or acetonitrile. Other highly polar, hydroxylic solvents such as lower alkanols (e.g., methanol, ethanol) are also particularly useful as co-solvents, because like water they readily dissolve 5 mineral acid salts of hydroxylamine and alkali metal hydroxides. Lower alkanols can give better results than water as a co-solvent when the other solvent is not water-miscible, e.g., tert-butyl methyl ether. When a lower alkanol is used as a co-solvent, particularly with another solvent that is not water-miscible, the base added is often an alkali metal alkoxide instead of an alkali metal hydroxide. 10 As long as base is present to deprotonate hydroxylamine, the hydroxylamine, the base and the enone of Formula 1 can be contacted in a variety of ways in the method of Scheme 6. For example, a mixture formed from hydroxylamine and the base (typically in a solvent such as water) can be added to the enone of Formula 1 (typically in a solvent such as tetrahydrofuran or acetonitrile). Alternatively, the hydroxylamine and the base can be 15 concurrently added separately to the enone of Formula 1. In another embodiment, the enone of Formula 1 (typically in a solvent such as tetrahydrofuran or acetonitrile) can be added to a mixture formed from the hydroxylamine and the base (typically in a solvent such as water). In these example embodiments other combinations of solvents can be used; for example, methanol with tert-butyl methyl ether instead of water with tetrahydrofuran or acetonitrile. 20 The method of Scheme 6 can be conducted at a reaction temperature between about 0 and 150 0 C, or most conveniently between 20 and 40 0 C. The product of Formula 7 is isolated by the usual methods known to those skilled in the art including extraction and crystallization. Compounds of Formulae 7a, 7b and 7c are subsets of compounds of Formula 7 that are 25 of particular note as insecticides. ~\F3C O'R FC O ' N 5 F CN (R2) N (R2)n |OR l 7a 7b O.--N F3C \ ( 0 N (R2)nIR3 7cR wherein R 2 , R 3 , R 4 , R 5 and Rv are as defined in the Summary of the Invention, Exhibit 1 and the Embodiments, and n is an integer from 0 to 5.
WO 2009/126668 PCT/US2009/039832 44 Therefore for preparation of compounds of Formulae 7a, 7b and 7c of particular note are embodiments of the method of Scheme 6 shown in Scheme 7 wherein the compound of Formula 1 is prepared by the method of Scheme 1. Scheme 7
F
3 C HONH 2
F
3 C O'N Base (nSolvent 27d 5 wherein H N. .- N N.-N Qis R5 3 or 3 O N (i.e. Formula 7a) (i.e. Formula 7b) (i.e. Formula 7c) Compounds of Formula 7 can often be prepared from other compounds of Formula 7 by modification of substituents. For example, compounds of Formula 7a can be prepared by aminocarbonylation of compounds of Formula 7d with appropriately substituted amine 10 compounds of Formula 15 as shown in Scheme 8. Scheme 8 H N R R5 F3C ON 15 7a 2 lt Br CO gas (R2)n 7d Pd catalyst This reaction is typically carried out with an aryl bromide of Formula 7d in the presence of a palladium catalyst under a CO atmosphere. The palladium catalysts used for this method typically comprises palladium in a formal oxidation state of either 0 (i.e. Pd(O)) 15 or 2 (i.e. Pd(II)). A wide variety of such palladium-containing compounds and complexes are useful as catalysts for this method. Examples of palladium-containing compounds and complexes useful as catalysts in the method of Scheme 8 include PdCl 2 (PPh 3
)
2 WO 2009/126668 PCT/US2009/039832 45 (bis(triphenylphosphine)palladium(II) dichloride), Pd(PPh 3
)
4 (tetrakis(triphenylphosphine) palladium(O)), Pd(C 5
H
7 0 2
)
2 (palladium(II) acetylacetonate), Pd 2 (dba) 3 (tris(dibenzylidene acetone)dipalladium(O)), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II). The method of Scheme 8 is generally conducted in a liquid phase, and therefore to be most 5 effective the palladium catalyst preferably has good solubility in the liquid phase. Useful solvents include, for example, ethers such as 1,2-dimethoxyethane, amides such as N,N-dimethylacetamide, and non-halogenated aromatic hydrocarbons such as toluene. The method of Scheme 8 can be conducted over a wide range of temperatures, ranging from about 25 to about 150 'C. Of note are temperatures from about 60 to about 110 'C, 10 which typically provide fast reaction rates and high product yields. The general methods and procedures for aminocarbonylation with an aryl bromide and an amine are well known in the literature; see, for example, H. Horino et al., Synthesis 1989, 715; and J. J. Li, G. W. Gribble, editors, Palladium in Heterocyclic Chemistry: A Guide for the Synthetic Chemist, 2000. Compounds of Formula 7d can be prepared by the method of Scheme 6 from 15 compounds of Formula 1, which are prepared by the method of Scheme 1 according to the present invention. Compounds of Formula 7a can also be prepared by coupling a carboxylic acid compound of Formula 7e with an appropriately substituted amino compound of Formula 15 as shown in Scheme 9. 20 Scheme 9 CO 2 H O/ N
HN(R
4
)R
5 15 0_ 7a
F
3 C 7e 2 (R )n This reaction is generally carried out in the presence of a dehydrating coupling reagent such as dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1 -propanephosphonic acid cyclic anhydride or carbonyl diimidazole in the presence of a base 25 such as triethylamine, pyridine, 4-(dimethylamino)pyridine or NN-diisopropylethylamine in an anhydrous aprotic solvent such as dichloromethane or tetrahydrofuran at a temperature typically between about 20 and about 70 'C. Compounds of Formula 7e can be prepared by the method of Scheme 6 from compounds of Formula 1, which are prepared by the method of Scheme 1 according to the WO 2009/126668 PCT/US2009/039832 46 present invention. Alternatively, compounds of Formula 7e can be prepared by hydrolyzing ester compounds of Formula 7f as shown in Scheme 10. Scheme 10 CO 2
R
5 a O Ester Hydrolysis
F
3 C 1 7e -- 7f (R )n 5 wherein R 5 a is, for example, methyl or ethyl. In this method, an ester of Formula 7f is converted to a corresponding carboxylic acid of Formula 7e by general procedures well known in the art. For example, treatment of a methyl or ethyl ester of Formula 7f with aqueous lithium hydroxide in tetrahydrofuran, followed by acidification yields the corresponding carboxylic acid of Formula 7e. 10 Compounds of Formula 7f can be prepared by the method of Scheme 6 from compounds of Formula 1, which are prepared by the method of Scheme 1 according to the present invention. Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples 15 are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Steps in the following Examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Percentages are by weight except for chromatographic solvent 20 mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. 1 H NMR spectra are reported in ppm downfield from tetramethylsilane; "s" means singlet, "d" means doublet, "t" means triplet, "q" means quartet, "m" means multiplet, "dd" means doublet of doublets, "dt" means doublet of triplets and "br" means broad.
WO 2009/126668 PCT/US2009/039832 47 EXAMPLE 1 Preparation of methyl 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3 isoxazolyl]- 1 -naphthalenecarboxylate Step A: Preparation of methyl 4-[3-(3,5-dichlorophenyl)-4,4,4-trifluoro-1-oxo-2 5 buten- 1-yl] -1 -naphthalenecarboxylate A mixture of methyl 4-acetyl-1-naphthalenecarboxylate (5.36 g, 23.4 mmol), 1-(3,5 dichlorophenyl)-2,2,2-trifluoroethanone (5.68 g, 23.4 mmol), calcium hydroxide (0.172 g, 2.3 mmol), NN-dimethylformamide (16 mL), and tert-butyl methyl ether (32 mL) was placed in a thermometer-equipped reaction vessel. The reaction vessel was connected to a 10 ten-plate Oldershaw column, the output of which was condensed and fed into a decanter initially filled with tert-butyl methyl ether. A nitrogen atmosphere was maintained in the apparatus. The upper part of the decanter was connected to return condensate to the fifth plate of the Oldershaw column. This arrangement ensured that wet (containing dissolved water) tert-butyl methyl ether from the decanter was not returned to the reaction vessel. A 15 drain valve at the bottom of the decanter allowed removing tert-butyl methyl ether in addition to water from the decanter. The reaction mixture was heated to distill the tert-butyl methyl ether/water azeotrope. As the decanter trap contained an amount of tert-butyl methyl ether sufficient to dissolve all of the water formed by the reaction, the condensate in the trap did not separate into layers containing predominately water and predominately tert-butyl 20 methyl ether. Because the reaction mixture initially contained mostly tert-butyl methyl ether, the mixture boiled at a temperature not much exceeding the normal boiling point of tert-butyl methyl ether (e.g., about 65-70 C). The reaction appeared to proceed relatively slowly at this temperature, so condensate was gradually drained from the decanter trap to remove tert-butyl methyl ether. As the concentration of tert-butyl methyl decreased in the 25 reaction mixture, the temperature of the boiling mixture increased. Tert-butyl methyl ether was removed by draining the decanter until the temperature of the boiling reaction mixture reached about 75 to 80 'C. To maintain this temperature range, tert-butyl methyl ether was added as needed to compensate for loss of solvent from the apparatus. The total time from beginning heating the reaction mixture to stopping distillation, not including a shutdown 30 period overnight, was about 15 h. During this time period a further portion of calcium hydroxide (1.34 g, 18.1 mmol) was added to increase the reaction rate. To isolate the product, the mixture was cooled to room temperature and filtered. The collected solid was washed with tert-butyl methyl ether (10 mL). Water (100 mL) was added, and the aqueous layer was acidified with hydrochloric acid. The organic phase was 35 washed with water (100 mL), dried, and evaporated to give the product as a yellow solid (10.1 g, 95% yield) melting at 91-91.5 'C (after recrystallization from hexanes). The following spectra were of the product recrystallized from hexanes.
WO 2009/126668 PCT/US2009/039832 48 IR (nujol) 1723, 1670, 1560, 1280, 1257, 1230, 1186, 1171, 1132, 1098, 1022, 804 cm- 1 . 1 H NMR (CDCl 3 ) 8.78-8.76 (m, 1H), 8.32-8.30 (m, 1H) 8.02 (d, J=7.6 Hz, 1H) 7.65-7.62 (m, 3H), 7.34 (s, 1H), 7.07-7.06 (m, 1H), 6.94 (d, J=1.7 Hz, 2H), 4.03 (s, 3H). Step B: Preparation of methyl 4-[5-(3,5-dichlorophenyl)-4,5-dihydro 5 5-(trifluoromethyl)-3-isoxazolyl]-1-naphthalenecarboxylate Sodium hydroxide (50%, 3.50 g, 43.7 mmol) was added to a solution of hydroxylamine sulfate (1.8 g, 11.0 mmol) in water (22 mL). When the mixture had cooled to room temperature a portion of the mixture (~50%) was added dropwise over 4 minutes to methyl 4-[3-(3,5-dichlorophenyl)-4,4,4-trifluoro- 1 -oxo-2-buten-1 -yl]-1 -naphthalene 10 carboxylate (i.e. the product of Step A) (5.00 g, 11.0 mmol) in tetrahydrofuran (55 mL) at room temperature. After 30 minutes a further portion (~10%) of the aqueous mixture was added. The mixture was stirred for a further 15 minutes. The mixture was partitioned between hydrochloric acid (1 N, 50 mL) and tert-butyl methyl ether (50 mL). The organic phase was evaporated, and the solid obtained was stirred in hot methanol. The mixture was 15 cooled and filtered to give the product as a white solid (4.50 g, 87%) melting at 137.3 138 'C (after recrystallization from methanol). The following spectra were of the product recrystallized from methanol. IR(nujol) 1716, 1569, 1518, 1433, 1332, 1309, 1288, 1251, 1192, 1167, 1139, 1114, 1102, 1027, 1006, 910, 867, 855 cm- 1 . 20 1 H NMR (CDCl 3 ) 8.89-8.87 (m, 1H), 8.80-8.78 (m, 1H), 8.10 (d, J=7.6 Hz, 1H), 7.69-7.66 (m, 2H), 7.56-7.53 (m, 3H), 7.46 (t, J=2 Hz, 1H), 4.27 (1/2ABq, J=17 Hz, 1H), 4.03 (s, 3H), 3.91 (1/2ABq, J=17 Hz, 1H). EXAMPLE 2 Preparation of methyl 4-[5-[3,5-bis(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl) 25 3-isoxazolyl]-1-naphthalenecarboxylate Step A: Preparation of methyl 4-[3-[3,5-bis(trifluoromethyl)phenyl]-4,4,4-trifluoro-1 oxo-2-buten- 1 -yl]- 1 -naphthalenecarboxylate A mixture of methyl 4-acetyl-1-naphthalenecarboxylate (5.36 g, 23.5 mmol), 1-[3,5 bis(trifluoromethyl)phenyl]-2,2,2-trifluoroethanone (7.28 g, 23.5 mmol), calcium hydroxide 30 (1.40 g, 18.9 mmol), NN-dimethylformamide (16 mL) and tert-butyl methyl ether (32 mL) was boiled with provision of the apparatus comprising a ten-plate Oldershaw column and decanter described in Example 1, Step A for removal of the tert-butyl methyl ether/water azeotrope. As the decanter trap contained an amount of tert-butyl methyl ether sufficient to dissolve all of the water formed by the reaction, the condensate in the trap did not separate 35 into layers containing predominately water and predominately tert-butyl methyl ether. Tert butyl methyl ether was removed by gradually draining the decanter trap until the pot temperature was 85 'C. To maintain this temperature, tert-butyl methyl ether was added as WO 2009/126668 PCT/US2009/039832 49 needed to compensate for loss of solvent from the apparatus. The total time from beginning heating the reaction mixture to stopping distillation, not including a shutdown period overnight, was about 10 h. During this time period no additional calcium hydroxide was added to the reaction mixture. 5 To isolate the product, the mixture was cooled to room temperature and was filtered. The solid was washed with tert-butyl methyl ether and the filtrate was washed with water (30 mL), and diluted with tert-butyl ether. The mixture was evaporated to give the product as a yellow solid (12.1 g, 99%) melting at 91.5-92 'C (after recrystallization from hexanes). The following spectra were of the product recrystallized from hexanes. 10 IR (nujol) 1720, 1685, 1515, 1441, 1405, 1345, 1280, 1261, 1187, 1171, 1147, 1129, 1097, 1024, 899, 856 cm- 1 . 1 H NMR (CDCl 3 ) 8.74-8.72 (m, 1H), 8.23-8.21 (m, 1H) 7.99 (d, J=7.3 Hz, 1H), 7.67 (d, J=7.6 Hz, 1H), 7.64-7.57 (m, 3H), 7.51 (s, 2H), 7.47 (d, J=1.4 Hz, 1H), 4.04 (s, 3H). Step B: Preparation of methyl 4-[5-[3,5-bis(trifluoromethyl)phenyl]-4,5-dihydro-5 15 (trifluoromethyl)-3-isoxazolyl]-1-naphthalenecarboxylate Sodium hydroxide (50%, 1.53 g, 38.2 mmol) was added to hydroxylamine sulfate (1.57 g, 9.57 mmol) in water (18 mL). A portion of the solution (~51%, ~9.8 mmol of hydroxylamine) was added dropwise to methyl 4-[3-[3,5-bis(trifluoromethyl)phenyl]-4,4,4 trifluoro-1-oxo-2-buten-1-yl]-1-naphthalenecarboxylate (i.e. the product of Step A) (5.00 g, 20 9.61 mmol) in tetrahydrofuran (45 mL). After ~45 min the mixture was poured into hydrochloric acid (1 N, 100 mL) and was extracted with ether (3 x 80 mL). The combined organic extracts were washed with water (80 mL), dried and evaporated. The material was stirred in hot methanol, then cooled to room temperature, collected under filtration and dried in vacuum to give the product as a white solid (4.14 g, 80% yield) 25 melting at 130-131 'C (after recrystallization from methanol). The following spectra were of the product recrystallized from methanol. IR (nujol) 1722, 1515, 1437, 1330, 1284, 1208, 1193, 1174, 1128, 1106, 1025, 1009, 916, 903, 859, 842 cm- 1 . 1 H NMR (CDC 3 ) 8.89-8.87 (m, 1H), 8.82-8.79 (m, 1H), 8.14-8.09 (m, 3H), 8.0 (s, 1H), 30 7.70-7.67 (m, 2H), 7.56 (d, J=7.6 Hz, 1H), 4.39 (1% ABq, J=17.3 Hz, 1H), 4.03 (s, 3H), 3.96 (1 ABq, J=17.6 Hz, 1H). EXAMPLE 3 Alternative preparation of methyl 4- [3 -(3,5 -dichlorophenyl)-4,4,4-trifluoro- 1 -oxo-2-buten- 1 yl]- 1 -naphthalenecarboxylate 35 A solution of 1-(3,5-dichlorophenyl)-2,2,2-trifluoroethanone (1.42 g, 5.84 mmol) in N,N-dimethylformamide (5.5 mL) was added to calcium hydride (0.280 g, 6.66 mmol). A solution of methyl 4-acetyl-1-naphthalenecarboxylate (1.34 g, 5.88 mmol) in WO 2009/126668 PCT/US2009/039832 50 N,N-dimethylformamide (5.5 mL) was added to the mixture. The mixture was warmed to 45-50 'C for 8 h. The mixture was cooled to room temperature overnight. After a further 4 h at 60 'C the mixture was cooled to room temperature and was added dropwise to hydrochloric acid (1 N, 100 mL). The mixture was extracted with ethyl acetate (2 x 100 5 mL), and the combined extracts were dried and evaporated to give the product (2.7 g, 102% yield), which contained a little NN-dimethylformamide. The 1 H NMR spectrum of the major isomer was recorded as follows. 1 H NMR (CDCl 3 ) 8.78-8.75 (m, 1H), 8.33-8.30 (m, 1H), 8.02 (d, J=7.7 Hz, 1H), 7.66-7.61 (m, 3H), 7.34 (s, 1H), 7.07-7.04 (m, 1H), 6.94 (d, J=2 Hz, 2H) 4.03 (s, 3H). 10 EXAMPLE 4 Preparation of 2-chloro-6-iodo-4-(trifluoromethyl)benzenamine Iodine monochloride (17.2 g, 108 mmol) in hydrochloric acid (36%, 21.4 g) and water (35 mL) was added dropwise to 2-chloro-4-(trifluoromethyl)benzenamine (20.0 g, 102 mmol) in hydrochloric acid (36%, 20.7 g) and water (140 mL). The mixture was warmed to 15 50 'C for a total of 8 h. Sodium hydroxide (50%, 33.5 g, 419 mmol) was added to the mixture at room temperature. The mixture was extracted with dichloromethane (2 x 250 mL), and the extracts were dried and evaporated to give the product as an oil (31.83 g, 97% yield). 1 H NMR (CDCl 3 ) 7.78 (s, 1H), 7.5 (s, 1H), 4.87 (br s, 2H). 20 EXAMPLE 5 Preparation of 1-chloro-3-iodo-5-(trifluoromethyl)benzene 2-Chloro-6-iodo-4-(trifluoromethyl)benzenamine (i.e. the product of Example 4) (31.8 g, 98.9 mmol) was added to hydrochloric acid (36%, 190 mL) and the mixture was warmed to 55-60 'C for 20 min. The mixture was cooled to 0 'C. Sodium nitrite (13.6 g, 197 mmol) 25 in water (36 mL) was added over 30 min. When the addition was complete the mixture was stirred at 0-5 'C for 70 min. Hypophosphorous acid (50%, 36.5 mL, 351 mmol) was added dropwise at 5-10 'C over 40 min. When the addition was complete the mixture spontaneously warmed briefly to 35 'C, and was then cooled to 10-20 'C. After stirring at 10-20 'C for 2 h, the mixture was stored in a refrigerator overnight. Then thee mixture was 30 warmed to room temperature and was stirred for 1 h. The mixture was diluted with water (400 mL) and extracted with ether (2 x 250 mL). The combined extracts were dried and evaporated. Distillation gave the product as an oil (19.93 g, 66% yield), b.p. 98-112 'C at 2.0 kPa. 1 H NMR (CDCl 3 ) 7.89 (s, 1H), 7.84 (s, 1H), 7.58 (s, 1H).
WO 2009/126668 PCT/US2009/039832 51 EXAMPLE 6 Preparation of 1-[3-chloro-5-(trifluoromethyl)phenyl]-2,2,2-trifluoroethanone A tetrahydrofuran solution of isopropylmagnesium chloride (2 M, 36.0 mL, 71.8 mmol) was added dropwise to a solution of 1-chloro-3-iodo-5-(trifluoromethyl)benzene (i.e. 5 the product of Example 5) (20.0 g, 65.3 mmol) in tetrahydrofuran (30 mL) at -5 'C. The mixture was stirred for 1 h at 0-5 'C. Methyl trifluoroacetate (10.0 g, 78.1 mmol) was added dropwise to the mixture while maintaining the temperature 0-5 'C. When the addition was complete the mixture was stirred for 90 min. Hydrochloric acid (1 N, 100 mL) was added dropwise to the mixture at 0-5 'C. When 10 the addition was complete the mixture was extracted with ether (2 x 100 mL). The combined extracts were dried and evaporated. The oil was dissolved in toluene (55 mL), and p-toluenesulfonic acid monohydrate (0.100 g, 0.525 mmol) was added to the mixture. The mixture was boiled for 30 min, and the water/toluene methanol/toluene azeotropes were removed by distillation at atmospheric pressure. The distillation was 15 continued at reduced pressure to give the product as an oil (12.4 g, 69% yield), b.p. 93 103 'C at 6.7 kPa. 1H NMR (CDCl 3 ) 8.21-8.19 (m, 2H), 7.95 (s, 1H). EXAMPLE 7 Preparation of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3 20 isoxazolyl]-N-[2-oxo-2- [(2,2,2-trifluoroethyl)amino] ethyl] -1 naphthalenecarboxamide Step A: Preparation of 4-acetyl-1-naphthalenecarbonyl chloride Thionyl chloride (35.00 g, 0.29 mol) was added to a solution of 4-acetyl-1 naphthalenecarboxylic acid (51.70 g, 0.24 mol) in toluene (350 mL). The mixture was 25 warmed to 90 0 C for 8.5 h. After cooling to 25 0 C, the solvent was removed under reduced pressure to give the title product as an off-white solid (55.1 g, 98.7% yield). IR (nujol) 1758, 1681, 1515, 1352, 1282, 1245,1218, 1190, 1117, 1053, 923, 762 cm- 1 . 1 H NMR (CDCl 3 ): 8.72-8.69 (m, 1H), 8.50 (d, J=7.6 Hz, 1H), 8.44-8.41 (m, 1H), 7.82 (d, J=7.9 Hz, 1H), 7.76-7.65 (m, 2H), 2.77 (s, 3H). 30 Step B: Preparation of 4-acetyl-N-[2-oxo-2- [(2,2,2-trifluoroethyl)amino] ethyl] -1 naphthalenecarboxamide A solution of 2-amino-N-(2,2,2-trifluoroethyl)acetamide (21.90 g, 0.14 mol) in 1,2 dichloroethane (80 mL) was added dropwise over 15 min to a solution of the product of Example 7, Step A (32.50 g, 0.14 mol) in 1,2-dichloroethane (160 mL) at a temperature of 35 25 to 30 0 C. The resulting mixture was further stirred for 10 min at 25 0 C. A solution of triethylamine (14.20 g, 0.14 mol) in 1,2-dichloroethane (80 mL) was then added dropwise over 44 min at 25 0 C, and the mixture was stirred further for 20 min at 25 0 C. The solvent was removed under reduced pressure, and the residue was dissolved in hot acetonitrile (50 WO 2009/126668 PCT/US2009/039832 52 mL). The mixture was then cooled to 25 0 C, and water (40 mL) was added dropwise. The mixture was further cooled to 0 0 C and filtered. The isolated solid was washed with water (100 mL) and dried overnight in a vacuum oven (approximately 16-33 kPa at 50 0 C) to provide the title product as an off-white solid (37 g, 75% yield) melting at 169-169 0 C. 5 IR (nujol) 3303, 3233, 3072, 1698, 1683, 1636, 1572, 1548, 1447, 1279, 1241, 1186, 1159 cm- 1 . 1 H NMR (CD 3
S(=O)CD
3 ): 8.95 (t, J=5.8 Hz, 1H), 8.72 (t, J=6.5 Hz, 1H), 8.55 (dd, J=6.5, 2 Hz, 1H), 8.37-8.33 (m, 1H), 8.13 (d, J=7.3 Hz, 1H), 7.70-7.60 (m, 3H), 4.07-3.95 (m, 4H), 2.75 (s, 3H). 10 Step C: Preparation of 4-[3-[3-chloro-5-(trifluoromethyl)phenyl]-4,4,4-trifluoro-1 oxo-2-buten- 1 -yl]-N- [2-oxo-2-[(2,2,2-trifluoroethyl)amino] ethyl] -1 naphthalenecarboxamide A mixture of the product of Example 7, Step B (10.00 g, 28.38 mmol), 1-[3-chloro-5 (trifluoromethyl)phenyl]-2,2,2-trifluoroethanone (9.00 g, 32.5 mmol), calcium hydroxide 15 (1.05 g, 14.2 mmol), NN-dimethylformamide (20 mL) and tert-butyl methyl ether (32 mL) was placed in a thermometer-equipped reaction vessel. The reaction vessel was connected to a ten-plate Oldershaw column, the output of which was condensed and fed into a decanter initially filled with tert-butyl methyl ether. A nitrogen atmosphere was maintained in the apparatus. The upper part of the decanter was connected to return condensate to the fifth 20 plate of the Oldershaw column. This arrangement ensured that wet (containing dissolved water) tert-butyl methyl ether was not returned from the decanter to the reaction vessel. A drain valve at the bottom of the decanter allowed removing tert-butyl methyl ether in addition to water from the decanter. The reaction mixture was heated to distill the tert-butyl methyl ether/water azeotrope. As the decanter trap contained an amount of tert-butyl methyl 25 ether sufficient to dissolve all of the water formed by the reaction, the condensate in the trap did not separate into layers containing predominately water and predominately tert-butyl methyl ether. Because the reaction mixture initially contained mostly tert-butyl methyl ether, the mixture boiled at a temperature not much exceeding the normal boiling point of tert-butyl methyl ether (e.g., about 65-70 C). The reaction proceeded relatively slowly at 30 this temperature, so condensate was gradually drained from the decanter trap to remove tert butyl methyl ether. As the concentration of tert-butyl methyl ether decreased in the reaction mixture, the temperature of the boiling reaction mixture increased. Tert-butyl methyl ether was removed by draining the decanter until the temperature of the boiling reaction mixture reached about 85 'C. To maintain this temperature, tert-butyl methyl ether was added as 35 needed to compensate for loss of solvent from the apparatus. The total time from the start of heating the reaction mixture to stopping distillation, not including a shutdown period overnight, was about 6 h.
WO 2009/126668 PCT/US2009/039832 53 To isolate the product, the mixture was cooled to room temperature and then added to a mixture of tert-butyl methyl ether (50 mL) and 1 N hydrochloric acid (100 mL). The organic phase was separated, and heptane (60 mL) was added dropwise. The mixture was filtered to provide the title product as an off-white solid mixture of isomers (14 g, 810% yield) 5 melting at 174.5-177 'C. IR (nujol) 3294, 1697, 1674, 1641, 1541, 1441, 1364, 1313, 1275, 1246, 1163, 1104 cm- 1 . 1 H NMR (CD 3
S(=O)CD
3 ): (major isomer) 8.91 (t , J=6.2 Hz, 1H), 8.73 (t, J=6.4 Hz, 1H), 8.44-8.30 (m, 2H), 8.18 (d, J=7.7 Hz, 1H), 7.97-7.61 (m, 7H), 4.06-3.95 (m, 4H). Step D: Preparation of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5 10 (trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2 trifluoroethyl)amino] ethyl]- 1 -naphthalenecarboxamide Aqueous sodium hydroxide (50%, 3.04 g, 38.0 mmol) was added dropwise to a stirred solution of hydroxylamine sulfate (1.48 g, 9.02 mmol) in water (28 mL) at 25 0 C. After this addition was complete the product of Example 7, Step C (10.00 g, 16.33 mmol) in 15 tetrahydrofuran (60 mL) was added dropwise over 40 min. After the addition was complete the mixture was stirred further for 30 min. The solvent was removed under reduced pressure and 1 N hydrochloric acid (100 mL) was added. The mixture was extracted with ether (2 x 100 mL), and the combined extracts were dried and evaporated. The residue was dissolved in acetonitrile (30 mL), cooled to 0 0 C, and filtered to afford the title product as a white solid 20 (7.84 g, 77% yield) melting at 107-108.5 0 C (after recrystallisation from acetonitrile). IR (nujol) 3312, 1681, 1642, 1536, 1328, 1304, 1271, 1237, 1173, 1116 cm- 1 . 1 H NMR (CD 3
S(=O)CD
3 ): 8.98 (t, J=5.8 Hz, 1H), 8.82 (d, J=7.4 Hz, 1H), 8.74 (t, J=6.5 Hz, 1H), 8.40 (d, J=9.7 Hz, 1H), 8.09 (d, J=15.3 Hz, 2H), 7.93 (d, J=7.6 Hz, 2H), 7.75-7.04 (m, 3H), 4.63 (s, 2H), 4.07-3.96 (4H, m). 25 EXAMPLE 7A Alternative Preparation of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5 (trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2 trifluoroethyl)amino] ethyl]- 1 -naphthalenecarboxamide Step A: Preparation of 4-[3-[3-chloro-5-(trifluoromethyl)phenyl]-4,4,4-trifluoro-1 30 oxo-2-buten- 1 -yl]-N- [2-oxo-2-[(2,2,2-trifluoroethyl)amino] ethyl] -1 naphthalenecarboxamide A mixture of 4-acetyl-N- [2-oxo-2- [(2,2,2-trifluoroethyl)amino] ethyl] -1 naphthalenecarboxamide (100.00 g, 267.23 mmol), 1-[3-chloro-5-(trifluoromethyl)phenyl] 2,2,2-trifluoroethanone (86.92 g, 288.6 mmol) and acetonitrile (500 mL) was placed in a 35 thermometer-equipped reaction vessel. The reaction vessel was connected to a ten-plate Oldershaw column. A nitrogen atmosphere was maintained in the apparatus. The mixture was heated to boiling, at which time the temperature of the top of the column was 82 'C. Potassium carbonate was added to the reaction mixture portionwise to control the rate of WO 2009/126668 PCT/US2009/039832 54 reaction. Initially, 0.40 g of potassium carbonate was added, followed sequentially by individual 0.1 g additions 30, 60, 120 and 180 minutes, and 0.40 g additions 240 and 300 minutes after the initial addition of potassium carbonate. Prior to addition to the reaction mixture, the potassium carbonate was slurried in a small amount of acetonitrile 5 (approximately 3 mL of acetonitrile was used to slurry the 0.40 g quantities of potassium carbonate, and approximately 2 mL of acetonitrile was used to slurry the 0.1 g quantities of potassium carbonate). The acetonitrile/water azeotrope (bp 76.5 C) was continuously removed from the top of the column as it was formed. After the final potassium carbonate addition the mixture was boiled for a further 60 minutes. After a total time of 6 h from the 10 initial addition of potassium carbonate, more acetonitrile was removed by distillation until a total of 265 mL of acetonitrile and acetonitrile/water azeotrope had been removed. The mixture was cooled to 25 'C, and water (48 mL) was added to the mixture. The mixture was cooled to 0 'C over 30 minutes, held at this temperature for 60 minutes, and then filtered. The isolated solid was washed with acetonitrile:water (96 mL, 26:5 acetonitrile:water). 15 The product was dried in a vacuum oven (approximately 16-33 kPa at 55 0 C) overnight to give the product as an off-white solid (150.51 g as a mixture of isomers, 92.2% yield). The 1 H NMR spectrum of the major isomer was identical to the spectrum of the material prepared in Example 7, Step C. 20 Step B: Preparation of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5 (trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2 trifluoroethyl)amino] ethyl]- 1 -naphthalenecarboxamide A solution of sodium hydroxide (15.10 g of a 50% aqueous solution, 0.19 mmol) in water (total volume 67.5 mL) and a solution of hydroxylamine sulfate (7.75 g, 47.3 mmol) in 25 water (total volume 67.5 mL) were added simultaneously to the product of Example 7A, Step A (51.90 g, 81.78 mmol) in tetrahydrofuran (300 mL) at 25 'C over 75 minutes. After the addition was complete, the mixture was stirred further for 180 minutes. The mixture was acidified to approximately pH 3 by addition of hydrochloric acid (concentrated, approximately 11 g). The aqueous layer was removed, and the remaining organic solution 30 was heated to boiling. Acetonitrile was added, and the acetonitrile/tetrahydrofuran distillate was removed until the distillate temperature reached 82 'C, indicating that all of the tetrahydrofuran had been removed. The mixture was allowed to cool to 25 'C, and the acetonitrile was removed under reduced pressure. The residue was dissolved in acetonitrile (200 mL), cooled to 0 'C, and the resulting mixture was filtered to afford the title product as 35 a white solid (43.45 g, 84% yield). The 1 H NMR spectrum of the product was identical to the spectrum of the material prepared in Example 7, Step D.
WO 2009/126668 PCT/US2009/039832 55 EXAMPLE 7B Alternative Preparation of 4-[3-[3-chloro-5-(trifluoromethyl)phenyl]-4,4,4-trifluoro-1 oxo-2-buten- 1 -yl]-N- [2-oxo-2-[(2,2,2-trifluoroethyl)amino] ethyl] -1 naphthalenecarboxamide 5 A mixture of 4-acetyl-N- [2-oxo-2- [(2,2,2-trifluoroethyl)amino] ethyl] -1 naphthalenecarboxamide (50.00 g, 135.1 mmol), 1-[3-chloro-5-(trifluoromethyl)phenyl] 2,2,2-trifluoroethanone (43.93 g, 145.8 mmol) and acetonitrile (250 mL) was placed in a thermometer-equipped reaction vessel. The reaction vessel was connected to a ten-plate Oldershaw column. A nitrogen atmosphere was maintained in the apparatus. The mixture 10 was heated to boiling, at which time the temperature of the top of the column was 82 'C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) was added to the reaction mixture portionwise to control the rate of reaction. Initially, 0.20 g of DBU was added, followed sequentially by individual 0.052 g additions 30, 90, 150 and 210 minutes, and 0.20 g additions 270 and 330 minutes after the initial addition of DBU. Each individual DBU portion was diluted with 15 acetonitrile (2 mL) prior to addition to the reaction mixture. The acetonitrile/water azeotrope (bp 76.5 C) was continously removed from the top of the column as it was formed. After the final DBU addition the mixture was boiled for a further 60 minutes. After a total time of 6 h from the initial addition of DBU, more acetonitrile was removed by distillation until a total of 138 mL of acetonitrile and acetonitrile/water azeotrope had been removed. The 20 mixture was cooled to 25 'C, and water (24 mL) was added to the mixture. The mixture was cooled to 0 'C over 30 minutes, held at this temperature for 60 minutes, and then filtered. The isolated solid was washed with acetonitrile:water (48 mL, 26:5 acetonitrile:water). The product was dried in a vacuum oven (approximately 16-33 kPa at 55 0 C) overnight to give the product as an off-white solid (76.0 g as a mixture of isomers, 92.0% 25 yield). The 1 H NMR spectrum of the major isomer was identical to the spectrum of the material prepared in Example 7, Step C. EXAMPLE 8 Preparation of methyl 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5 30 (trifluoromethyl)-3-isoxazolyl]-1-naphthalenecarboxylate Step A: Preparation of methyl 4-[3-[3-chloro-5-(trifluoromethyl)phenyl]-4,4,4 trifluoro-1-oxo-2-buten-1-yl]-1-naphthalenecarboxylate A mixture of methyl 4-acetyl-1-naphthalenecarboxylate (7.83 g, 34.3 mmol), 1-[3 chloro-5-(trifluoromethyl)phenyl]-2,2,2-trifluoroethanone (10.43 g, 37.71 mmol), calcium 35 hydroxide (1.25 g, 16.9 mmol), NN-dimethylformamide (27 mL) and tert-butyl methyl ether (44 mL) was heated to reflux. The tert-butyl methyl ether/water azeotrope was removed as described in Example 7, Step C. As the decanter trap contained an amount of tert-butyl WO 2009/126668 PCT/US2009/039832 56 methyl ether sufficient to dissolve all of the water formed by the reaction, the condensate in the trap did not separate into layers containing predominately water and predominately tert butyl methyl ether. Tert-butyl methyl ether was removed by gradually draining the decanter trap until the reaction temperature was 85 'C. To maintain this temperature, tert-butyl 5 methyl ether was added as needed to compensate for loss of solvent from the apparatus. The total time from the start of heating the reaction mixture to stopping distillation was about 4.5 h. The mixture was cooled to 25 'C and poured into a mixture of 0.5 N hydrochloric acid (100 mL) and tert-butyl methyl ether (50 mL). The mixture was acidified with 10 concentrated hydrochloric acid and evaporated, and the residue was crystallized from hexanes (40 mL) to give the title product as a yellow solid (13.24 g, 79% yield) melting at 90-90.5 'C (after recrystallization from hexanes). IR (nujol) 3071, 1721, 1710, 1671, 1516, 1439, 1316, 1280, 1252, 1178, 1129, 1103, 1026, 888, 861 cm- 1 . 15 1 H NMR (CDCl 3 ): 8.77-8.73 (m, 1H), 8.28-8.25 (m, 1H), 8.0 (d, J= 7.6 Hz, 1H), 7.67-7.60 (m, 3H), 7.40 (d, J= 1.4 Hz, 1H), 7.32 (s, 1H), 7.23 (s, 1H), 7.20 (s, 1H), 4.02 (s, 3H). Step B: Preparation of methyl 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro 5-(trifluoromethyl)-3-isoxazolyl]-1-naphthalenecarboxylate Aqueous sodium hydroxide (50%, 2.08 g, 25.5 mmol) was added dropwise to a stirred 20 solution of hydroxylamine sulfate (1.07 g, 6.52 mmol) in water (20 mL) at 25 0 C. After this addition was complete the product of Example 8, Step A (5 g, 10.27 mmol) in tetrahydrofuran (20 mL) was added dropwise over 40 min. After the addition was complete the mixture was stirred further for 30 min. The organic phase was separated and added to hydrochloric acid (100 mL). The mixture was extracted with ethyl acetate (2 x 20 mL). The 25 organic solvent was evaporated under reduced pressure. The residue was redissolved in acetic acid (16 mL) and then warmed to 100 'C. Water (2 mL) was added dropwise, and the mixture was cooled to 50 0 C. The mixture was seeded with a small amount of previously prepared methyl 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl) 3-isoxazolyl]-1-naphthalenecarboxylate and then cooled to 25 'C. Water (2 mL) was added 30 and the mixture was cooled to 0 'C. The mixture was filtered, and the solid was washed with acetic acid:water (8 mL:2 mL). The solid was dried in a vacuum oven to give the title product as a white solid (3.91 g, 76% yield) melting at 111.5-112 0 C (after recrystallisation from acetonitrile). IR (nujol) 1716, 1328, 1306, 1287, 1253, 1242, 1197, 1173, 1137, 1114, 1028, 771 cm- 1 . 35 1 H NMR (CDCl 3 ): 8.90-8.87 (m, 1H), 8.82-8.79 (m, 1H), 8.10 (d, J=7.7 Hz), 7.87 (s, 1H), 7.81 (s, 1H), 7.72-7.67 (m, 3H) 7.55 (d, J=7.6 Hz, 1H), 4.34 (1/2 ABq, J=17.3 Hz, 1H), 4.03 (s, 3H), 3.93 (1/2 ABq, J=17.3 Hz, 1H).
WO 2009/126668 PCT/US2009/039832 57 The following Tables 1-8 identify specific combinations of reactants, intermediates and products illustrating the methods of the present invention. These tables specifically disclose compounds as well as particular transformations. In these tables: Et means ethyl, Me means methyl, CN means cyano, Ph means phenyl, Py means pyridinyl, c-Pr means 5 cyclopropyl, i-Pr means isopropyl, n-Pr means normal propyl, s-Bu means secondary butyl, t-Bu means tertiary butyl, SMe means methylthio, S(0)2 means sulfonyl and Thz means thiazole. Concatenations of groups are abbreviated similarly; for example, "S(0) 2 Me" means methylsulfonyl. Tables 1-6 relate to the method of Scheme 1 converting compounds of Formulae 2 and 10 3 to corresponding compounds of Formula 1. This transformation is believed to occur through the intermediacy of compounds of Formula 11.
F
3 C O M(OH) 2
F
3 C O M(OH) 2 F + H 3 C 4 Q4 Z Azeotropic z 2 3 water removal 1 In the example transformations embodied in Tables 1-6, M is Ca, and water is distilled as an azeotrope from a reaction mixture comprising NN-dimethylformamide as the polar aprotic 15 solvent and tert-butyl methyl ether as the aprotic solvent capable of forming a low-boiling azeotrope with water. TABLE 1
R
2 a Z is /; and Q is H R2bII R2c '1N , 5
R
2 R 0
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Cl H Cl CH 2
CH
3
CF
3 H Cl CH 2
CH
3 Cl H Cl CH 2 -i-Pr CF 3 H Cl CH 2 -i-Pr Cl H Cl CH 2
CH
2 C1 CF 3 H Cl CH 2
CH
2 C1 Cl H Cl CH 2
CH
2 OH CF 3 H Cl CH 2
CH
2 OH Cl H Cl CH(Me)CH 2 OH CF 3 H Cl CH(Me)CH 2 OH Cl H Cl CH 2 CH(Me)OH CF 3 H Cl CH 2 CH(Me)OH Cl H Cl CH 2 C(Me) 2 0H CF 3 H Cl CH 2 C(Me) 2 0H Cl H Cl CH 2
CH
2
CH
2 OH CF 3 H Cl CH 2
CH
2
CH
2
OH
WO 2009/126668 PCT/US2009/039832 58
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Cl H Cl CH 2 C(Me) 2
CH
2 OH CF 3 H Cl CH 2 C(Me) 2
CH
2 OH Cl H Cl CH 2
CH
2 CH(Me)OH CF 3 H Cl CH 2
CH
2 CH(Me)OH Cl H Cl CH 2 C(=O)N(H)Et CF 3 H Cl CH 2 C(=O)N(H)Et Cl H Cl CH 2 C(=O)N(H)-i-Pr CF 3 H Cl CH 2 C(=O)N(H)-i-Pr Cl H Cl CH 2
C(=O)N(H)CH
2 -i-Pr CF 3 H Cl CH 2
C(=O)N(H)CH
2 -i-Pr Cl H Cl CH(Me)C(=O)N(H)CH 2 -i-Pr CF 3 H Cl CH(Me)C(=O)N(H)CH 2 -i-Pr Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2 C CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 C Cl H Cl CH(Me)C(=O)N(H)CH 2
CH
2 C CF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 C Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2 F CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 F Cl H Cl CH(Me)C(=O)N(H)CH 2
CH
2 F CF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 F Cl H Cl CH 2
CF
3
CF
3 H Cl CH 2
CF
3 Cl H Cl CH 2 -(2-Py) CF 3 H Cl CH 2 -(2-Py) Cl H Cl CH 2 -(4-Thz) CF 3 H Cl CH 2 -(4-Thz) Cl H Cl CH 2 -c-Pr CF 3 H Cl CH 2 -c-Pr Cl H Cl CH 2
CH
2 SMe CF 3 H Cl CH 2
CH
2 SMe Cl H Cl CH(Me)CH 2 SMe CF 3 H Cl CH(Me)CH 2 SMe Cl H Cl CH 2
CH
2
CH
2 SMe CF 3 H Cl CH 2
CH
2
CH
2 SMe Cl H Cl CH 2
CH
2 S(=O)Me CF 3 H Cl CH 2
CH
2 S(=O)Me Cl H Cl CH(Me)CH 2 S(=O)Me CF 3 H Cl CH(Me)CH 2 S(=O)Me Cl H Cl CH 2
CH
2
CH
2 S(=O)Me CF 3 H Cl CH 2
CH
2
CH
2 S(=O)Me Cl H Cl CH 2
CH
2
S(O)
2 Me CF 3 H Cl CH 2
CH
2
S(O)
2 Me Cl H Cl CH(Me)CH 2
S(O)
2 Me CF 3 H Cl CH(Me)CH 2
S(O)
2 Me Cl H Cl CH 2
CH
2
CH
2
S(O)
2 Me CF 3 H Cl CH 2
CH
2
CH
2
S(O)
2 Me Cl H Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H Cl CH 2
C(=O)N(H)CH
2
CF
3 Cl H Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H Cl CH(Me)C(=O)N(H)CH 2
CF
3 Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me Br H Br CH 2
CH
3
CF
3 H CF 3
CH
2
CH
3 Br H Br CH 2 -i-Pr CF 3 H CF 3
CH
2 -i-Pr Br H Br CH 2
CH
2 C1 CF 3 H CF 3
CH
2
CH
2 C1 Br H Br CH 2
CH
2 OH CF 3 H CF 3
CH
2
CH
2 OH Br H Br CH(Me)CH 2 OH CF 3 H CF 3 CH(Me)CH 2 OH Br H Br CH 2 CH(Me)OH CF 3 H CF 3
CH
2 CH(Me)OH Br H Br CH 2 C(Me) 2 0H CF 3 H CF 3
CH
2 C(Me) 2 0H Br H Br CH 2
CH
2
CH
2 OH CF 3 H CF 3
CH
2
CH
2
CH
2
OH
WO 2009/126668 PCT/US2009/039832 59
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Br H Br CH 2 C(Me) 2
CH
2 OH CF 3 H CF 3
CH
2 C(Me) 2
CH
2 OH Br H Br CH 2
CH
2 CH(Me)OH CF 3 H CF 3
CH
2
CH
2 CH(Me)OH Br H Br CH 2 C(=O)N(H)Et CF 3 H CF 3
CH
2 C(=0)N(H)Et Br H Br CH 2 C(=O)N(H)-i-Pr CF 3 H CF 3
CH
2 C(=O)N(H)-i-Pr Br H Br CH 2
C(=O)N(H)CH
2 -i-Pr CF 3 H CF 3
CH
2
C(=O)N(H)CH
2 -i-Pr Br H Br CH(Me)C(=O)N(H)CH 2 -i-Pr CF 3 H CF 3 CH(Me)C(=O)N(H)CH 2 -i-Pr Br H Br CH 2
C(=O)N(H)CH
2
CH
2 C1 CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2 C Br H Br CH(Me)C(=O)N(H)CH 2
CH
2 C1 CF 3 H CF 3 CH(Me)C(=O)N(H)CH 2
CH
2 C Br H Br CH 2
C(=O)N(H)CH
2
CH
2 F CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2 F Br H Br CH(Me)C(=O)N(H)CH 2
CH
2 F CF 3 H CF 3 CH(Me)C(=O)N(H)CH 2
CH
2 F Br H Br CH 2
CF
3
CF
3 H CF 3
CH
2
CF
3 Br H Br CH 2 -(2-Py) CF 3 H CF 3
CH
2 -(2-Py) Br H Br CH 2 -(4-Thz) CF 3 H CF 3
CH
2 -(4-Thz) Br H Br CH 2 -c-Pr CF 3 H CF 3
CH
2 -c-Pr Br H Br CH 2
CH
2 SMe CF 3 H CF 3
CH
2
CH
2 SMe Br H Br CH(Me)CH 2 SMe CF 3 H CF 3 CH(Me)CH 2 SMe Br H Br CH 2
CH
2
CH
2 SMe CF 3 H CF 3
CH
2
CH
2
CH
2 SMe Br H Br CH 2
CH
2 S(=O)Me CF 3 H CF 3
CH
2
CH
2 S(=0)Me Br H Br CH(Me)CH 2 S(=O)Me CF 3 H CF 3 CH(Me)CH 2 S(=0)Me Br H Br CH 2
CH
2
CH
2 S(=O)Me CF 3 H CF 3
CH
2
CH
2
CH
2 S(=0)Me Br H Br CH 2
CH
2
S(O)
2 Me CF 3 H CF 3
CH
2
CH
2
S(O)
2 Me Br H Br CH(Me)CH 2
S(O)
2 Me CF 3 H CF 3 CH(Me)CH 2
S(O)
2 Me Br H Br CH 2
CH
2
CH
2
S(O)
2 Me CF 3 H CF 3
CH
2
CH
2
CH
2
S(O)
2 Me Br H Br CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H CF 3
CH
2 C(=0)N(H)CH 2
CF
3 Br H Br CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H CF 3 CH(Me)C(=O)N(H)CH 2
CF
3 Br H Br CH 2
C(=O)N(H)CH
2
CH
2 SMe CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2 SMe Br H Br CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2
S(O)
2 Me
CF
3 H H CH 2
CH
3 Cl Cl Cl CH 2
CH
3
CF
3 H H CH 2 -i-Pr Cl Cl Cl CH 2 -i-Pr
CF
3 H H CH 2
CH
2 C1 Cl Cl Cl CH 2
CH
2 C1
CF
3 H H CH 2
CH
2 OH Cl Cl Cl CH 2
CH
2
OH
WO 2009/126668 PCT/US2009/039832 60
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H H CH(Me)CH 2 OH Cl Cl Cl CH(Me)CH 2 OH
CF
3 H H CH 2 CH(Me)OH Cl Cl Cl CH 2 CH(Me)OH
CF
3 H H CH 2 C(Me) 2 0H Cl Cl Cl CH 2 C(Me) 2 0H
CF
3 H H CH 2
CH
2
CH
2 OH Cl Cl Cl CH 2
CH
2
CH
2 OH
CF
3 H H CH 2 C(Me) 2
CH
2 OH Cl Cl Cl CH 2 C(Me) 2
CH
2 OH
CF
3 H H CH 2
CH
2 CH(Me)OH Cl Cl Cl CH 2
CH
2 CH(Me)OH
CF
3 H H CH 2 C(=O)N(H)Et Cl Cl Cl CH 2 C(=O)N(H)Et
CF
3 H H CH 2 C(=O)N(H)-i-Pr Cl Cl Cl CH 2 C(=O)N(H)-i-Pr
CF
3 H H CH 2
C(=O)N(H)CH
2 -i-Pr Cl Cl Cl CH 2
C(=O)N(H)CH
2 -i-Pr
CF
3 H H CH(Me)C(=O)N(H)CH 2 -i-Pr Cl Cl Cl CH(Me)C(=O)N(H)CH 2 -i-Pr
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2 C1 Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2 C
CF
3 H H CH(Me)C(=O)N(H)CH 2
CH
2 C1 Cl Cl Cl CH(Me)C(=O)N(H)CH 2
CH
2 C
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2 F Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2 F
CF
3 H H CH(Me)C(=O)N(H)CH 2
CH
2 F Cl Cl Cl CH(Me)C(=O)N(H)CH 2
CH
2 F
CF
3 H H CH 2
CF
3 Cl Cl Cl CH 2
CF
3
CF
3 H H CH 2 -(2-Py) Cl Cl Cl CH 2 -(2-Py)
CF
3 H H CH 2 -(4-Thz) Cl Cl Cl CH 2 -(4-Thz)
CF
3 H H CH 2 -c-Pr Cl Cl Cl CH 2 -c-Pr
CF
3 H H CH 2
CH
2 SMe Cl Cl Cl CH 2
CH
2 SMe
CF
3 H H CH(Me)CH 2 SMe Cl Cl Cl CH(Me)CH 2 SMe
CF
3 H H CH 2
CH
2
CH
2 SMe Cl Cl Cl CH 2
CH
2
CH
2 SMe
CF
3 H H CH 2
CH
2 S(=O)Me Cl Cl Cl CH 2
CH
2 S(=O)Me
CF
3 H H CH(Me)CH 2 S(=O)Me Cl Cl Cl CH(Me)CH 2 S(=O)Me
CF
3 H H CH 2
CH
2
CH
2 S(=O)Me Cl Cl Cl CH 2
CH
2
CH
2 S(=O)Me
CF
3 H H CH 2
CH
2
S(O)
2 Me Cl Cl Cl CH 2
CH
2
S(O)
2 Me
CF
3 H H CH(Me)CH 2
S(O)
2 Me Cl Cl Cl CH(Me)CH 2
S(O)
2 Me
CF
3 H H CH 2
CH
2
CH
2
S(O)
2 Me Cl Cl Cl CH 2
CH
2
CH
2
S(O)
2 Me
CF
3 H H CH 2
C(=O)N(H)CH
2
CF
3 Cl Cl Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H H CH(Me)C(=O)N(H)CH 2
CF
3 Cl Cl Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2 SMe Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me WO 2009/126668 PCT/US2009/039832 61
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H F CH 2
CH
3 Cl F Cl CH 2
CH
3
CF
3 H F CH 2 -i-Pr Cl F Cl CH 2 -i-Pr
CF
3 H F CH 2
CH
2 C1 Cl F Cl CH 2
CH
2 C1
CF
3 H F CH 2
CH
2 OH Cl F Cl CH 2
CH
2 OH
CF
3 H F CH(Me)CH 2 OH Cl F Cl CH(Me)CH 2 OH
CF
3 H F CH 2 CH(Me)OH Cl F Cl CH 2 CH(Me)OH
CF
3 H F CH 2 C(Me) 2 0H Cl F Cl CH 2 C(Me) 2 0H
CF
3 H F CH 2
CH
2
CH
2 OH Cl F Cl CH 2
CH
2
CH
2 OH
CF
3 H F CH 2 C(Me) 2
CH
2 OH Cl F Cl CH 2 C(Me) 2
CH
2 OH
CF
3 H F CH 2
CH
2 CH(Me)OH Cl F Cl CH 2
CH
2 CH(Me)OH
CF
3 H F CH 2 C(=O)N(H)Et Cl F Cl CH 2 C(=O)N(H)Et
CF
3 H F CH 2 C(=O)N(H)-i-Pr Cl F Cl CH 2 C(=O)N(H)-i-Pr
CF
3 H F CH 2
C(=O)N(H)CH
2 -i-Pr Cl F Cl CH 2
C(=O)N(H)CH
2 -i-Pr
CF
3 H F CH(Me)C(=O)N(H)CH 2 -i-Pr Cl F Cl CH(Me)C(=O)N(H)CH 2 -i-Pr
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2 C Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2 C1
CF
3 H F CH(Me)C(=O)N(H)CH 2
CH
2 C1 Cl F Cl CH(Me)C(=O)N(H)CH 2
CH
2 C
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2 F Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2 F
CF
3 H F CH(Me)C(=O)N(H)CH 2
CH
2 F Cl F Cl CH(Me)C(=O)N(H)CH 2
CH
2 F
CF
3 H F CH 2
CF
3 Cl F Cl CH 2
CF
3
CF
3 H F CH 2 -(2-Py) Cl F Cl CH 2 -(2-Py)
CF
3 H F CH 2 -(4-Thz) Cl F Cl CH 2 -(4-Thz)
CF
3 H F CH 2 -c-Pr Cl F Cl CH 2 -c-Pr
CF
3 H F CH 2
CH
2 SMe Cl F Cl CH 2
CH
2 SMe
CF
3 H F CH(Me)CH 2 SMe Cl F Cl CH(Me)CH 2 SMe
CF
3 H F CH 2
CH
2
CH
2 SMe Cl F Cl CH 2
CH
2
CH
2 SMe
CF
3 H F CH 2
CH
2 S(=O)Me Cl F Cl CH 2
CH
2 S(=O)Me
CF
3 H F CH(Me)CH 2 S(=O)Me Cl F Cl CH(Me)CH 2 S(=O)Me
CF
3 H F CH 2
CH
2
CH
2 S(=O)Me Cl F Cl CH 2
CH
2
CH
2 S(=O)Me
CF
3 H F CH 2
CH
2
S(O)
2 Me Cl F Cl CH 2
CH
2
S(O)
2 Me
CF
3 H F CH(Me)CH 2
S(O)
2 Me Cl F Cl CH(Me)CH 2
S(O)
2 Me
CF
3 H F CH 2
CH
2
CH
2
S(O)
2 Me Cl F Cl CH 2
CH
2
CH
2
S(O)
2 Me
CF
3 H F CH 2
C(=O)N(H)CH
2
CF
3 Cl F Cl CH 2
C(=O)N(H)CH
2
CF
3 WO 2009/126668 PCT/US2009/039832 62
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H F CH(Me)C(=O)N(H)CH 2
CF
3 Cl F Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2 SMe Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me
CF
3 H Br CH 2
CH
3
OCF
3 H Cl CH 2
CH
3
CF
3 H Br CH 2 -i-Pr OCF 3 H Cl CH 2 -i-Pr
CF
3 H Br CH 2
CH
2 C1 OCF 3 H Cl CH 2
CH
2 C1
CF
3 H Br CH 2
CH
2 OH OCF 3 H Cl CH 2
CH
2 OH
CF
3 H Br CH(Me)CH 2 OH OCF 3 H Cl CH(Me)CH 2 OH
CF
3 H Br CH 2 CH(Me)OH OCF 3 H Cl CH 2 CH(Me)OH
CF
3 H Br CH 2 C(Me) 2 0H OCF 3 H Cl CH 2 C(Me) 2 0H
CF
3 H Br CH 2
CH
2
CH
2 OH OCF 3 H Cl CH 2
CH
2
CH
2 OH
CF
3 H Br CH 2 C(Me) 2
CH
2 OH OCF 3 H Cl CH 2 C(Me) 2
CH
2 OH
CF
3 H Br CH 2
CH
2 CH(Me)OH OCF 3 H Cl CH 2
CH
2 CH(Me)OH
CF
3 H Br CH 2 C(=O)N(H)Et OCF 3 H Cl CH 2 C(=O)N(H)Et
CF
3 H Br CH 2 C(=O)N(H)-i-Pr OCF 3 H Cl CH 2 C(=O)N(H)-i-Pr
CF
3 H Br CH 2
C(=O)N(H)CH
2 -i-Pr OCF 3 H Cl CH 2
C(=O)N(H)CH
2 -i-Pr
CF
3 H Br CH(Me)C(=O)N(H)CH 2 -i-Pr OCF 3 H Cl CH(Me)C(=O)N(H)CH 2 -i-Pr
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2 C1 OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 C1
CF
3 H Br CH(Me)C(=O)N(H)CH 2
CH
2 C1 OCF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 C1
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2 F OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 F
CF
3 H Br CH(Me)C(=O)N(H)CH 2
CH
2 F OCF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 F
CF
3 H Br CH 2
CF
3
OCF
3 H Cl CH 2
CF
3
CF
3 H Br CH 2 -(2-Py) OCF 3 H Cl CH 2 -(2-Py)
CF
3 H Br CH 2 -(4-Thz) OCF 3 H Cl CH 2 -(4-Thz)
CF
3 H Br CH 2 -c-Pr OCF 3 H Cl CH 2 -c-Pr
CF
3 H Br CH 2
CH
2 SMe OCF 3 H Cl CH 2
CH
2 SMe
CF
3 H Br CH(Me)CH 2 SMe OCF 3 H Cl CH(Me)CH 2 SMe
CF
3 H Br CH 2
CH
2
CH
2 SMe OCF 3 H Cl CH 2
CH
2
CH
2 SMe
CF
3 H Br CH 2
CH
2 S(=O)Me OCF 3 H Cl CH 2
CH
2 S(=O)Me
CF
3 H Br CH(Me)CH 2 S(=O)Me OCF 3 H Cl CH(Me)CH 2 S(=O)Me
CF
3 H Br CH 2
CH
2
CH
2 S(=O)Me OCF 3 H Cl CH 2
CH
2
CH
2 S(=O)Me
CF
3 H Br CH 2
CH
2
S(O)
2 Me OCF 3 H Cl CH 2
CH
2
S(O)
2 Me
CF
3 H Br CH(Me)CH 2
S(O)
2 Me OCF 3 H Cl CH(Me)CH 2
S(O)
2 Me
CF
3 H Br CH 2
CH
2
CH
2
S(O)
2 Me OCF 3 H Cl CH 2
CH
2
CH
2
S(O)
2 Me
CF
3 H Br CH 2
C(=O)N(H)CH
2
CF
3
OCF
3 H Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H Br CH(Me)C(=O)N(H)CH 2
CF
3
OCF
3 H Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2 SMe OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe WO 2009/126668 PCT/US2009/039832 63
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me TABLE 2
R
2 a Z is / ; and Q is
R
2 b 5
R
2 c OR 0
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Cl H Cl CH 3
CF
3 H Cl CH 3 Cl H Cl CH 2
CH
3
CF
3 H Cl CH 2
CH
3 Cl H Cl CH 2 -i-Pr CF 3 H Cl CH 2 -i-Pr Cl H Cl n-Pr CF 3 H Cl n-Pr Cl H Cl i-Pr CF 3 H Cl i-Pr Cl H Cl s-Bu CF 3 H Cl s-Bu Cl H Cl t-Bu CF 3 H Cl t-Bu Cl H Cl (CH2) 5
CH
3
CF
3 H Cl (CH2) 5
CH
3 Cl H Cl CH 2 Ph CF 3 H Cl CH 2 Ph Br H Br CH 3
CF
3 H CF 3
CH
3 Br H Br CH 2
CH
3
CF
3 H CF 3
CH
2
CH
3 Br H Br CH 2 -i-Pr CF 3 H CF 3
CH
2 -i-Pr Br H Br n-Pr CF 3 H CF 3 n-Pr Br H Br i-Pr CF 3 H CF 3 i-Pr Br H Br s-Bu CF 3 H CF 3 s-Bu Br H Br t-Bu CF 3 H CF 3 t-Bu Br H Br (CH2) 5
CH
3
CF
3 H CF 3 (CH2) 5
CH
3 Br H Br CH 2 Ph CF 3 H CF 3
CH
2 Ph
CF
3 H H CH 3 Cl Cl Cl CH 3
CF
3 H H CH 2
CH
3 Cl Cl Cl CH 2
CH
3
CF
3 H H CH 2 -i-Pr Cl Cl Cl CH 2 -i-Pr
CF
3 H H n-Pr Cl Cl Cl n-Pr
CF
3 H H i-Pr Cl Cl Cl i-Pr
CF
3 H H s-Bu Cl Cl Cl s-Bu WO 2009/126668 PCT/US2009/039832 64
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H H t-Bu Cl Cl Cl t-Bu
CF
3 H H (CH 2
)
5
CH
3 Cl Cl Cl (CH 2
)
5
CH
3
CF
3 H H CH 2 Ph Cl Cl Cl CH 2 Ph
CF
3 H F CH 3 Cl F Cl CH 3
CF
3 H F CH 2
CH
3 Cl F Cl CH 2
CH
3
CF
3 H F CH 2 -i-Pr Cl F Cl CH 2 -i-Pr
CF
3 H F n-Pr Cl F Cl n-Pr
CF
3 H F i-Pr Cl F Cl i-Pr
CF
3 H F s-Bu Cl F Cl s-Bu
CF
3 H F t-Bu Cl F Cl t-Bu
CF
3 H F (CH 2
)
5
CH
3 Cl F Cl (CH 2
)
5
CH
3
CF
3 H F CH 2 Ph Cl F Cl CH 2 Ph
CF
3 H Br CH 3
OCF
3 H Cl CH 3
CF
3 H Br CH 2
CH
3
OCF
3 H Cl CH 2
CH
3
CF
3 H Br CH 2 -i-Pr OCF 3 H Cl CH 2 -i-Pr
CF
3 H Br n-Pr OCF 3 H Cl n-Pr
CF
3 H Br i-Pr OCF 3 H Cl i-Pr
CF
3 H Br s-Bu OCF 3 H Cl s-Bu
CF
3 H Br t-Bu OCF 3 H Cl t-Bu
CF
3 H Br (CH 2
)
5
CH
3
OCF
3 H Cl (CH 2
)
5
CH
3
CF
3 H Br CH 2 Ph OCF 3 H Cl CH 2 Ph TABLE 3
R
2 a Z is ; and Q is
R
2 b R 2c / 3 R
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3 Cl H Cl Cl CF 3 H Cl Cl Cl H Cl Br CF 3 H Cl Br Cl H Cl I CF 3 H Cl I Cl H Cl OH CF 3 H Cl OH WO 2009/126668 PCT/US2009/039832 65
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3 Cl H Cl OMe CF 3 H Cl OMe Cl H Cl OS(O) 2
CF
3
CF
3 H Cl OS(O) 2
CF
3 Cl H Cl nitro CF 3 H Cl nitro Cl H Cl NH 2
CF
3 H Cl NH 2 Cl H Cl cyano CF 3 H Cl cyano Cl H Cl Me CF 3 H Cl Me Cl H Cl CH 2 C1 CF 3 H Cl CH 2 C1 Cl H Cl CH 2 Br CF 3 H Cl CH 2 Br Cl H Cl CH 2 OH CF 3 H Cl CH 2 OH Cl H Cl CH 2 OC(O)Me CF 3 H Cl CH 2 OC(O)Me Cl H Cl CO 2 H CF 3 H Cl CO 2 H Cl H Cl n-Pr CF 3 H Cl n-Pr Br H Br Cl CF 3 H CF 3 Cl Br H Br Br CF 3 H CF 3 Br Br H Br
CF
3 H CF 3 I Br H Br OH CF 3 H CF 3 OH Br H Br OMe CF 3 H CF 3 OMe Br H Br OS(O) 2
CF
3
CF
3 H CF 3
OS(O)
2
CF
3 Br H Br nitro CF 3 H CF 3 nitro Br H Br
NH
2 CF 3 H CF 3 NH 2 Br H Br cyano CF 3 H CF 3 cyano Br H Br Me CF 3 H CF 3 Me Br H Br CH 2 C1 CF 3 H CF 3
CH
2 C1 Br H Br CH 2 Br CF 3 H CF 3
CH
2 Br Br H Br CH 2 OH CF 3 H CF 3
CH
2 OH Br H Br CH 2 OC(O)Me CF 3 H CF 3
CH
2 OC(O)Me Br H Br CO 2 H CF 3 H CF 3
CO
2 H Br H Br n-Pr CF 3 H CF 3 n-Pr
CF
3 H H Cl Cl Cl Cl Cl
CF
3 H H Br Cl Cl Cl Br
CF
3 H H I Cl Cl Cl I
CF
3 H H OH Cl Cl Cl OH
CF
3 H H OMe Cl Cl Cl OMe
CF
3 H H OS(O) 2
CF
3 Cl Cl Cl OS(O) 2
CF
3
CF
3 H H nitro Cl Cl Cl nitro WO 2009/126668 PCT/US2009/039832 66
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3
CF
3 H H NH 2 Cl Cl Cl NH 2
CF
3 H H cyano Cl Cl Cl cyano
CF
3 H H Me Cl Cl Cl Me
CF
3 H H CH 2 C1 Cl Cl Cl CH 2 C1
CF
3 H H CH 2 Br Cl Cl Cl CH 2 Br
CF
3 H H CH 2 OH Cl Cl Cl CH 2 OH
CF
3 H H CH 2 OC(O)Me Cl Cl Cl CH 2 OC(O)Me
CF
3 H H CO 2 H Cl Cl Cl CO 2 H
CF
3 H H n-Pr Cl Cl Cl n-Pr
CF
3 H F Cl Cl F Cl Cl
CF
3 H F Br Cl F Cl Br
CF
3 H F I Cl F Cl I
CF
3 H F OH Cl F Cl OH
CF
3 H F OMe Cl F Cl OMe
CF
3 H F OS(O) 2
CF
3 Cl F Cl OS(O) 2
CF
3
CF
3 H F nitro Cl F Cl nitro
CF
3 H F NH 2 Cl F Cl NH 2
CF
3 H F cyano Cl F Cl cyano
CF
3 H F Me Cl F Cl Me
CF
3 H F CH 2 C1 Cl F Cl CH 2 C1
CF
3 H F CH 2 Br Cl F Cl CH 2 Br
CF
3 H F CH 2 OH Cl F Cl CH 2 OH
CF
3 H F CH 2 OC(O)Me Cl F Cl CH 2 OC(O)Me
CF
3 H F CO 2 H Cl F Cl CO 2 H
CF
3 H F n-Pr Cl F Cl n-Pr
CF
3 H Br Cl OCF 3 H Cl Cl
CF
3 H Br Br OCF 3 H Cl Br
CF
3 H Br I OCF 3 H Cl I
CF
3 H Br OH OCF 3 H Cl OH
CF
3 H Br OMe OCF 3 H Cl OMe
CF
3 H Br OS(O) 2
CF
3
OCF
3 H Cl OS(O) 2
CF
3
CF
3 H Br nitro OCF 3 H Cl nitro
CF
3 H Br NH 2
OCF
3 H Cl NH 2
CF
3 H Br cyano OCF 3 H Cl cyano
CF
3 H Br Me OCF 3 H Cl Me
CF
3 H Br CH 2 C1 OCF 3 H Cl CH 2 C1
CF
3 H Br CH 2 Br OCF 3 H Cl CH 2 Br WO 2009/126668 PCT/US2009/039832 67
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3
CF
3 H Br CH 2 OH OCF 3 H Cl CH 2 OH
CF
3 H Br CH 2 OC(O)Me OCF 3 H Cl CH 2 OC(O)Me
CF
3 H Br CO 2 H OCF 3 H Cl CO 2 H
CF
3 H Br n-Pr OCF 3 H Cl n-Pr TABLE 4
R
2 a Z is / ; and Qis N
R
2 b R 2 c R N
R
2 a R2b R 2 c R R3 R 2 a R2b R 2 c R 1 R3 Cl H Cl CF 3 H Br H Br CF 3 H Cl H Cl CF 3 Me Br H Br CF 3 Me Cl Cl CN CF 3 CN Br H Br CF 3 CN
CF
3 H H CF 3 H CF 3 H F CF 3 H
CF
3 H Me CF 3 Me CF 3 H F CF 3 Me
CF
3 H H CF 3 CN CF 3 H F CF 3 CN
CF
3 H Cl CF 3 H CF 3 H CF 3
CF
3 H
CF
3 H Cl CF 3 Me CF 3 H CF 3
CF
3 Me
CF
3 H Cl CF 3 CN CF 3 H CF 3
CF
3 CN Cl Cl Cl CF 3 H Cl F Cl CF 3 H Cl Cl Cl CF 3 CN Cl F Cl CF 3 CN Cl Cl Cl CF 3 Me Cl F Cl CF 3 Me Cl H Cl CF 2 C1 H Cl H Cl CF 2
CF
2 H H Cl H Cl CF 2 C1 CN Cl H Cl CF 2
CF
2 H CN Cl H Cl CC1 2 F H Cl H Cl CF 2
CF
3 H Cl H Cl CC1 2 F CN Cl H Cl CF 2
CF
3 CN TABLE 5
R
2 a Z is ; and Q is N R 2 b 3 R2c R N 5 WO 2009/126668 PCT/US2009/039832 68
R
2 a R2b R 2 c R R3 R 2 a R2b R 2 c R 1 R3 Cl H Cl CF 3 H Br H Br CF 3 H Cl H Cl CF 3 Me Br H Br CF 3 Me Cl Cl CN CF 3 CN Br H Br CF 3 CN
CF
3 H H CF 3 H CF 3 H F CF 3 H
CF
3 H Me CF 3 Me CF 3 H F CF 3 Me
CF
3 H H CF 3 CN CF 3 H F CF 3 CN
CF
3 H Cl CF 3 H CF 3 H CF 3
CF
3 H
CF
3 H Cl CF 3 Me CF 3 H CF 3
CF
3 Me
CF
3 H Cl CF 3 CN CF 3 H CF 3
CF
3 CN Cl Cl Cl CF 3 H Cl F Cl CF 3 H Cl Cl Cl CF 3 CN Cl F Cl CF 3 CN Cl Cl Cl CF 3 Me Cl F Cl CF 3 Me Cl H Cl CF 2 C1 H Cl H Cl CF 2
CF
2 H H Cl H Cl CF 2 C1 CN Cl H Cl CF 2
CF
2 H CN Cl H Cl CC1 2 F H Cl H Cl CF 2
CF
3 H Cl H Cl CC1 2 F CN Cl H Cl CF 2
CF
3 CN TABLE 6
R
2 a Z is / ; and Q is N...-
R
2 b R 3
R
2 a R 2 b R 2 c Rv R3 R 2 a R 2 b R 2 c Rv R3 Cl H Cl Br H Br H Br Br H Cl H Cl Br Me Br H Br Br Me Cl Cl Cl Br CN Br H Br Br CN
CF
3 H H Br H CF 3 H F Br H
CF
3 H H Br Me CF 3 H F Br Me
CF
3 H H Br CN CF 3 H F Br CN
CF
3 H Cl Br H CF 3 H CF 3 Br H
CF
3 H Cl Br Me CF 3 H CF 3 Br Me
CF
3 H Cl Br CN CF 3 H CF 3 Br CN Cl Cl Cl Br H Cl F Cl Br H WO 2009/126668 PCT/US2009/039832 69
R
2 a R2b R 2 c Rv R 3
R
2 a R2b R 2 c Rv R 3 Cl Cl Cl Br CN Cl F Cl Br CN Cl Cl Cl Br Me Cl F Cl Br Me Tables 7-9 relate to the method of Scheme la converting compounds of Formulae 2 and 3 to corresponding compounds of Formula 1. This transformation is believed to occur through the intermediacy of compounds of Formula 11. F3C O (MI) 2
CO
3
F
3 C\ O (M I) 2 CO3 O
H
3 C>Q 4a F 4a F3C 2 3 QZ Azeotropic Z 2 3 water removal 1 5 In the example transformations embodied in Tables 7-9, M 1 is K (i.e. the base is potassium carbonate), and water is distilled as an azeotrope from a reaction mixture comprising acetonitrile as the aprotic solvent capable of forming a low-boiling azeotrope with water. TABLE 7
R
2 a Zis / ;andQis H R2bI
R
2 c " 5 0
R
2 a R 2 b R 2 c R5 R 2 a R 2 b R 2 c R5 Cl H Cl CH 2
CH
3
CF
3 H Cl CH 2
CH
3 Cl H Cl CH 2 -i-Pr CF 3 H Cl CH 2 -i-Pr Cl H Cl CH 2
CH
2 C1 CF 3 H Cl CH 2
CH
2 C Cl H Cl CH 2
CH
2 OH CF 3 H Cl CH 2
CH
2 OH Cl H Cl CH(Me)CH 2 OH CF 3 H Cl CH(Me)CH 2 OH Cl H Cl CH 2 CH(Me)OH CF 3 H Cl CH 2 CH(Me)OH Cl H Cl CH 2 C(Me) 2 0H CF 3 H Cl CH 2 C(Me) 2 0H Cl H Cl CH 2
CH
2
CH
2 OH CF 3 H Cl CH 2
CH
2
CH
2 OH Cl H Cl CH 2 C(Me) 2
CH
2 OH CF 3 H Cl CH 2 C(Me) 2
CH
2 OH Cl H Cl CH 2
CH
2 CH(Me)OH CF 3 H Cl CH 2
CH
2 CH(Me)OH Cl H Cl CH 2 C(=O)N(H)Et CF 3 H Cl CH 2 C(=O)N(H)Et Cl H Cl CH 2 C(=O)N(H)-i-Pr CF 3 H Cl CH 2 C(=)N(H)-i-Pr Cl H Cl CH 2
C(=O)N(H)CH
2 -i-Pr CF 3 H Cl CH 2
C(=O)N(H)CH
2 -i-Pr Cl H Cl CH(Me)C(=O)N(H)CH 2 -i-Pr CF 3 H Cl CH(Me)C(=O)N(H)CH 2 -i-Pr WO 2009/126668 PCT/US2009/039832 70
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2 C CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 C Cl H Cl CH(Me)C(=O)N(H)CH 2
CH
2 C CF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 C Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2 F CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 F Cl H Cl CH(Me)C(=O)N(H)CH 2
CH
2 F CF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 F Cl H Cl CH 2
CF
3
CF
3 H Cl CH 2
CF
3 Cl H Cl CH 2 -(2-Py) CF 3 H Cl CH 2 -(2-Py) Cl H Cl CH 2 -(4-Thz) CF 3 H Cl CH 2 -(4-Thz) Cl H Cl CH 2 -c-Pr CF 3 H Cl CH 2 -c-Pr Cl H Cl CH 2
CH
2 SMe CF 3 H Cl CH 2
CH
2 SMe Cl H Cl CH(Me)CH 2 SMe CF 3 H Cl CH(Me)CH 2 SMe Cl H Cl CH 2
CH
2
CH
2 SMe CF 3 H Cl CH 2
CH
2
CH
2 SMe Cl H Cl CH 2
CH
2 S(=O)Me CF 3 H Cl CH 2
CH
2 S(=O)Me Cl H Cl CH(Me)CH 2 S(=O)Me CF 3 H Cl CH(Me)CH 2 S(=O)Me Cl H Cl CH 2
CH
2
CH
2 S(=O)Me CF 3 H Cl CH 2
CH
2
CH
2 S(=O)Me Cl H Cl CH 2
CH
2
S(O)
2 Me CF 3 H Cl CH 2
CH
2
S(O)
2 Me Cl H Cl CH(Me)CH 2
S(O)
2 Me CF 3 H Cl CH(Me)CH 2
S(O)
2 Me Cl H Cl CH 2
CH
2
CH
2
S(O)
2 Me CF 3 H Cl CH 2
CH
2
CH
2
S(O)
2 Me Cl H Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H Cl CH 2
C(=O)N(H)CH
2
CF
3 Cl H Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H Cl CH(Me)C(=O)N(H)CH 2
CF
3 Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me Br H Br CH 2
CH
3
CF
3 H CF 3
CH
2
CH
3 Br H Br CH 2 -i-Pr CF 3 H CF 3
CH
2 -i-Pr Br H Br CH 2
CH
2 C1 CF 3 H CF 3
CH
2
CH
2 C1 Br H Br CH 2
CH
2 OH CF 3 H CF 3
CH
2
CH
2 OH Br H Br CH(Me)CH 2 OH CF 3 H CF 3 CH(Me)CH 2 OH Br H Br CH 2 CH(Me)OH CF 3 H CF 3
CH
2 CH(Me)OH Br H Br CH 2 C(Me) 2 0H CF 3 H CF 3
CH
2 C(Me) 2 0H Br H Br CH 2
CH
2
CH
2 OH CF 3 H CF 3
CH
2
CH
2
CH
2 OH Br H Br CH 2 C(Me) 2
CH
2 OH CF 3 H CF 3
CH
2 C(Me) 2
CH
2 OH Br H Br CH 2
CH
2 CH(Me)OH CF 3 H CF 3
CH
2
CH
2 CH(Me)OH Br H Br CH 2 C(=O)N(H)Et CF 3 H CF 3
CH
2 C(=0)N(H)Et Br H Br CH 2 C(=O)N(H)-i-Pr CF 3 H CF 3
CH
2 C(=O)N(H)-i-Pr Br H Br CH 2
C(=O)N(H)CH
2 -i-Pr CF 3 H CF 3
CH
2
C(=O)N(H)CH
2 -i-Pr WO 2009/126668 PCT/US2009/039832 71
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Br H Br CH(Me)C(=O)N(H)CH 2 -i-Pr CF 3 H CF 3 CH(Me)C(=O)N(H)CH 2 -i-Pr Br H Br CH 2
C(=O)N(H)CH
2
CH
2 C CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2 C Br H Br CH(Me)C(=O)N(H)CH 2
CH
2 C CF 3 H CF 3 CH(Me)C(=O)N(H)CH 2
CH
2 C Br H Br CH 2
C(=O)N(H)CH
2
CH
2 F CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2 F Br H Br CH(Me)C(=O)N(H)CH 2
CH
2 F CF 3 H CF 3 CH(Me)C(=O)N(H)CH 2
CH
2 F Br H Br CH 2
CF
3
CF
3 H CF 3
CH
2
CF
3 Br H Br CH 2 -(2-Py) CF 3 H CF 3
CH
2 -(2-Py) Br H Br CH 2 -(4-Thz) CF 3 H CF 3
CH
2 -(4-Thz) Br H Br CH 2 -c-Pr CF 3 H CF 3
CH
2 -c-Pr Br H Br CH 2
CH
2 SMe CF 3 H CF 3
CH
2
CH
2 SMe Br H Br CH(Me)CH 2 SMe CF 3 H CF 3 CH(Me)CH 2 SMe Br H Br CH 2
CH
2
CH
2 SMe CF 3 H CF 3
CH
2
CH
2
CH
2 SMe Br H Br CH 2
CH
2 S(=O)Me CF 3 H CF 3
CH
2
CH
2 S(=0)Me Br H Br CH(Me)CH 2 S(=O)Me CF 3 H CF 3 CH(Me)CH 2 S(=0)Me Br H Br CH 2
CH
2
CH
2 S(=O)Me CF 3 H CF 3
CH
2
CH
2
CH
2 S(=0)Me Br H Br CH 2
CH
2
S(O)
2 Me CF 3 H CF 3
CH
2
CH
2
S(O)
2 Me Br H Br CH(Me)CH 2
S(O)
2 Me CF 3 H CF 3 CH(Me)CH 2
S(O)
2 Me Br H Br CH 2
CH
2
CH
2
S(O)
2 Me CF 3 H CF 3
CH
2
CH
2
CH
2
S(O)
2 Me Br H Br CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H CF 3
CH
2 C(=0)N(H)CH 2
CF
3 Br H Br CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H CF 3 CH(Me)C(=O)N(H)CH 2
CF
3 Br H Br CH 2
C(=O)N(H)CH
2
CH
2 SMe CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2 SMe Br H Br CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2
S(O)
2 Me
CF
3 H H CH 2
CH
3 Cl Cl Cl CH 2
CH
3
CF
3 H H CH 2 -i-Pr Cl Cl Cl CH 2 -i-Pr
CF
3 H H CH 2
CH
2 C1 Cl Cl Cl CH 2
CH
2 C1
CF
3 H H CH 2
CH
2 OH Cl Cl Cl CH 2
CH
2 OH
CF
3 H H CH(Me)CH 2 OH Cl Cl Cl CH(Me)CH 2 OH
CF
3 H H CH 2 CH(Me)OH Cl Cl Cl CH 2 CH(Me)OH
CF
3 H H CH 2 C(Me) 2 0H Cl Cl Cl CH 2 C(Me) 2 0H
CF
3 H H CH 2
CH
2
CH
2 OH Cl Cl Cl CH 2
CH
2
CH
2 OH
CF
3 H H CH 2 C(Me) 2
CH
2 OH Cl Cl Cl CH 2 C(Me) 2
CH
2
OH
WO 2009/126668 PCT/US2009/039832 72
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H H CH 2
CH
2 CH(Me)OH Cl Cl Cl CH 2
CH
2 CH(Me)OH
CF
3 H H CH 2 C(=O)N(H)Et Cl Cl Cl CH 2 C(=O)N(H)Et
CF
3 H H CH 2 C(=O)N(H)-i-Pr Cl Cl Cl CH 2 C(=O)N(H)-i-Pr
CF
3 H H CH 2
C(=O)N(H)CH
2 -i-Pr Cl Cl Cl CH 2
C(=O)N(H)CH
2 -i-Pr
CF
3 H H CH(Me)C(=O)N(H)CH 2 -i-Pr Cl Cl Cl CH(Me)C(=O)N(H)CH 2 -i-Pr
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2 C1 Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2 C
CF
3 H H CH(Me)C(=O)N(H)CH 2
CH
2 C1 Cl Cl Cl CH(Me)C(=O)N(H)CH 2
CH
2 C
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2 F Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2 F
CF
3 H H CH(Me)C(=O)N(H)CH 2
CH
2 F Cl Cl Cl CH(Me)C(=O)N(H)CH 2
CH
2 F
CF
3 H H CH 2
CF
3 Cl Cl Cl CH 2
CF
3
CF
3 H H CH 2 -(2-Py) Cl Cl Cl CH 2 -(2-Py)
CF
3 H H CH 2 -(4-Thz) Cl Cl Cl CH 2 -(4-Thz)
CF
3 H H CH 2 -c-Pr Cl Cl Cl CH 2 -c-Pr
CF
3 H H CH 2
CH
2 SMe Cl Cl Cl CH 2
CH
2 SMe
CF
3 H H CH(Me)CH 2 SMe Cl Cl Cl CH(Me)CH 2 SMe
CF
3 H H CH 2
CH
2
CH
2 SMe Cl Cl Cl CH 2
CH
2
CH
2 SMe
CF
3 H H CH 2
CH
2 S(=O)Me Cl Cl Cl CH 2
CH
2 S(=O)Me
CF
3 H H CH(Me)CH 2 S(=O)Me Cl Cl Cl CH(Me)CH 2 S(=O)Me
CF
3 H H CH 2
CH
2
CH
2 S(=O)Me Cl Cl Cl CH 2
CH
2
CH
2 S(=O)Me
CF
3 H H CH 2
CH
2
S(O)
2 Me Cl Cl Cl CH 2
CH
2
S(O)
2 Me
CF
3 H H CH(Me)CH 2
S(O)
2 Me Cl Cl Cl CH(Me)CH 2
S(O)
2 Me
CF
3 H H CH 2
CH
2
CH
2
S(O)
2 Me Cl Cl Cl CH 2
CH
2
CH
2
S(O)
2 Me
CF
3 H H CH 2
C(=O)N(H)CH
2
CF
3 Cl Cl Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H H CH(Me)C(=O)N(H)CH 2
CF
3 Cl Cl Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2 SMe Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me
CF
3 H F CH 2
CH
3 Cl F Cl CH 2
CH
3
CF
3 H F CH 2 -i-Pr Cl F Cl CH 2 -i-Pr
CF
3 H F CH 2
CH
2 C1 Cl F Cl CH 2
CH
2 C1
CF
3 H F CH 2
CH
2 OH Cl F Cl CH 2
CH
2 OH
CF
3 H F CH(Me)CH 2 OH Cl F Cl CH(Me)CH 2
OH
WO 2009/126668 PCT/US2009/039832 73
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H F CH 2 CH(Me)OH Cl F Cl CH 2 CH(Me)OH
CF
3 H F CH 2 C(Me) 2 0H Cl F Cl CH 2 C(Me) 2 0H
CF
3 H F CH 2
CH
2
CH
2 OH Cl F Cl CH 2
CH
2
CH
2 OH
CF
3 H F CH 2 C(Me) 2
CH
2 OH Cl F Cl CH 2 C(Me) 2
CH
2 OH
CF
3 H F CH 2
CH
2 CH(Me)OH Cl F Cl CH 2
CH
2 CH(Me)OH
CF
3 H F CH 2 C(=O)N(H)Et Cl F Cl CH 2 C(=O)N(H)Et
CF
3 H F CH 2 C(=O)N(H)-i-Pr Cl F Cl CH 2 C(=O)N(H)-i-Pr
CF
3 H F CH 2
C(=O)N(H)CH
2 -i-Pr Cl F Cl CH 2
C(=O)N(H)CH
2 -i-Pr
CF
3 H F CH(Me)C(=O)N(H)CH 2 -i-Pr Cl F Cl CH(Me)C(=O)N(H)CH 2 -i-Pr
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2 C Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2 C
CF
3 H F CH(Me)C(=O)N(H)CH 2
CH
2 C1 Cl F Cl CH(Me)C(=O)N(H)CH 2
CH
2 C
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2 F Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2 F
CF
3 H F CH(Me)C(=O)N(H)CH 2
CH
2 F Cl F Cl CH(Me)C(=O)N(H)CH 2
CH
2 F
CF
3 H F CH 2
CF
3 Cl F Cl CH 2
CF
3
CF
3 H F CH 2 -(2-Py) Cl F Cl CH 2 -(2-Py)
CF
3 H F CH 2 -(4-Thz) Cl F Cl CH 2 -(4-Thz)
CF
3 H F CH 2 -c-Pr Cl F Cl CH 2 -c-Pr
CF
3 H F CH 2
CH
2 SMe Cl F Cl CH 2
CH
2 SMe
CF
3 H F CH(Me)CH 2 SMe Cl F Cl CH(Me)CH 2 SMe
CF
3 H F CH 2
CH
2
CH
2 SMe Cl F Cl CH 2
CH
2
CH
2 SMe
CF
3 H F CH 2
CH
2 S(=O)Me Cl F Cl CH 2
CH
2 S(=O)Me
CF
3 H F CH(Me)CH 2 S(=O)Me Cl F Cl CH(Me)CH 2 S(=O)Me
CF
3 H F CH 2
CH
2
CH
2 S(=O)Me Cl F Cl CH 2
CH
2
CH
2 S(=O)Me
CF
3 H F CH 2
CH
2
S(O)
2 Me Cl F Cl CH 2
CH
2
S(O)
2 Me
CF
3 H F CH(Me)CH 2
S(O)
2 Me Cl F Cl CH(Me)CH 2
S(O)
2 Me
CF
3 H F CH 2
CH
2
CH
2
S(O)
2 Me Cl F Cl CH 2
CH
2
CH
2
S(O)
2 Me
CF
3 H F CH 2
C(=O)N(H)CH
2
CF
3 Cl F Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H F CH(Me)C(=O)N(H)CH 2
CF
3 Cl F Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2 SMe Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me
CF
3 H Br CH 2
CH
3
OCF
3 H Cl CH 2
CH
3
CF
3 H Br CH 2 -i-Pr OCF 3 H Cl CH 2 -i-Pr
CF
3 H Br CH 2
CH
2 C1 OCF 3 H Cl CH 2
CH
2 C1 WO 2009/126668 PCT/US2009/039832 74
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H Br CH 2
CH
2 OH OCF 3 H Cl CH 2
CH
2 OH
CF
3 H Br CH(Me)CH 2 OH OCF 3 H Cl CH(Me)CH 2 OH
CF
3 H Br CH 2 CH(Me)OH OCF 3 H Cl CH 2 CH(Me)OH
CF
3 H Br CH 2 C(Me) 2 0H OCF 3 H Cl CH 2 C(Me) 2 0H
CF
3 H Br CH 2
CH
2
CH
2 OH OCF 3 H Cl CH 2
CH
2
CH
2 OH
CF
3 H Br CH 2 C(Me) 2
CH
2 OH OCF 3 H Cl CH 2 C(Me) 2
CH
2 OH
CF
3 H Br CH 2
CH
2 CH(Me)OH OCF 3 H Cl CH 2
CH
2 CH(Me)OH
CF
3 H Br CH 2 C(=O)N(H)Et OCF 3 H Cl CH 2 C(=O)N(H)Et
CF
3 H Br CH 2 C(=O)N(H)-i-Pr OCF 3 H Cl CH 2 C(=O)N(H)-i-Pr
CF
3 H Br CH 2
C(=O)N(H)CH
2 -i-Pr OCF 3 H Cl CH 2
C(=O)N(H)CH
2 -i-Pr
CF
3 H Br CH(Me)C(=O)N(H)CH 2 -i-Pr OCF 3 H Cl CH(Me)C(=O)N(H)CH 2 -i-Pr
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2 C1 OCF 3 H Cl CH 2 C(=0)N(H)CH 2
CH
2 C
CF
3 H Br CH(Me)C(=O)N(H)CH 2
CH
2 C1 OCF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 C1
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2 F OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 F
CF
3 H Br CH(Me)C(=O)N(H)CH 2
CH
2 F OCF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 F
CF
3 H Br CH 2
CF
3
OCF
3 H Cl CH 2
CF
3
CF
3 H Br CH 2 -(2-Py) OCF 3 H Cl CH 2 -(2-Py)
CF
3 H Br CH 2 -(4-Thz) OCF 3 H Cl CH 2 -(4-Thz)
CF
3 H Br CH 2 -c-Pr OCF 3 H Cl CH 2 -c-Pr
CF
3 H Br CH 2
CH
2 SMe OCF 3 H Cl CH 2
CH
2 SMe
CF
3 H Br CH(Me)CH 2 SMe OCF 3 H Cl CH(Me)CH 2 SMe
CF
3 H Br CH 2
CH
2
CH
2 SMe OCF 3 H Cl CH 2
CH
2
CH
2 SMe
CF
3 H Br CH 2
CH
2 S(=O)Me OCF 3 H Cl CH 2
CH
2 S(=O)Me
CF
3 H Br CH(Me)CH 2 S(=O)Me OCF 3 H Cl CH(Me)CH 2 S(=O)Me
CF
3 H Br CH 2
CH
2
CH
2 S(=O)Me OCF 3 H Cl CH 2
CH
2
CH
2 S(=O)Me
CF
3 H Br CH 2
CH
2
S(O)
2 Me OCF 3 H Cl CH 2
CH
2
S(O)
2 Me
CF
3 H Br CH(Me)CH 2
S(O)
2 Me OCF 3 H Cl CH(Me)CH 2
S(O)
2 Me
CF
3 H Br CH 2
CH
2
CH
2
S(O)
2 Me OCF 3 H Cl CH 2
CH
2
CH
2
S(O)
2 Me
CF
3 H Br CH 2
C(=O)N(H)CH
2
CF
3
OCF
3 H Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H Br CH(Me)C(=O)N(H)CH 2
CF
3
OCF
3 H Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2 SMe OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me WO 2009/126668 PCT/US2009/039832 75 TABLE 8
R
2 a Z is / ; and Q is
R
2 b 5
R
2 c OR 0
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Cl H Cl CH 3
CF
3 H Cl CH 3 Cl H Cl CH 2
CH
3
CF
3 H Cl CH 2
CH
3 Cl H Cl CH 2 -i-Pr CF 3 H Cl CH 2 -i-Pr Cl H Cl n-Pr CF 3 H Cl n-Pr Cl H Cl i-Pr CF 3 H Cl i-Pr Cl H Cl s-Bu CF 3 H Cl s-Bu Cl H Cl t-Bu CF 3 H Cl t-Bu Cl H Cl (CH2) 5
CH
3
CF
3 H Cl (CH2) 5
CH
3 Cl H Cl CH 2 Ph CF 3 H Cl CH 2 Ph Br H Br CH 3
CF
3 H CF 3
CH
3 Br H Br CH 2
CH
3
CF
3 H CF 3
CH
2
CH
3 Br H Br CH 2 -i-Pr CF 3 H CF 3
CH
2 -i-Pr Br H Br n-Pr CF 3 H CF 3 n-Pr Br H Br i-Pr CF 3 H CF 3 i-Pr Br H Br s-Bu CF 3 H CF 3 s-Bu Br H Br t-Bu CF 3 H CF 3 t-Bu Br H Br (CH2) 5
CH
3
CF
3 H CF 3 (CH2) 5
CH
3 Br H Br CH 2 Ph CF 3 H CF 3
CH
2 Ph
CF
3 H H CH 3 Cl Cl Cl CH 3
CF
3 H H CH 2
CH
3 Cl Cl Cl CH 2
CH
3
CF
3 H H CH 2 -i-Pr Cl Cl Cl CH 2 -i-Pr
CF
3 H H n-Pr Cl Cl Cl n-Pr
CF
3 H H i-Pr Cl Cl Cl i-Pr
CF
3 H H s-Bu Cl Cl Cl s-Bu
CF
3 H H t-Bu Cl Cl Cl t-Bu
CF
3 H H (CH2) 5
CH
3 Cl Cl Cl (CH2) 5
CH
3 WO 2009/126668 PCT/US2009/039832 76
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H H CH 2 Ph Cl Cl Cl CH 2 Ph
CF
3 H F CH 3 Cl F Cl CH 3
CF
3 H F CH 2
CH
3 Cl F Cl CH 2
CH
3
CF
3 H F CH 2 -i-Pr Cl F Cl CH 2 -i-Pr
CF
3 H F n-Pr Cl F Cl n-Pr
CF
3 H F i-Pr Cl F Cl i-Pr
CF
3 H F s-Bu Cl F Cl s-Bu
CF
3 H F t-Bu Cl F Cl t-Bu
CF
3 H F (CH2) 5
CH
3 Cl F Cl (CH2) 5
CH
3
CF
3 H F CH 2 Ph Cl F Cl CH 2 Ph
CF
3 H Br CH 3
OCF
3 H Cl CH 3
CF
3 H Br CH 2
CH
3
OCF
3 H Cl CH 2
CH
3
CF
3 H Br CH 2 -i-Pr OCF 3 H Cl CH 2 -i-Pr
CF
3 H Br n-Pr OCF 3 H Cl n-Pr
CF
3 H Br i-Pr OCF 3 H Cl i-Pr
CF
3 H Br s-Bu OCF 3 H Cl s-Bu
CF
3 H Br t-Bu OCF 3 H Cl t-Bu
CF
3 H Br (CH 2
)
5
CH
3
OCF
3 H Cl (CH 2
)
5
CH
3
CF
3 H Br CH 2 Ph OCF 3 H Cl CH 2 Ph TABLE 9
R
2 a Z is / ; and Q is
R
2 b R 2c / 3 R
R
2 a R 2 b R 2 c R3 R 2 a R 2 b R 2 c R3 Cl H Cl Cl CF 3 H Cl Cl Cl H Cl Br CF 3 H Cl Br Cl H Cl I CF 3 H Cl I Cl H Cl OH CF 3 H Cl OH Cl H Cl OMe CF 3 H Cl OMe Cl H Cl OS(O) 2
CF
3
CF
3 H Cl OS(O) 2
CF
3 WO 2009/126668 PCT/US2009/039832 77
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3 Cl H Cl nitro CF 3 H Cl nitro Cl H Cl NH 2
CF
3 H Cl NH 2 Cl H Cl cyano CF 3 H Cl cyano Cl H Cl Me CF 3 H Cl Me Cl H Cl CH 2 C1 CF 3 H Cl CH 2 C1 Cl H Cl CH 2 Br CF 3 H Cl CH 2 Br Cl H Cl CH 2 OH CF 3 H Cl CH 2 OH Cl H Cl CH 2 OC(O)Me CF 3 H Cl CH 2 OC(O)Me Cl H Cl CO 2 H CF 3 H Cl CO 2 H Cl H Cl n-Pr CF 3 H Cl n-Pr Br H Br Cl CF 3 H CF 3 Cl Br H Br Br CF 3 H CF 3 Br Br H Br
CF
3 H CF 3 I Br H Br OH CF 3 H CF 3 OH Br H Br OMe CF 3 H CF 3 OMe Br H Br OS(O) 2
CF
3 CF 3 H CF 3
OS(O)
2
CF
3 Br H Br nitro CF 3 H CF 3 nitro Br H Br
NH
2 CF 3 H CF 3 NH 2 Br H Br cyano CF 3 H CF 3 cyano Br H Br Me CF 3 H CF 3 Me Br H Br CH 2 C1 CF 3 H CF 3
CH
2 C1 Br H Br CH 2 Br CF 3 H CF 3
CH
2 Br Br H Br CH 2 OH CF 3 H CF 3
CH
2 OH Br H Br CH 2 OC(O)Me CF 3 H CF 3
CH
2 OC(O)Me Br H Br CO 2 H CF 3 H CF 3
CO
2 H Br H Br n-Pr CF 3 H CF 3 n-Pr
CF
3 H H Cl Cl Cl Cl Cl
CF
3 H H Br Cl Cl Cl Br
CF
3 H H I Cl Cl Cl I
CF
3 H H OH Cl Cl Cl OH
CF
3 H H OMe Cl Cl Cl OMe
CF
3 H H OS(O) 2
CF
3 Cl Cl Cl OS(O) 2
CF
3
CF
3 H H nitro Cl Cl Cl nitro
CF
3 H H NH 2 Cl Cl Cl NH 2
CF
3 H H cyano Cl Cl Cl cyano WO 2009/126668 PCT/US2009/039832 78
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3
CF
3 H H Me Cl Cl Cl Me
CF
3 H H CH 2 C1 Cl Cl Cl CH 2 C1
CF
3 H H CH 2 Br Cl Cl Cl CH 2 Br
CF
3 H H CH 2 OH Cl Cl Cl CH 2 OH
CF
3 H H CH 2 OC(O)Me Cl Cl Cl CH 2 OC(O)Me
CF
3 H H CO 2 H Cl Cl Cl CO 2 H
CF
3 H H n-Pr Cl Cl Cl n-Pr
CF
3 H F Cl Cl F Cl Cl
CF
3 H F Br Cl F Cl Br
CF
3 H F I Cl F Cl I
CF
3 H F OH Cl F Cl OH
CF
3 H F OMe Cl F Cl OMe
CF
3 H F OS(O) 2
CF
3 Cl F Cl OS(O) 2
CF
3
CF
3 H F nitro Cl F Cl nitro
CF
3 H F NH 2 Cl F Cl NH 2
CF
3 H F cyano Cl F Cl cyano
CF
3 H F Me Cl F Cl Me
CF
3 H F CH 2 C1 Cl F Cl CH 2 C1
CF
3 H F CH 2 Br Cl F Cl CH 2 Br
CF
3 H F CH 2 OH Cl F Cl CH 2 OH
CF
3 H F CH 2 OC(O)Me Cl F Cl CH 2 OC(O)Me
CF
3 H F CO 2 H Cl F Cl CO 2 H
CF
3 H F n-Pr Cl F Cl n-Pr
CF
3 H Br Cl OCF 3 H Cl Cl
CF
3 H Br Br OCF 3 H Cl Br
CF
3 H Br I OCF 3 H Cl I
CF
3 H Br OH OCF 3 H Cl OH
CF
3 H Br OMe OCF 3 H Cl OMe
CF
3 H Br OS(O) 2
CF
3
OCF
3 H Cl OS(O) 2
CF
3
CF
3 H Br nitro OCF 3 H Cl nitro
CF
3 H Br NH 2
OCF
3 H Cl NH 2
CF
3 H Br cyano OCF 3 H Cl cyano
CF
3 H Br Me OCF 3 H Cl Me
CF
3 H Br CH 2 C1 OCF 3 H Cl CH 2 C1
CF
3 H Br CH 2 Br OCF 3 H Cl CH 2 Br
CF
3 H Br CH 2 OH OCF 3 H Cl CH 2 OH
CF
3 H Br CH 2 OC(O)Me OCF 3 H Cl CH 2 OC(O)Me WO 2009/126668 PCT/US2009/039832 79
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3
CF
3 H Br CO 2 H OCF 3 H Cl CO 2 H
CF
3 H Br n-Pr OCF 3 H Cl n-Pr Tables 10-12 relate to the method of Scheme lb converting compounds of Formulae 2 and 3 to corresponding compounds of Formula 1. This transformation is believed to occur through the intermediacy of compounds of Formula 11.
F
3 C O base F 3 C base F 3 C 0 Z Azeotropic Z 2 3 water removal 1 5 In the example transformations embodied in Tables 10-12, the base is 1,8 diazabicyclo[5.4.0]undec-7-ene, and water is distilled as an azeotrope from a reaction mixture comprising acetonitrile as the aprotic solvent capable of forming a low-boiling azeotrope with water. TABLE 10
R
2 a Z is /; and Q is N H R2bII
R
2 c %N 5 R 0 10
R
2 a R 2 b R 2 c R5 R 2 a R 2 b R 2 c R5 Cl H Cl CH 2
CH
3
CF
3 H Cl CH 2
CH
3 Cl H Cl CH 2 -i-Pr CF 3 H Cl CH 2 -i-Pr Cl H Cl CH 2
CH
2 C1 CF 3 H Cl CH 2
CH
2 C1 Cl H Cl CH 2
CH
2 OH CF 3 H Cl CH 2
CH
2 OH Cl H Cl CH(Me)CH 2 OH CF 3 H Cl CH(Me)CH 2 OH Cl H Cl CH 2 CH(Me)OH CF 3 H Cl CH 2 CH(Me)OH Cl H Cl CH 2 C(Me) 2 0H CF 3 H Cl CH 2 C(Me) 2 0H Cl H Cl CH 2
CH
2
CH
2 OH CF 3 H Cl CH 2
CH
2
CH
2 OH Cl H Cl CH 2 C(Me) 2
CH
2 OH CF 3 H Cl CH 2 C(Me) 2
CH
2 OH Cl H Cl CH 2
CH
2 CH(Me)OH CF 3 H Cl CH 2
CH
2 CH(Me)OH Cl H Cl CH 2 C(=O)N(H)Et CF 3 H Cl CH 2 C(=O)N(H)Et Cl H Cl CH 2 C(=O)N(H)-i-Pr CF 3 H Cl CH 2 C(=O)N(H)-i-Pr Cl H Cl CH 2
C(=O)N(H)CH
2 -i-Pr CF 3 H Cl CH 2
C(=O)N(H)CH
2 -i-Pr WO 2009/126668 PCT/US2009/039832 80
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Cl H Cl CH(Me)C(=O)N(H)CH 2 -i-Pr CF 3 H Cl CH(Me)C(=O)N(H)CH 2 -i-Pr Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2 C CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 C Cl H Cl CH(Me)C(=O)N(H)CH 2
CH
2 C CF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 C Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2 F CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 F Cl H Cl CH(Me)C(=O)N(H)CH 2
CH
2 F CF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 F Cl H Cl CH 2
CF
3
CF
3 H Cl CH 2
CF
3 Cl H Cl CH 2 -(2-Py) CF 3 H Cl CH 2 -(2-Py) Cl H Cl CH 2 -(4-Thz) CF 3 H Cl CH 2 -(4-Thz) Cl H Cl CH 2 -c-Pr CF 3 H Cl CH 2 -c-Pr Cl H Cl CH 2
CH
2 SMe CF 3 H Cl CH 2
CH
2 SMe Cl H Cl CH(Me)CH 2 SMe CF 3 H Cl CH(Me)CH 2 SMe Cl H Cl CH 2
CH
2
CH
2 SMe CF 3 H Cl CH 2
CH
2
CH
2 SMe Cl H Cl CH 2
CH
2 S(=O)Me CF 3 H Cl CH 2
CH
2 S(=O)Me Cl H Cl CH(Me)CH 2 S(=O)Me CF 3 H Cl CH(Me)CH 2 S(=O)Me Cl H Cl CH 2
CH
2
CH
2 S(=O)Me CF 3 H Cl CH 2
CH
2
CH
2 S(=O)Me Cl H Cl CH 2
CH
2
S(O)
2 Me CF 3 H Cl CH 2
CH
2
S(O)
2 Me Cl H Cl CH(Me)CH 2
S(O)
2 Me CF 3 H Cl CH(Me)CH 2
S(O)
2 Me Cl H Cl CH 2
CH
2
CH
2
S(O)
2 Me CF 3 H Cl CH 2
CH
2
CH
2
S(O)
2 Me Cl H Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H Cl CH 2
C(=O)N(H)CH
2
CF
3 Cl H Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H Cl CH(Me)C(=O)N(H)CH 2
CF
3 Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe Cl H Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me CF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me Br H Br CH 2
CH
3
CF
3 H CF 3
CH
2
CH
3 Br H Br CH 2 -i-Pr CF 3 H CF 3
CH
2 -i-Pr Br H Br CH 2
CH
2 C1 CF 3 H CF 3
CH
2
CH
2 C1 Br H Br CH 2
CH
2 OH CF 3 H CF 3
CH
2
CH
2 OH Br H Br CH(Me)CH 2 OH CF 3 H CF 3 CH(Me)CH 2 OH Br H Br CH 2 CH(Me)OH CF 3 H CF 3
CH
2 CH(Me)OH Br H Br CH 2 C(Me) 2 0H CF 3 H CF 3
CH
2 C(Me) 2 0H Br H Br CH 2
CH
2
CH
2 OH CF 3 H CF 3
CH
2
CH
2
CH
2 OH Br H Br CH 2 C(Me) 2
CH
2 OH CF 3 H CF 3
CH
2 C(Me) 2
CH
2 OH Br H Br CH 2
CH
2 CH(Me)OH CF 3 H CF 3
CH
2
CH
2 CH(Me)OH Br H Br CH 2 C(=O)N(H)Et CF 3 H CF 3
CH
2 C(=0)N(H)Et Br H Br CH 2 C(=O)N(H)-i-Pr CF 3 H CF 3
CH
2 C(=O)N(H)-i-Pr WO 2009/126668 PCT/US2009/039832 81
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Br H Br CH 2
C(=O)N(H)CH
2 -i-Pr CF 3 H CF 3
CH
2
C(=O)N(H)CH
2 -i-Pr Br H Br CH(Me)C(=O)N(H)CH 2 -i-Pr CF 3 H CF 3 CH(Me)C(=O)N(H)CH 2 -i-Pr Br H Br CH 2
C(=O)N(H)CH
2
CH
2 C CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2 C Br H Br CH(Me)C(=O)N(H)CH 2
CH
2 C CF 3 H CF 3 CH(Me)C(=O)N(H)CH 2
CH
2 C Br H Br CH 2
C(=O)N(H)CH
2
CH
2 F CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2 F Br H Br CH(Me)C(=O)N(H)CH 2
CH
2 F CF 3 H CF 3 CH(Me)C(=O)N(H)CH 2
CH
2 F Br H Br CH 2
CF
3
CF
3 H CF 3
CH
2
CF
3 Br H Br CH 2 -(2-Py) CF 3 H CF 3
CH
2 -(2-Py) Br H Br CH 2 -(4-Thz) CF 3 H CF 3
CH
2 -(4-Thz) Br H Br CH 2 -c-Pr CF 3 H CF 3
CH
2 -c-Pr Br H Br CH 2
CH
2 SMe CF 3 H CF 3
CH
2
CH
2 SMe Br H Br CH(Me)CH 2 SMe CF 3 H CF 3 CH(Me)CH 2 SMe Br H Br CH 2
CH
2
CH
2 SMe CF 3 H CF 3
CH
2
CH
2
CH
2 SMe Br H Br CH 2
CH
2 S(=O)Me CF 3 H CF 3
CH
2
CH
2 S(=0)Me Br H Br CH(Me)CH 2 S(=O)Me CF 3 H CF 3 CH(Me)CH 2 S(=0)Me Br H Br CH 2
CH
2
CH
2 S(=O)Me CF 3 H CF 3
CH
2
CH
2
CH
2 S(=0)Me Br H Br CH 2
CH
2
S(O)
2 Me CF 3 H CF 3
CH
2
CH
2
S(O)
2 Me Br H Br CH(Me)CH 2
S(O)
2 Me CF 3 H CF 3 CH(Me)CH 2
S(O)
2 Me Br H Br CH 2
CH
2
CH
2
S(O)
2 Me CF 3 H CF 3
CH
2
CH
2
CH
2
S(O)
2 Me Br H Br CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H CF 3
CH
2 C(=0)N(H)CH 2
CF
3 Br H Br CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H CF 3 CH(Me)C(=O)N(H)CH 2
CF
3 Br H Br CH 2
C(=O)N(H)CH
2
CH
2 SMe CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2 SMe Br H Br CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me CF 3 H CF 3
CH
2 C(=0)N(H)CH 2
CH
2
S(O)
2 Me
CF
3 H H CH 2
CH
3 Cl Cl Cl CH 2
CH
3
CF
3 H H CH 2 -i-Pr Cl Cl Cl CH 2 -i-Pr
CF
3 H H CH 2
CH
2 C1 Cl Cl Cl CH 2
CH
2 C1
CF
3 H H CH 2
CH
2 OH Cl Cl Cl CH 2
CH
2 OH
CF
3 H H CH(Me)CH 2 OH Cl Cl Cl CH(Me)CH 2 OH
CF
3 H H CH 2 CH(Me)OH Cl Cl Cl CH 2 CH(Me)OH
CF
3 H H CH 2 C(Me) 2 0H Cl Cl Cl CH 2 C(Me) 2 0H
CF
3 H H CH 2
CH
2
CH
2 OH Cl Cl Cl CH 2
CH
2
CH
2
OH
WO 2009/126668 PCT/US2009/039832 82
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H H CH 2 C(Me) 2
CH
2 OH Cl Cl Cl CH 2 C(Me) 2
CH
2 OH
CF
3 H H CH 2
CH
2 CH(Me)OH Cl Cl Cl CH 2
CH
2 CH(Me)OH
CF
3 H H CH 2 C(=O)N(H)Et Cl Cl Cl CH 2 C(=O)N(H)Et
CF
3 H H CH 2 C(=O)N(H)-i-Pr Cl Cl Cl CH 2 C(=O)N(H)-i-Pr
CF
3 H H CH 2
C(=O)N(H)CH
2 -i-Pr Cl Cl Cl CH 2
C(=O)N(H)CH
2 -i-Pr
CF
3 H H CH(Me)C(=O)N(H)CH 2 -i-Pr Cl Cl Cl CH(Me)C(=O)N(H)CH 2 -i-Pr
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2 C1 Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2 C
CF
3 H H CH(Me)C(=O)N(H)CH 2
CH
2 C1 Cl Cl Cl CH(Me)C(=O)N(H)CH 2
CH
2 C
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2 F Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2 F
CF
3 H H CH(Me)C(=O)N(H)CH 2
CH
2 F Cl Cl Cl CH(Me)C(=O)N(H)CH 2
CH
2 F
CF
3 H H CH 2
CF
3 Cl Cl Cl CH 2
CF
3
CF
3 H H CH 2 -(2-Py) Cl Cl Cl CH 2 -(2-Py)
CF
3 H H CH 2 -(4-Thz) Cl Cl Cl CH 2 -(4-Thz)
CF
3 H H CH 2 -c-Pr Cl Cl Cl CH 2 -c-Pr
CF
3 H H CH 2
CH
2 SMe Cl Cl Cl CH 2
CH
2 SMe
CF
3 H H CH(Me)CH 2 SMe Cl Cl Cl CH(Me)CH 2 SMe
CF
3 H H CH 2
CH
2
CH
2 SMe Cl Cl Cl CH 2
CH
2
CH
2 SMe
CF
3 H H CH 2
CH
2 S(=O)Me Cl Cl Cl CH 2
CH
2 S(=O)Me
CF
3 H H CH(Me)CH 2 S(=O)Me Cl Cl Cl CH(Me)CH 2 S(=O)Me
CF
3 H H CH 2
CH
2
CH
2 S(=O)Me Cl Cl Cl CH 2
CH
2
CH
2 S(=O)Me
CF
3 H H CH 2
CH
2
S(O)
2 Me Cl Cl Cl CH 2
CH
2
S(O)
2 Me
CF
3 H H CH(Me)CH 2
S(O)
2 Me Cl Cl Cl CH(Me)CH 2
S(O)
2 Me
CF
3 H H CH 2
CH
2
CH
2
S(O)
2 Me Cl Cl Cl CH 2
CH
2
CH
2
S(O)
2 Me
CF
3 H H CH 2
C(=O)N(H)CH
2
CF
3 Cl Cl Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H H CH(Me)C(=O)N(H)CH 2
CF
3 Cl Cl Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2 SMe Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe
CF
3 H H CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me Cl Cl Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me
CF
3 H F CH 2
CH
3 Cl F Cl CH 2
CH
3
CF
3 H F CH 2 -i-Pr Cl F Cl CH 2 -i-Pr
CF
3 H F CH 2
CH
2 C1 Cl F Cl CH 2
CH
2 C1
CF
3 H F CH 2
CH
2 OH Cl F Cl CH 2
CH
2
OH
WO 2009/126668 PCT/US2009/039832 83
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H F CH(Me)CH 2 OH Cl F Cl CH(Me)CH 2 OH
CF
3 H F CH 2 CH(Me)OH Cl F Cl CH 2 CH(Me)OH
CF
3 H F CH 2 C(Me) 2 0H Cl F Cl CH 2 C(Me) 2 0H
CF
3 H F CH 2
CH
2
CH
2 OH Cl F Cl CH 2
CH
2
CH
2 OH
CF
3 H F CH 2 C(Me) 2
CH
2 OH Cl F Cl CH 2 C(Me) 2
CH
2 OH
CF
3 H F CH 2
CH
2 CH(Me)OH Cl F Cl CH 2
CH
2 CH(Me)OH
CF
3 H F CH 2 C(=O)N(H)Et Cl F Cl CH 2 C(=O)N(H)Et
CF
3 H F CH 2 C(=O)N(H)-i-Pr Cl F Cl CH 2 C(=O)N(H)-i-Pr
CF
3 H F CH 2
C(=O)N(H)CH
2 -i-Pr Cl F Cl CH 2
C(=O)N(H)CH
2 -i-Pr
CF
3 H F CH(Me)C(=O)N(H)CH 2 -i-Pr Cl F Cl CH(Me)C(=O)N(H)CH 2 -i-Pr
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2 C Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2 C
CF
3 H F CH(Me)C(=O)N(H)CH 2
CH
2 C1 Cl F Cl CH(Me)C(=O)N(H)CH 2
CH
2 C
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2 F Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2 F
CF
3 H F CH(Me)C(=O)N(H)CH 2
CH
2 F Cl F Cl CH(Me)C(=O)N(H)CH 2
CH
2 F
CF
3 H F CH 2
CF
3 Cl F Cl CH 2
CF
3
CF
3 H F CH 2 -(2-Py) Cl F Cl CH 2 -(2-Py)
CF
3 H F CH 2 -(4-Thz) Cl F Cl CH 2 -(4-Thz)
CF
3 H F CH 2 -c-Pr Cl F Cl CH 2 -c-Pr
CF
3 H F CH 2
CH
2 SMe Cl F Cl CH 2
CH
2 SMe
CF
3 H F CH(Me)CH 2 SMe Cl F Cl CH(Me)CH 2 SMe
CF
3 H F CH 2
CH
2
CH
2 SMe Cl F Cl CH 2
CH
2
CH
2 SMe
CF
3 H F CH 2
CH
2 S(=O)Me Cl F Cl CH 2
CH
2 S(=O)Me
CF
3 H F CH(Me)CH 2 S(=O)Me Cl F Cl CH(Me)CH 2 S(=O)Me
CF
3 H F CH 2
CH
2
CH
2 S(=O)Me Cl F Cl CH 2
CH
2
CH
2 S(=O)Me
CF
3 H F CH 2
CH
2
S(O)
2 Me Cl F Cl CH 2
CH
2
S(O)
2 Me
CF
3 H F CH(Me)CH 2
S(O)
2 Me Cl F Cl CH(Me)CH 2
S(O)
2 Me
CF
3 H F CH 2
CH
2
CH
2
S(O)
2 Me Cl F Cl CH 2
CH
2
CH
2
S(O)
2 Me
CF
3 H F CH 2
C(=O)N(H)CH
2
CF
3 Cl F Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H F CH(Me)C(=O)N(H)CH 2
CF
3 Cl F Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2 SMe Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe
CF
3 H F CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me Cl F Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me
CF
3 H Br CH 2
CH
3
OCF
3 H Cl CH 2
CH
3
CF
3 H Br CH 2 -i-Pr OCF 3 H Cl CH 2 -i-Pr WO 2009/126668 PCT/US2009/039832 84
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H Br CH 2
CH
2 C1 OCF 3 H Cl CH 2
CH
2 C1
CF
3 H Br CH 2
CH
2 OH OCF 3 H Cl CH 2
CH
2 OH
CF
3 H Br CH(Me)CH 2 OH OCF 3 H Cl CH(Me)CH 2 OH
CF
3 H Br CH 2 CH(Me)OH OCF 3 H Cl CH 2 CH(Me)OH
CF
3 H Br CH 2 C(Me) 2 0H OCF 3 H Cl CH 2 C(Me) 2 0H
CF
3 H Br CH 2
CH
2
CH
2 OH OCF 3 H Cl CH 2
CH
2
CH
2 OH
CF
3 H Br CH 2 C(Me) 2
CH
2 OH OCF 3 H Cl CH 2 C(Me) 2
CH
2 OH
CF
3 H Br CH 2
CH
2 CH(Me)OH OCF 3 H Cl CH 2
CH
2 CH(Me)OH
CF
3 H Br CH 2 C(=O)N(H)Et OCF 3 H Cl CH 2 C(=O)N(H)Et
CF
3 H Br CH 2 C(=O)N(H)-i-Pr OCF 3 H Cl CH 2 C(=O)N(H)-i-Pr
CF
3 H Br CH 2
C(=O)N(H)CH
2 -i-Pr OCF 3 H Cl CH 2
C(=O)N(H)CH
2 -i-Pr
CF
3 H Br CH(Me)C(=O)N(H)CH 2 -i-Pr OCF 3 H Cl CH(Me)C(=O)N(H)CH 2 -i-Pr
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2 C1 OCF 3 H Cl CH 2 C(=0)N(H)CH 2
CH
2 C
CF
3 H Br CH(Me)C(=O)N(H)CH 2
CH
2 C1 OCF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 C1
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2 F OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 F
CF
3 H Br CH(Me)C(=O)N(H)CH 2
CH
2 F OCF 3 H Cl CH(Me)C(=O)N(H)CH 2
CH
2 F
CF
3 H Br CH 2
CF
3
OCF
3 H Cl CH 2
CF
3
CF
3 H Br CH 2 -(2-Py) OCF 3 H Cl CH 2 -(2-Py)
CF
3 H Br CH 2 -(4-Thz) OCF 3 H Cl CH 2 -(4-Thz)
CF
3 H Br CH 2 -c-Pr OCF 3 H Cl CH 2 -c-Pr
CF
3 H Br CH 2
CH
2 SMe OCF 3 H Cl CH 2
CH
2 SMe
CF
3 H Br CH(Me)CH 2 SMe OCF 3 H Cl CH(Me)CH 2 SMe
CF
3 H Br CH 2
CH
2
CH
2 SMe OCF 3 H Cl CH 2
CH
2
CH
2 SMe
CF
3 H Br CH 2
CH
2 S(=O)Me OCF 3 H Cl CH 2
CH
2 S(=O)Me
CF
3 H Br CH(Me)CH 2 S(=O)Me OCF 3 H Cl CH(Me)CH 2 S(=O)Me
CF
3 H Br CH 2
CH
2
CH
2 S(=O)Me OCF 3 H Cl CH 2
CH
2
CH
2 S(=O)Me
CF
3 H Br CH 2
CH
2
S(O)
2 Me OCF 3 H Cl CH 2
CH
2
S(O)
2 Me
CF
3 H Br CH(Me)CH 2
S(O)
2 Me OCF 3 H Cl CH(Me)CH 2
S(O)
2 Me
CF
3 H Br CH 2
CH
2
CH
2
S(O)
2 Me OCF 3 H Cl CH 2
CH
2
CH
2
S(O)
2 Me
CF
3 H Br CH 2
C(=O)N(H)CH
2
CF
3
OCF
3 H Cl CH 2
C(=O)N(H)CH
2
CF
3
CF
3 H Br CH(Me)C(=O)N(H)CH 2
CF
3
OCF
3 H Cl CH(Me)C(=O)N(H)CH 2
CF
3
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2 SMe OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2 SMe
CF
3 H Br CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me OCF 3 H Cl CH 2
C(=O)N(H)CH
2
CH
2
S(O)
2 Me WO 2009/126668 PCT/US2009/039832 85 TABLE 11
R
2 a Z is / ; and Q is
R
2 b 5
R
2 c OR 0
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5 Cl H Cl CH 3
CF
3 H Cl CH 3 Cl H Cl CH 2
CH
3
CF
3 H Cl CH 2
CH
3 Cl H Cl CH 2 -i-Pr CF 3 H Cl CH 2 -i-Pr Cl H Cl n-Pr CF 3 H Cl n-Pr Cl H Cl i-Pr CF 3 H Cl i-Pr Cl H Cl s-Bu CF 3 H Cl s-Bu Cl H Cl t-Bu CF 3 H Cl t-Bu Cl H Cl (CH2) 5
CH
3
CF
3 H Cl (CH2) 5
CH
3 Cl H Cl CH 2 Ph CF 3 H Cl CH 2 Ph Br H Br CH 3
CF
3 H CF 3
CH
3 Br H Br CH 2
CH
3
CF
3 H CF 3
CH
2
CH
3 Br H Br CH 2 -i-Pr CF 3 H CF 3
CH
2 -i-Pr Br H Br n-Pr CF 3 H CF 3 n-Pr Br H Br i-Pr CF 3 H CF 3 i-Pr Br H Br s-Bu CF 3 H CF 3 s-Bu Br H Br t-Bu CF 3 H CF 3 t-Bu Br H Br (CH2) 5
CH
3
CF
3 H CF 3 (CH2) 5
CH
3 Br H Br CH 2 Ph CF 3 H CF 3
CH
2 Ph
CF
3 H H CH 3 Cl Cl Cl CH 3
CF
3 H H CH 2
CH
3 Cl Cl Cl CH 2
CH
3
CF
3 H H CH 2 -i-Pr Cl Cl Cl CH 2 -i-Pr
CF
3 H H n-Pr Cl Cl Cl n-Pr
CF
3 H H i-Pr Cl Cl Cl i-Pr
CF
3 H H s-Bu Cl Cl Cl s-Bu
CF
3 H H t-Bu Cl Cl Cl t-Bu
CF
3 H H (CH2) 5
CH
3 Cl Cl Cl (CH2) 5
CH
3 WO 2009/126668 PCT/US2009/039832 86
R
2 a R2b R 2 c R5 R 2 a R2b R 2 c R5
CF
3 H H CH 2 Ph Cl Cl Cl CH 2 Ph
CF
3 H F CH 3 Cl F Cl CH 3
CF
3 H F CH 2
CH
3 Cl F Cl CH 2
CH
3
CF
3 H F CH 2 -i-Pr Cl F Cl CH 2 -i-Pr
CF
3 H F n-Pr Cl F Cl n-Pr
CF
3 H F i-Pr Cl F Cl i-Pr
CF
3 H F s-Bu Cl F Cl s-Bu
CF
3 H F t-Bu Cl F Cl t-Bu
CF
3 H F (CH2) 5
CH
3 Cl F Cl (CH2) 5
CH
3
CF
3 H F CH 2 Ph Cl F Cl CH 2 Ph
CF
3 H Br CH 3
OCF
3 H Cl CH 3
CF
3 H Br CH 2
CH
3
OCF
3 H Cl CH 2
CH
3
CF
3 H Br CH 2 -i-Pr OCF 3 H Cl CH 2 -i-Pr
CF
3 H Br n-Pr OCF 3 H Cl n-Pr
CF
3 H Br i-Pr OCF 3 H Cl i-Pr
CF
3 H Br s-Bu OCF 3 H Cl s-Bu
CF
3 H Br t-Bu OCF 3 H Cl t-Bu
CF
3 H Br (CH 2
)
5
CH
3
OCF
3 H Cl (CH 2
)
5
CH
3
CF
3 H Br CH 2 Ph OCF 3 H Cl CH 2 Ph TABLE 12
R
2 a Z is / ; and Q is
R
2 b R 2c / 3 R
R
2 a R 2 b R 2 c R3 R 2 a R 2 b R 2 c R3 Cl H Cl Cl CF 3 H Cl Cl Cl H Cl Br CF 3 H Cl Br Cl H Cl I CF 3 H Cl I Cl H Cl OH CF 3 H Cl OH Cl H Cl OMe CF 3 H Cl OMe Cl H Cl OS(O) 2
CF
3
CF
3 H Cl OS(O) 2
CF
3 WO 2009/126668 PCT/US2009/039832 87
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3 Cl H Cl nitro CF 3 H Cl nitro Cl H Cl NH 2
CF
3 H Cl NH 2 Cl H Cl cyano CF 3 H Cl cyano Cl H Cl Me CF 3 H Cl Me Cl H Cl CH 2 C1 CF 3 H Cl CH 2 C1 Cl H Cl CH 2 Br CF 3 H Cl CH 2 Br Cl H Cl CH 2 OH CF 3 H Cl CH 2 OH Cl H Cl CH 2 OC(O)Me CF 3 H Cl CH 2 OC(O)Me Cl H Cl CO 2 H CF 3 H Cl CO 2 H Cl H Cl n-Pr CF 3 H Cl n-Pr Br H Br Cl CF 3 H CF 3 Cl Br H Br Br CF 3 H CF 3 Br Br H Br
CF
3 H CF 3 I Br H Br OH CF 3 H CF 3 OH Br H Br OMe CF 3 H CF 3 OMe Br H Br OS(O) 2
CF
3 CF 3 H CF 3
OS(O)
2
CF
3 Br H Br nitro CF 3 H CF 3 nitro Br H Br
NH
2 CF 3 H CF 3 NH 2 Br H Br cyano CF 3 H CF 3 cyano Br H Br Me CF 3 H CF 3 Me Br H Br CH 2 C1 CF 3 H CF 3
CH
2 C1 Br H Br CH 2 Br CF 3 H CF 3
CH
2 Br Br H Br CH 2 OH CF 3 H CF 3
CH
2 OH Br H Br CH 2 OC(O)Me CF 3 H CF 3
CH
2 OC(O)Me Br H Br CO 2 H CF 3 H CF 3
CO
2 H Br H Br n-Pr CF 3 H CF 3 n-Pr
CF
3 H H Cl Cl Cl Cl Cl
CF
3 H H Br Cl Cl Cl Br
CF
3 H H I Cl Cl Cl I
CF
3 H H OH Cl Cl Cl OH
CF
3 H H OMe Cl Cl Cl OMe
CF
3 H H OS(O) 2
CF
3 Cl Cl Cl OS(O) 2
CF
3
CF
3 H H nitro Cl Cl Cl nitro
CF
3 H H NH 2 Cl Cl Cl NH 2
CF
3 H H cyano Cl Cl Cl cyano WO 2009/126668 PCT/US2009/039832 88
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3
CF
3 H H Me Cl Cl Cl Me
CF
3 H H CH 2 C1 Cl Cl Cl CH 2 C1
CF
3 H H CH 2 Br Cl Cl Cl CH 2 Br
CF
3 H H CH 2 OH Cl Cl Cl CH 2 OH
CF
3 H H CH 2 OC(O)Me Cl Cl Cl CH 2 OC(O)Me
CF
3 H H CO 2 H Cl Cl Cl CO 2 H
CF
3 H H n-Pr Cl Cl Cl n-Pr
CF
3 H F Cl Cl F Cl Cl
CF
3 H F Br Cl F Cl Br
CF
3 H F I Cl F Cl I
CF
3 H F OH Cl F Cl OH
CF
3 H F OMe Cl F Cl OMe
CF
3 H F OS(O) 2
CF
3 Cl F Cl OS(O) 2
CF
3
CF
3 H F nitro Cl F Cl nitro
CF
3 H F NH 2 Cl F Cl NH 2
CF
3 H F cyano Cl F Cl cyano
CF
3 H F Me Cl F Cl Me
CF
3 H F CH 2 C1 Cl F Cl CH 2 C1
CF
3 H F CH 2 Br Cl F Cl CH 2 Br
CF
3 H F CH 2 OH Cl F Cl CH 2 OH
CF
3 H F CH 2 OC(O)Me Cl F Cl CH 2 OC(O)Me
CF
3 H F CO 2 H Cl F Cl CO 2 H
CF
3 H F n-Pr Cl F Cl n-Pr
CF
3 H Br Cl OCF 3 H Cl Cl
CF
3 H Br Br OCF 3 H Cl Br
CF
3 H Br I OCF 3 H Cl I
CF
3 H Br OH OCF 3 H Cl OH
CF
3 H Br OMe OCF 3 H Cl OMe
CF
3 H Br OS(O) 2
CF
3
OCF
3 H Cl OS(O) 2
CF
3
CF
3 H Br nitro OCF 3 H Cl nitro
CF
3 H Br NH 2
OCF
3 H Cl NH 2
CF
3 H Br cyano OCF 3 H Cl cyano
CF
3 H Br Me OCF 3 H Cl Me
CF
3 H Br CH 2 C1 OCF 3 H Cl CH 2 C1
CF
3 H Br CH 2 Br OCF 3 H Cl CH 2 Br
CF
3 H Br CH 2 OH OCF 3 H Cl CH 2 OH
CF
3 H Br CH 2 OC(O)Me OCF 3 H Cl CH 2 OC(O)Me WO 2009/126668 PCT/US2009/039832 89
R
2 a R2b R 2 c R3 R 2 a R2b R 2 c R3
CF
3 H Br CO 2 H OCF 3 H C1 CO 2 H
CF
3 H Br n-Pr OCF 3 H C1 n-Pr Tables 13-14 relate to the method of Scheme 2 converting compounds of Formula 5 to Grignard reagents, which are contacted with compounds of Formula 6 to prepare compounds of Formula 2. X 1 can be the same as or different than X, as explained in the description of the method of Scheme 2. 0 Y -CF3 [Mg] 1 6 F 3 C z-x ,_____ Iz-Mg-x1 5 12 z 5 2 In the example transformations embodied in these tables the solvent comprises tetrahydrofuran. TABLE 13
R
2 a Z is R ; and [Mg] is magnesium metal (e.g., turnings).
R
2 b
R
2 c
R
2 a R 2 b R 2 c X Y R 2 a R 2 b R 2 c X Y C1 H C1 I OMe CF 3 H C1 I OMe Cl H C1 I OEt CF 3 H C1 I OEt C1 H C1 I 0-i-Pr CF 3 H C1 I 0-i-Pr C1 H C1 I O(CH 2
)
4
CH
3
CF
3 H C1 I O(CH 2
)
4
CH
3 C1 H C1 I N(CH 3
)
2
CF
3 H C1 I N(CH 3
)
2 C1 H C1 I N(CH 3
)(CH
2
CH
3 ) CF 3 H C1 I N(CH 3
)(CH
2
CH
3 ) C1 H C1 I N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H C1 I N(CH 2
CH
2
OCH
2
CH
2 ) C1 H C1 Br OMe CF 3 H C1 Br OMe C1 H C1 Br OEt CF 3 H C1 Br OEt C1 H C1 Br 0-i-Pr CF 3 H C1 Br 0-i-Pr C1 H C1 Br O(CH 2
)
4
CH
3
CF
3 H C1 Br O(CH 2
)
4
CH
3 C1 H C1 Br N(CH 3
)
2
CF
3 H C1 Br N(CH 3
)
2 C1 H C1 Br N(CH 3
)(CH
2
CH
3 ) CF 3 H C1 Br N(CH 3
)(CH
2
CH
3 ) C1 H C1 Br N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H C1 Br N(CH 2
CH
2
OCH
2
CH
2
)
WO 2009/126668 PCT/US2009/039832 90
R
2 a R2b R 2 c X Y R 2 a R2b R 2 c X Y
CF
3 H Br I OMe CF 3 H CF 3 I OMe
CF
3 H Br I OEt CF 3 H CF 3 I OEt
CF
3 H Br I O-i-Pr CF 3 H CF 3 I O-i-Pr
CF
3 H Br I O(CH 2
)
4
CH
3
CF
3 H CF 3 I O(CH 2
)
4
CH
3
CF
3 H Br I N(CH 3
)
2
CF
3 H CF 3 I N(CH 3
)
2
CF
3 H Br I N(CH 3
)(CH
2
CH
3 ) CF 3 H CF 3 I N(CH 3
)(CH
2
CH
3 )
CF
3 H Br I N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H CF 3 I N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H H I OMe CF 3 H CF 3 Br OMe
CF
3 H H I OEt CF 3 H CF 3 Br OEt
CF
3 H H I O-i-Pr CF 3 H CF 3 Br O-i-Pr
CF
3 H H I O(CH 2
)
4
CH
3
CF
3 H CF 3 Br O(CH 2
)
4
CH
3
CF
3 H H I N(CH 3
)
2
CF
3 H CF 3 Br N(CH 3
)
2
CF
3 H H I N(CH 3
)(CH
2
CH
3 ) CF 3 H CF 3 Br N(CH 3
)(CH
2
CH
3 )
CF
3 H H I N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H CF 3 Br N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H H Br OMe CF 3 H CF 3 Cl OMe
CF
3 H H Br OEt CF 3 H CF 3 Cl OEt
CF
3 H H Br O-i-Pr CF 3 H CF 3 Cl 0-i-Pr
CF
3 H H Br O(CH 2
)
4
CH
3
CF
3 H CF 3 Cl O(CH 2
)
4
CH
3
CF
3 H H Br N(CH 3
)
2
CF
3 H CF 3 Cl N(CH 3
)
2
CF
3 H H Br N(CH 3
)(CH
2
CH
3 ) CF 3 H CF 3 Cl N(CH 3
)(CH
2
CH
3 )
CF
3 H H Br N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H CF 3 Cl N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H H Cl OMe Cl Cl Cl I OMe
CF
3 H H Cl OEt Cl Cl Cl I OEt
CF
3 H H Cl 0-i-Pr Cl Cl Cl I O-i-Pr
CF
3 H H Cl O(CH2) 4
CH
3 Cl Cl Cl I O(CH2) 4
CH
3
CF
3 H H Cl N(CH 3
)
2 Cl Cl Cl I N(CH 3
)
2
CF
3 H H Cl N(CH 3
)(CH
2
CH
3 ) Cl Cl Cl I N(CH 3
)(CH
2
CH
3 )
CF
3 H H Cl N(CH 2
CH
2
OCH
2
CH
2 ) Cl Cl Cl I N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H F I OMe Cl Cl Cl Br OMe
CF
3 H F I OEt Cl Cl Cl Br OEt
CF
3 H F I O-i-Pr Cl Cl Cl Br O-i-Pr WO 2009/126668 PCT/US2009/039832 91
R
2 a R2b R 2 c X Y R 2 a R2b R 2 c X Y
CF
3 H F I O(CH2) 4
CH
3 C1 C1 CI Br O(CH2) 4
CH
3
CF
3 H F I N(CH 3
)
2 C1 C1 CI Br N(CH 3
)
2
CF
3 H F I N(CH 3
)(CH
2
CH
3 ) C1 C1 CI Br N(CH 3
)(CH
2
CH
3 )
CF
3 H F I N(CH 2
CH
2
OCH
2
CH
2 ) C1 C1 CI Br N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H F Br OMe C1 F C1 I OMe
CF
3 H F Br OEt C1 F C1 I OEt
CF
3 H F Br 0-i-Pr C1 F C1 I 0-i-Pr
CF
3 H F Br O(CH2) 4
CH
3 C1 F C1 I O(CH2) 4
CH
3
CF
3 H F Br N(CH 3
)
2 C1 F C1 I N(CH 3
)
2
CF
3 H F Br N(CH 3
)(CH
2
CH
3 ) C1 F C1 I N(CH 3
)(CH
2
CH
3 )
CF
3 H F Br N(CH 2
CH
2
OCH
2
CH
2 ) C1 F C1 I N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H F CI OMe C1 F CI Br OMe
CF
3 H F CI OEt C1 F CI Br OEt
CF
3 H F CI 0-i-Pr C1 F CI Br 0-i-Pr
CF
3 H F CI O(CH2) 4
CH
3 C1 F CI Br O(CH2) 4
CH
3
CF
3 H F CI N(CH 3
)
2 C1 F CI Br N(CH 3
)
2
CF
3 H F CI N(CH 3
)(CH
2
CH
3 ) C1 F CI Br N(CH 3
)(CH
2
CH
3 )
CF
3 H F CI N(CH 2
CH
2
OCH
2
CH
2 ) C1 F CI Br N(CH 2
CH
2
OCH
2
CH
2 ) TABLE 14
R
2 a Z is / ; and [Mg] is isopropylmagnesium chloride.
R
2 b
R
2 c
R
2 a R 2 b R 2 c X Y R 2 a R 2 b R 2 c X Y CI H CI I OMe CF 3 H C1 I OMe CI H CI I OEt CF 3 H C1 I OEt CI H CI I 0-i-Pr CF 3 H C1 I 0-i-Pr CI H CI I O(CH 2
)
4
CH
3
CF
3 H C1 I O(CH 2
)
4
CH
3 CI H CI I N(CH 3
)
2
CF
3 H C1 I N(CH 3
)
2 CI H CI I N(CH 3
)(CH
2
CH
3 ) CF 3 H C1 I N(CH 3
)(CH
2
CH
3 ) CI H CI I N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H C1 I N(CH 2
CH
2
OCH
2
CH
2
)
WO 2009/126668 PCT/US2009/039832 92
R
2 a R2b R 2 c X Y R 2 a R2b R 2 c X Y Cl H Cl Br OMe CF 3 H Cl Br OMe Cl H Cl Br OEt CF 3 H Cl Br OEt Cl H Cl Br O-i-Pr CF 3 H Cl Br O-i-Pr Cl H Cl Br O(CH2) 4
CH
3
CF
3 H Cl Br O(CH2) 4
CH
3 Cl H Cl Br N(CH 3
)
2
CF
3 H Cl Br N(CH 3
)
2 Cl H Cl Br N(CH 3
)(CH
2
CH
3 ) CF 3 H Cl Br N(CH 3
)(CH
2
CH
3 ) Cl H Cl Br N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H Cl Br N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H Br I OMe CF 3 H CF 3 I OMe
CF
3 H Br I OEt CF 3 H CF 3 I OEt
CF
3 H Br I O-i-Pr CF 3 H CF 3 I O-i-Pr
CF
3 H Br I O(CH 2
)
4
CH
3
CF
3 H CF 3 I O(CH 2
)
4
CH
3
CF
3 H Br I N(CH 3
)
2
CF
3 H CF 3 I N(CH 3
)
2
CF
3 H Br I N(CH 3
)(CH
2
CH
3 ) CF 3 H CF 3 I N(CH 3
)(CH
2
CH
3 )
CF
3 H Br I N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H CF 3 I N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H H I OMe CF 3 H CF 3 Br OMe
CF
3 H H I OEt CF 3 H CF 3 Br OEt
CF
3 H H I O-i-Pr CF 3 H CF 3 Br O-i-Pr
CF
3 H H I O(CH 2
)
4
CH
3
CF
3 H CF 3 Br O(CH 2
)
4
CH
3
CF
3 H H I N(CH 3
)
2
CF
3 H CF 3 Br N(CH 3
)
2
CF
3 H H I N(CH 3
)(CH
2
CH
3 ) CF 3 H CF 3 Br N(CH 3
)(CH
2
CH
3 )
CF
3 H H I N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H CF 3 Br N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H H Br OMe CF 3 H CF 3 Cl OMe
CF
3 H H Br OEt CF 3 H CF 3 Cl OEt
CF
3 H H Br O-i-Pr CF 3 H CF 3 Cl 0-i-Pr
CF
3 H H Br O(CH 2
)
4
CH
3
CF
3 H CF 3 Cl O(CH 2
)
4
CH
3
CF
3 H H Br N(CH 3
)
2
CF
3 H CF 3 Cl N(CH 3
)
2
CF
3 H H Br N(CH 3
)(CH
2
CH
3 ) CF 3 H CF 3 Cl N(CH 3
)(CH
2
CH
3 )
CF
3 H H Br N(CH 2
CH
2
OCH
2
CH
2 ) CF 3 H CF 3 Cl N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H H Cl OMe Cl Cl Cl I OMe
CF
3 H H Cl OEt Cl Cl Cl I OEt
CF
3 H H Cl 0-i-Pr Cl Cl Cl I O-i-Pr
CF
3 H H Cl O(CH2) 4
CH
3 Cl Cl Cl I O(CH2) 4
CH
3 WO 2009/126668 PCT/US2009/039832 93
R
2 a R2b R 2 c X Y R 2 a R2b R 2 c X Y
CF
3 H H CI N(CH 3
)
2 C1 C1 C1 I N(CH 3
)
2
CF
3 H H CI N(CH 3
)(CH
2
CH
3 ) C1 C1 C1 I N(CH 3
)(CH
2
CH
3 )
CF
3 H H CI N(CH 2
CH
2
OCH
2
CH
2 ) C1 C1 C1 I N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H F I OMe C1 C1 CI Br OMe
CF
3 H F I OEt C1 C1 CI Br OEt
CF
3 H F I 0-i-Pr C1 C1 CI Br 0-i-Pr
CF
3 H F I O(CH2) 4
CH
3 C1 C1 CI Br O(CH2) 4
CH
3
CF
3 H F I N(CH 3
)
2 C1 C1 CI Br N(CH 3
)
2
CF
3 H F I N(CH 3
)(CH
2
CH
3 ) C1 C1 CI Br N(CH 3
)(CH
2
CH
3 )
CF
3 H F I N(CH 2
CH
2
OCH
2
CH
2 ) C1 C1 CI Br N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H F Br OMe C1 F C1 I OMe
CF
3 H F Br OEt C1 F C1 I OEt
CF
3 H F Br 0-i-Pr C1 F C1 I 0-i-Pr
CF
3 H F Br O(CH2) 4
CH
3 C1 F C1 I O(CH2) 4
CH
3
CF
3 H F Br N(CH 3
)
2 C1 F C1 I N(CH 3
)
2
CF
3 H F Br N(CH 3
)(CH
2
CH
3 ) C1 F C1 I N(CH 3
)(CH
2
CH
3 )
CF
3 H F Br N(CH 2
CH
2
OCH
2
CH
2 ) C1 F C1 I N(CH 2
CH
2
OCH
2
CH
2 )
CF
3 H F CI OMe C1 F CI Br OMe
CF
3 H F CI OEt C1 F CI Br OEt
CF
3 H F CI 0-i-Pr C1 F CI Br 0-i-Pr
CF
3 H F CI O(CH 2
)
4
CH
3 C1 F CI Br O(CH 2
)
4
CH
3
CF
3 H F CI N(CH 3
)
2 C1 F CI Br N(CH 3
)
2
CF
3 H F CI N(CH 3
)(CH
2
CH
3 ) C1 F CI Br N(CH 3
)(CH
2
CH
3 )
CF
3 H F CI N(CH 2
CH
2
OCH
2
CH
2 ) C1 F CI Br N(CH 2
CH
2
OCH
2
CH
2 ) The following compounds of Formula 3 defined in Table 15 are of particular note as intermediates for preparing the corresponding compounds of Formula 1 as shown in Schemes 1, la and lb by the procedures described herein together with methods known in 5 the art.
WO 2009/126668 PCT/US2009/039832 94 TABLE 15 0
-
, *
H
3 C H 0
CH
2
CH
3
CH
2 -c-Pr CH 2
CH
2
SO
2 Et
CH
2 -i-Pr CH 2
CH
2 SMe CH 2
CH
2
SO
2 (n-Pr)
CH
2
CH
2 C1 CH(Me)CH 2 SMe CH 2
CH
2
CH
2
SO
2 Et
CH
2
CH
2 OH CH 2
CH
2
CH
2 SMe CH 2 C(O)NH(Me) CH(Me)CH 2 OH CH 2
CH
2 S(O)Me CH 2 C(O)NH(n-Pr)
CH
2 CH(Me)OH CH(Me)CH 2 S(O)Me CH 2 C(O)NH(s-Bu)
CH
2 C(Me) 2 0H CH 2
CH
2
CH
2 S(O)Me CH 2 C(O)NMe 2
CH
2
CH
2
CH
2 OH CH 2
CH
2
SO
2 Me CH 2 C(O)NMe(Et)
CH
2 C(Me) 2
CH
2 OH CH(Me)CH 2
SO
2 Me CH(Me)C(0)NH(Me)
CH
2
CH
2 CH(Me)OH CH 2
CH
2
CH
2
SO
2 Me CH(Me)C(0)NH(Et)
CH
2 C(O)N(H)Et CH 2
C(O)N(H)CH
2
CF
3 CH(Me)C(0)NH(n-Pr)
CH
2 C(O)N(H)-i-Pr CH(Me)C(O)N(H)CH 2
CF
3 CH(Me)C(0)NH(i-Pr)
CH
2
C(O)N(H)CH
2 -i-Pr CH 2
C(O)N(H)CH
2
CH
2 SMe CH(Me)C(O)NH(s-Bu) CH(Me)C(O)N(H)CH 2 -i-Pr CH 2
C(O)N(H)CH
2
CH
2
SO
2 Me CH 2
C(O)NHCH
2
CHF
2
CH
2
C(O)N(H)CH
2
CH
2 C1 CH 2
C(O)NHCH
2
CH
2
CF
3 CH(Me)C(O)N(H)CH 2
CH
2 C1 CH 2
CH
2 SEt CH 2 C(O)NHCH(Me)CF 3
CH
2
C(O)N(H)CH
2
CH
2 F CH 2
CH
2 S(n-Pr) CH 2
C(O)NHCH
2 CH(Me)CF 3 CH(Me)C(O)N(H)CH 2
CH
2 F CH 2
CH
2
CH
2 SEt CH(Me)C(O)NHCH 2
CHF
2
CH
2
CF
3
CH
2
CH
2 S(O)Et CH(Me)C(O)NHCH 2
CH
2
CF
3
CH
2 -(2-Py) CH 2
CH
2 S(O)(n-Pr) CH(Me)C(O)NHCH(Me)CF 3
CH
2 -(4-Thz) CH 2
CH
2
CH
2 S(O)Et CH(Me)C(O)NHCH 2 CH(Me)CF 3

Claims (22)

1. A method for preparing a compound of Formula 1 0 F 3 C z 5 wherein Z is optionally substituted phenyl; and Q is phenyl or 1 -naphthalenyl, each optionally substituted; comprising distilling water from a mixture comprising a compound of Formula 2 F 3 C >_O zj~ 2 a compound of Formula 3 0 H 3 C <Q 3 10 a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4 M(OH) 2 4 wherein M is Ca, Sr or Ba, alkali metal carbonates of Formula 4a (M ) 2 CO3 4a 15 wherein M 1 is Li, Na or K, 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water.
2. The method of Claim 1 wherein the base comprises an alkaline earth metal hydroxide of Formula 4 and the mixture further comprises a polar aprotic solvent. WO 2009/126668 PCT/US2009/039832 96
3. The method of Claim 2 wherein M is Ca.
4. The method of Claim 2 wherein the polar aprotic solvent comprises N,N-dimethylformamide.
5. The method of Claim 2 wherein the aprotic solvent capable of forming a low 5 boiling azeotrope with water comprises tert-butyl methyl ether.
6. The method of Claim 1 wherein the base comprises an alkali metal carbonate of Formula 4a.
7. The method of Claim 6 wherein M 1 is K.
8. The method of Claim 1 wherein the base comprises 1,5-diazabicyclo[4.3.0]non 10 5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene, or a mixture thereof.
9. The method of any one of Claims 6, 7 or 8 wherein the aprotic solvent capable of forming a low-boiling azeotrope with water comprises acetonitrile.
10. The method of Claim 1 wherein Z is phenyl optionally substituted with up to 5 substituents independently selected 15 from R 2 ; Q is phenyl or 1 -naphthalenyl, each optionally substituted with up to four substituents independently selected from R 3 ; each R 2 is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylamino, C 2 -C 6 20 dialkylamino, -CN or -NO 2 ; each R 3 is independently halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 2 -C 6 alkynyl, C 3 -C 6 haloalkynyl, C 3 -C 6 cycloalkyl, C 3 C 6 halocycloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, C 2 -C 7 alkylcarbonyl, C 2 -C 7 haloalkylcarbonyl, Ci-C 6 haloalkylthio, Ci-C 6 25 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, -N(R 4 )R 5 , -C(=W)N(R 4 )R 5 , -C(=W)OR 5 , -CN, -OR 11 or -NO 2 ; or a phenyl ring or a 5- or 6-membered saturated or unsaturated heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 3 -C 6 30 cycloalkyl, C 3 -C 6 halocycloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, -CN, -NO 2 , -N(R 4 )R 5 , -C(=W)N(R 4 )R 5 , -C(=O)OR 5 and R 7 ; WO 2009/126668 PCT/US2009/039832 97 each R 4 is independently H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 7 alkylcycloalkyl, C 4 -C 7 cycloalkylalkyl, C 2 -C 7 alkylcarbonyl or C 2 -C 7 alkoxycarbonyl; each R 5 is independently H; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 5 cycloalkyl, C 4 -C 7 alkylcycloalkyl or C 4 -C 7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R 6 ; each R 6 is independently halogen, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 alkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 alkylamino, C 2 -C 8 dialkylamino, C 3 -C 6 cycloalkylamino, C 2 -C 7 alkylcarbonyl, C 2 -C 7 10 alkoxycarbonyl, C 2 -C 7 alkylaminocarbonyl, C 3 -C 9 dialkylaminocarbonyl, C 2 -C 7 haloalkylcarbonyl, C 2 -C 7 haloalkoxycarbonyl, C 2 -C 7 haloalkylaminocarbonyl, C 3 -C 9 halodialkylaminocarbonyl, -OH, -NH 2 , -CN or -NO 2 ; or Q1; each R 7 is independently a phenyl ring or a pyridinyl ring, each ring optionally 15 substituted with one or more substituents independently selected from R 8 ; each R 8 is independently halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, Ci-C 6 alkylamino, C 2 -C 6 dialkylamino, C 2 -C 4 alkylcarbonyl, C 2 -C 4 alkoxycarbonyl, 20 C 2 -C 7 alkylaminocarbonyl, C 3 -C 7 dialkylaminocarbonyl, -OH, -NH 2 , -C(=O)OH, -CN or -NO 2 ; each Q 1 is independently a phenyl ring or a 5- or 6-membered saturated or unsaturated heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 3 -C 6 25 cycloalkyl, C 3 -C 6 halocycloalkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkylthio, Ci-C 6 haloalkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 haloalkylsulfinyl, Ci-C 6 alkylsulfonyl, Ci-C 6 haloalkylsulfonyl, Ci-C 6 alkylamino, C 2 -C 6 dialkylamino, -CN, -NO 2 , -C(=W)N(R 9 )R 10 and -C(=O)OR10; each R 9 is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 30 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 7 alkylcycloalkyl, C 4 -C 7 cycloalkylalkyl, C 2 -C 7 alkylcarbonyl or C 2 -C 7 alkoxycarbonyl; each R 10 is independently H; or C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 4 -C 7 alkylcycloalkyl or C 4 -C 7 cycloalkylalkyl; each R 11 is independently H; or C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 35 C 4 -C 7 alkylcycloalkyl, C4-C 7 cycloalkylalkyl, C 2 -C 7 alkylcarbonyl, C 2 -C 7 alkoxycarbonyl, Ci-C 6 alkylsulfonyl or Ci-C 6 haloalkylsulfonyl; and WO 2009/126668 PCT/US2009/039832 98 each W is independently 0 or S.
11. The method of Claim 10 wherein R 2 a Z is 2 b /Q is R 2 c R R 2 a is halogen, Ci-C 2 haloalkyl or Ci-C 2 haloalkoxy; R2b is H, halogen or cyano; 5 R 2 c is H, halogen or CF 3 ; R 3 is C(O)N(R 4 )R 5 or C(O)OR 5 a; R 4 is H, C 2 -C 7 alkylcarbonyl or C 2 -C 7 alkoxycarbonyl; and R 5 is C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, each substituted with one substituent independently selected from hydroxy, Ci-C 6 alkoxy, Ci-C 6 alkylthio, Ci-C 6 10 alkylsulfinyl, Ci-C 6 alkylsulfonyl, C 2 -C 7 alkylaminocarbonyl, C 3 -C 9 dialkylaminocarbonyl, C 2 -C 7 haloalkylaminocarbonyl and C 3 -C 9 halodialkylaminocarbonyl; and R 5 a is Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each optionally substituted with one or more substituents independently selected from halogen, Ci-C 2 alkoxy 15 and phenyl optionally substituted with up to 5 substituents selected from halogen and Ci-C 3 alkyl.
12. The method of Claim 1 wherein Z is phenyl optionally substituted with up to 5 substituents independently selected from R2; and 20 each R 2 is independently F, Cl, Br, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, Ci-C 6 alkoxy, Ci-C 6 fluoroalkoxy, Ci-C 6 alkylthio or Ci-C 6 fluoroalkylthio; further comprising preparing the compound of Formula 2 by (1) forming a reaction mixture comprising a Grignard reagent derived from a compound of Formula 5 z-X 5 25 wherein X is Cl, Br or I, by contacting the compound of Formula 5 with (a) magnesium metal, or (b) an alkylmagnesium halide WO 2009/126668 PCT/US2009/039832 99 in the presence of an ethereal solvent; and then (2) contacting the reaction mixture with a compound of Formula 6 O Y CF 3 6 wherein Y is OR 11 or NR 12 R 13 ; 5 R 11 is C 1 -C 5 alkyl; and R 12 and R 13 are independently Ci-C 2 alkyl; or R 1 2 and R 13 are taken together as -CH 2 CH 2 0CH 2 CH 2 -
13. The method of Claim 12 wherein Z is R 2 a R2b /\ R 2 c R 2 a is F, Cl, Br, C 1 -C 2 fluoroalkyl or C 1 -C 2 fluoroalkoxy; 10 R2b is H, F, Cl or Br; and R 2 c is H, F, Cl, Br or CF 3
14. A method for preparing a compound of Formula 2 F 3 C zo 2 wherein Z is phenyl optionally substituted with up to 5 substituents independently selected 15 from R 2 ; and each R 2 is independently F, Cl, Br, Ci-C 6 alkyl, Ci-C 6 fluoroalkyl, Ci-C 6 alkoxy, Ci-C 6 fluoroalkoxy, Ci-C 6 alkylthio or Ci-C 6 fluoroalkylthio; comprising (1) forming a reaction mixture comprising a Grignard reagent derived from a compound of 20 Formula 5 z-X 5 WO 2009/126668 PCT/US2009/039832 100 wherein X is I, by contacting the compound of Formula 5 with (a) magnesium metal, or (b) an alkylmagnesium halide 5 in the presence of an ethereal solvent; and then (2) contacting the reaction mixture with a compound of Formula 6 O Y CF 3 6 wherein Y is OR 11 or NR 12 R 13 ; R 11 is C 1 -C 5 alkyl; and 10 R 12 and R 13 are independently Ci-C 2 alkyl; or R 1 2 and R 13 are taken together as -CH 2 CH 2 0CH 2 CH 2 -
15. The method of Claim 14 wherein Z is R 2 a R2b /\ R 2 c R 2 a is F, Cl, Br, C 1 -C 2 fluoroalkyl or C 1 -C 2 fluoroalkoxy; R2b is H, F, Cl or Br; and 15 R 2 c is H, F, Cl, Br or CF 3
16. A method for preparing a compound of Formula 7 F 3 C ON Z YQ 7 wherein Z is optionally substituted phenyl; and 20 Q is phenyl or 1 -naphthalenyl, each optionally substituted; using a compound of Formula 1 WO 2009/126668 PCT/US2009/039832 101 0 F 3 C characterized by: preparing said compound of Formula 1 by the method of Claim 1.
17. The method of Claim 16 wherein R 2 a Zis R 2 b; Q is R 4 R 2 C R5 0 5 R 2 a is halogen, Ci-C 2 haloalkyl or Ci-C 2 haloalkoxy; R2b is H, halogen or cyano; R 2 c is H, halogen or CF 3 ; R 4 is H, C 2 -C 7 alkylcarbonyl or C 2 -C 7 alkoxycarbonyl; and R 5 is C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, each substituted with one substituent 10 independently selected from hydroxy, Ci-C 6 alkoxy, Ci-C 6 alkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 alkylsulfonyl, C 2 -C 7 alkylaminocarbonyl, C 3 -C 9 dialkylaminocarbonyl, C 2 -C 7 haloalkylaminocarbonyl and C 3 -C 9 halodialkylaminocarbonyl.
18. A method for preparing a compound of Formula 7 F3 O''N ZQ 15 wherein Z is optionally substituted phenyl; and Q is phenyl or 1 -naphthalenyl, each optionally substituted; using a compound of Formula 1 0 F 3 C 20 1 WO 2009/126668 PCT/US2009/039832 102 characterized by: using as said compound of Formula 1 a compound of Formula 1 prepared by the method of Claim 1.
19. The method of Claim 18 wherein R 2 a Zis R 2 b; Q is R 4 R 2 C R5 0 5 R 2 a is halogen, Ci-C 2 haloalkyl or Ci-C 2 haloalkoxy; R2b is H, halogen or cyano; R 2 c is H, halogen or CF 3 ; R4 is H, C 2 -C 7 alkylcarbonyl or C 2 -C 7 alkoxycarbonyl; and R 5 is C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, each substituted with one substituent 10 independently selected from hydroxy, Ci-C 6 alkoxy, Ci-C 6 alkylthio, Ci-C 6 alkylsulfinyl, Ci-C 6 alkylsulfonyl, C 2 -C 7 alkylaminocarbonyl, C 3 -C 9 dialkylaminocarbonyl, C 2 -C 7 haloalkylaminocarbonyl and C 3 -C 9 halodialkylaminocarbonyl.
20. A compound of Formula 2 F 3 C >--O Z 2 15 wherein Z is R 2 a R2b /\ R 2 c R 2 a is CF 3 ; R2b is H or halogen; and R 2 c is halogen.
21. A compound of Claim 20 selected from the group consisting of 1-[3-chloro-5-(trifluoromethyl)]-2,2,2-trifluoroethanone; and 20 1-[3-bromo-5-(trifluoromethyl)]-2,2,2-trifluoroethanone. WO 2009/126668 PCT/US2009/039832 103
22. A compound which is 1-chloro-3-iodo-5-(trifluoromethyl)benzene.
AU2009233858A 2008-04-09 2009-04-08 Method for preparing 3-trifluoromethyl chalcones Active AU2009233858B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2015202910A AU2015202910B2 (en) 2008-04-09 2015-05-28 Method for preparing 3-trifluoromethyl chalcones
AU2015202911A AU2015202911B2 (en) 2008-04-09 2015-05-28 Method for preparing 3-trifluoromethyl chalcones
AU2017235974A AU2017235974B2 (en) 2008-04-09 2017-09-28 Method for preparing 3-trifluoromethyl chalcones

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4345208P 2008-04-09 2008-04-09
US61/043,452 2008-04-09
US8043708P 2008-07-14 2008-07-14
US61/080,437 2008-07-14
PCT/US2009/039832 WO2009126668A2 (en) 2008-04-09 2009-04-08 Method for preparing 3-trifluoromethyl chalcones

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2015202911A Division AU2015202911B2 (en) 2008-04-09 2015-05-28 Method for preparing 3-trifluoromethyl chalcones
AU2015202910A Division AU2015202910B2 (en) 2008-04-09 2015-05-28 Method for preparing 3-trifluoromethyl chalcones

Publications (2)

Publication Number Publication Date
AU2009233858A1 true AU2009233858A1 (en) 2009-10-15
AU2009233858B2 AU2009233858B2 (en) 2015-03-12

Family

ID=40941677

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2009233858A Active AU2009233858B2 (en) 2008-04-09 2009-04-08 Method for preparing 3-trifluoromethyl chalcones
AU2015202910A Active AU2015202910B2 (en) 2008-04-09 2015-05-28 Method for preparing 3-trifluoromethyl chalcones
AU2015202911A Active AU2015202911B2 (en) 2008-04-09 2015-05-28 Method for preparing 3-trifluoromethyl chalcones
AU2017235974A Active AU2017235974B2 (en) 2008-04-09 2017-09-28 Method for preparing 3-trifluoromethyl chalcones

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2015202910A Active AU2015202910B2 (en) 2008-04-09 2015-05-28 Method for preparing 3-trifluoromethyl chalcones
AU2015202911A Active AU2015202911B2 (en) 2008-04-09 2015-05-28 Method for preparing 3-trifluoromethyl chalcones
AU2017235974A Active AU2017235974B2 (en) 2008-04-09 2017-09-28 Method for preparing 3-trifluoromethyl chalcones

Country Status (25)

Country Link
US (7) US8546618B2 (en)
EP (3) EP2706053B1 (en)
JP (2) JP5755135B2 (en)
KR (2) KR20160118372A (en)
CN (3) CN105646215B (en)
AR (1) AR071361A1 (en)
AU (4) AU2009233858B2 (en)
BR (1) BRPI0906906B8 (en)
CA (3) CA3052421C (en)
CO (1) CO6310992A2 (en)
DK (1) DK2260016T3 (en)
ES (3) ES2554511T3 (en)
HK (1) HK1154563A1 (en)
HU (1) HUE028299T2 (en)
IL (3) IL208118A (en)
LT (2) LT2706050T (en)
MX (1) MX2010011014A (en)
MY (3) MY198064A (en)
PL (1) PL2260016T3 (en)
PT (2) PT2706050T (en)
RU (1) RU2502720C2 (en)
TW (4) TWI583664B (en)
UA (1) UA112324C2 (en)
WO (1) WO2009126668A2 (en)
ZA (1) ZA201006482B (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1930136B (en) 2004-03-05 2012-02-08 日产化学工业株式会社 Isoxazoline-substituted benzamide compound and noxious organism control agent
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (en) 2005-12-30 2013-10-21 Du Pont Isoxazolines for controlling invertebrate pests
AU2008261793A1 (en) 2007-06-13 2008-12-18 E. I. Du Pont De Nemours And Company Isoxazoline insecticides
US8952175B2 (en) 2007-06-27 2015-02-10 Nissan Chemical Industries, Ltd. Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound
MX361762B (en) 2007-06-27 2018-12-17 Du Pont Animal pest control method.
TWI583664B (en) 2008-04-09 2017-05-21 杜邦股份有限公司 Carbonyl compound and method for preparing thereof
JP2011527307A (en) 2008-07-09 2011-10-27 ビーエーエスエフ ソシエタス・ヨーロピア Pesticide active mixture comprising isoxazoline compound I
JP5488835B2 (en) * 2008-09-04 2014-05-14 日産化学工業株式会社 Substituted acetophenone compound, method for producing the same, and use thereof
WO2010072781A2 (en) 2008-12-23 2010-07-01 Basf Se Imine compounds for combating invertebrate pests
JP5715065B2 (en) 2008-12-23 2015-05-07 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Substituted amidine compounds for combating harmful animals
WO2010112545A1 (en) 2009-04-01 2010-10-07 Basf Se Isoxazoline compounds for combating invertebrate pests
WO2010129345A2 (en) 2009-04-28 2010-11-11 Basf Corporation Foamable pesticide compositions
EP2424862B1 (en) 2009-04-30 2014-10-08 Basf Se Process for preparing substituted isoxazoline compounds and their precursors
MX2012002308A (en) 2009-08-28 2012-03-29 Basf Corp Foamable pesticide compositions and methods of application.
WO2011057942A1 (en) 2009-11-12 2011-05-19 Basf Se Insecticidal methods using pyridine compounds
MX2012005612A (en) 2009-11-17 2012-11-30 Merial Ltd Fluorinated oxa or thia heteroarylalkylsulfide derivatives for combating invertebrate pests.
WO2011064188A1 (en) 2009-11-27 2011-06-03 Basf Se Insecticidal methods using nitrogen-containing heteroaromatic compounds
MX2012006366A (en) 2009-12-04 2012-06-27 Basf Se Pesticidal bis-organosulfur compounds.
WO2011069955A1 (en) 2009-12-07 2011-06-16 Basf Se Sulfonimidamide compounds for combating animal pests
NZ600922A (en) 2009-12-17 2013-10-25 Merial Ltd Anti parasitic dihydroazole compounds and compositions comprising same
BR112012014944A2 (en) 2009-12-18 2015-09-15 Basf Se substituted azoline compounds, composition, use of a compound, and methods for controlling invertebrate pests and for treating, controlling, preventing or protecting animals against infestation or parasite infection.
EP2531493B1 (en) 2010-02-01 2015-07-22 Basf Se Substituted ketonic isoxazoline compounds and derivatives for combating animal pests
EP2550261B1 (en) 2010-03-23 2016-03-16 Basf Se Pyridazine compounds for controlling invertebrate pests
WO2011117804A1 (en) 2010-03-23 2011-09-29 Basf Se Pyridazine compounds for controlling invertebrate pests
CN103025161A (en) 2010-05-24 2013-04-03 明治制果药业株式会社 Noxious organism control agent
US8598087B2 (en) * 2010-05-27 2013-12-03 E. I. Du Pont De Nemours And Company Crystalline form of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4, 5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-0X0-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1- naph-thalenecarboxamide
JP5948320B2 (en) 2010-05-28 2016-07-06 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Pesticide mixture
US9085541B2 (en) 2010-06-23 2015-07-21 Basf Se Process for producing imine compounds for combating invertebrate pests
WO2012007426A1 (en) 2010-07-13 2012-01-19 Basf Se Azoline substituted isoxazoline benzamide compounds for combating animal pests
CN103003263B (en) 2010-07-22 2015-07-22 巴斯夫欧洲公司 Novel hetaryl (thio)carboxamide compounds for controlling invertebrate pests
CN103097376A (en) 2010-09-13 2013-05-08 巴斯夫欧洲公司 Pyridine compounds for controlling invertebrate pests ii
US20130180014A1 (en) 2010-09-13 2013-07-11 Basf Se Pyridine Compounds for Controlling Invertebrate Pests III
EP2616459B1 (en) 2010-09-13 2016-05-04 Basf Se Pyridine compounds for controlling invertebrate pests i
LT3150575T (en) * 2010-09-27 2023-12-27 Corteva Agriscience Llc Method for preparing 2-amino-n-(2,2,2-trifluoroethyl) acetamide
US8653000B2 (en) 2010-10-01 2014-02-18 Basf Se Imine substituted 2,4-diaryl-pyrroline derivatives as pesticides
EP2621897A1 (en) 2010-10-01 2013-08-07 Basf Se Imine compounds
WO2012059441A2 (en) 2010-11-03 2012-05-10 Basf Se Method for preparing substituted isoxazoline compounds and their precursors 4-chloro, 4-bromo- or 4-iodobenzaldehyde oximes
JP2014028758A (en) 2010-11-19 2014-02-13 Nissan Chem Ind Ltd Agent for controlling parasite and sanitary insect pest
US20130253012A1 (en) 2010-12-10 2013-09-26 Basf Se Pyrazole Compounds for Controlling Invertebrate Pests
BR112013014913A2 (en) 2010-12-20 2016-07-19 Basf Se pesticide mixtures, pesticidal or parasiticidal composition, method to protect vegetables from insect attack or infestation, to control insects, to control harmful phytopathogenic fungi, to protect vegetables from harmful phytopathogenic fungi, to protect material propagation of plants, for the protection of animals against parasitic infestation or infection, for the treatment of parasites infected or infected with
WO2012085081A1 (en) 2010-12-22 2012-06-28 Basf Se Sulfoximinamide compounds for combating invertebrate pests ii
EP2694502A1 (en) 2011-04-06 2014-02-12 Basf Se Substituted pyrimidinium compounds for combating animal pests
CN103492378B (en) 2011-04-21 2016-09-28 巴斯夫欧洲公司 Parasite killing pyrazole compound
EP2742027A1 (en) 2011-08-12 2014-06-18 Basf Se N-thio-anthranilamide compounds and their use as pesticides
CA2843083A1 (en) 2011-08-12 2013-02-21 Basf Se Anthranilamide compounds and their use as pesticides
AR087516A1 (en) 2011-08-12 2014-03-26 Basf Se N-TIO-ANTRANILAMIDE COMPOUNDS AND THEIR USES AS PESTICIDES
AR088786A1 (en) 2011-08-12 2014-07-10 Basf Se ANTRANILAMIDE COMPOUNDS AND THEIR USES AS PESTICIDES
JP2014522872A (en) 2011-08-12 2014-09-08 ビーエーエスエフ ソシエタス・ヨーロピア N-thio-anthranilamide compounds and their use as pesticides
BR112014003186A2 (en) 2011-08-12 2017-04-04 Basf Se compound of general formula (i), pesticide combination, agricultural or veterinary composition, method for combating or controlling invertebrate pests, method for protecting plants and seeds, seed, use of a compound and method for treating an animal
EP2744785A1 (en) 2011-08-18 2014-06-25 Basf Se Carbamoylmethoxy- and carbamoylmethylthio- and carbamoylmethylamino benzamides for combating invertebrate pests
JP2014524432A (en) 2011-08-18 2014-09-22 ビーエーエスエフ ソシエタス・ヨーロピア Carbamoylmethoxybenzamide and carbamoylmethylthiobenzamide and carbamoylmethylaminobenzamide for combating harmful invertebrates
EP2744784A1 (en) 2011-08-18 2014-06-25 Basf Se Carbamoylmethoxy- and carbamoylmethylthio- and carbamoylmethylamino benzamides for combating invertebrate pests
US20140213445A1 (en) 2011-09-02 2014-07-31 Basf Se Use of Pesticidal Active 3-Arylquinazolin-4-One Derivatives in Soil Application Methods
EP2750503A1 (en) 2011-09-02 2014-07-09 Basf Se Insecticidal active mixtures comprising arylquinazolinone compounds
WO2013069731A1 (en) 2011-11-08 2013-05-16 日産化学工業株式会社 Method for catalytic asymmetric synthesis of optically active isoxazoline compound, and optically active isoxazoline compound
ES2727479T3 (en) 2011-12-23 2019-10-16 Basf Se Isothiazoline compounds to fight invertebrate pests
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
CN104703982B (en) 2012-06-20 2018-01-05 巴斯夫欧洲公司 Pyrazole compound and the pesticide combination comprising pyrazole compound
EP2684879A1 (en) 2012-07-09 2014-01-15 Basf Se Substituted mesoionic compounds for combating animal pests
US20150230470A1 (en) 2012-09-21 2015-08-20 Basf Se Pyrethroid Insecticide For Protecting Plants And Seed
CN102964233A (en) * 2012-11-18 2013-03-13 大连九信生物化工科技有限公司 Synthetic method of 3,5-2-fluoro-(trifluoromethyl)benzophenone
SI2922845T1 (en) 2012-11-20 2018-10-30 Merial, Inc. Anthelmintic compounds and compositions and method of using thereof
CA2929234C (en) 2013-11-01 2022-01-11 Merial Limited Antiparisitic and pesticidal isoxazoline compounds
CN103664511B (en) * 2013-12-13 2015-07-08 浙江林江化工股份有限公司 Preparation method of 5-bromo-1,3-dichloro-2-fluorobenzene
NZ726874A (en) 2014-05-19 2018-03-23 Merial Inc Anthelmintic compounds
KR20170058883A (en) * 2014-09-19 2017-05-29 도오레 화인케미칼 가부시키가이샤 Method for producing 2'-trifluoromethyl group-substituted aromatic ketone
EP3207018B1 (en) * 2014-10-14 2018-07-25 Syngenta Participations AG Process for the preparation of 1-(3,5-dichloro-4-fluoro-phenyl)-2,2,2-trifluoro-ethanone
EP3207024B1 (en) * 2014-10-14 2018-07-25 Syngenta Participations AG Process for the preparation of halo-substituted trifluoroacetophenones
EP3207009B1 (en) * 2014-10-14 2020-05-06 Syngenta Participations AG Process for the preparation of halo-substituted benzenes
US10864193B2 (en) 2014-10-31 2020-12-15 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising fipronil at high concentrations
UY37137A (en) 2016-02-24 2017-09-29 Merial Inc ANTIPARASITARY COMPOUNDS OF ISOXAZOLINE, INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE THEM, METHODS AND USES OF THE SAME
CN106748695B (en) * 2016-11-28 2020-09-22 常州市阳光药业有限公司 Preparation method of m-trifluoromethyl cinnamaldehyde
MY202302A (en) 2017-09-06 2024-04-23 Bayer Animal Health Gmbh Topically administrable formulation for the control and prevention of animal parasites
TWI812673B (en) 2018-02-12 2023-08-21 美商富曼西公司 Naphthalene isoxazoline compounds for controlling invertebrate pests
TW202012399A (en) 2018-09-12 2020-04-01 美商富曼西公司 Isoxazoline compounds for controlling invertebrate pests
KR20210100149A (en) 2018-12-04 2021-08-13 바스프 에스이 Process for the preparation of 5-bromo-1,3-dichloro-2-fluoro-benzene
WO2022061918A1 (en) * 2020-09-28 2022-03-31 杭州臻挚生物科技有限公司 Preparation methods for 3,5-dihalobenzotrifluoride and 3'-chloro-5'-(trifluoromethyl)phenyltrifluoroethanone
CN112110790B (en) * 2020-09-28 2023-06-23 台州臻挚生物科技有限公司 Preparation method of 3, 5-dihalide benzotrifluoride and 3 '-chloro-5' -trifluoromethyl phenyl trifluoro-ethanone
CN113024390B (en) * 2021-02-22 2023-12-05 台州臻挚生物科技有限公司 Synthesis method of 3',5' -dichloro-2, 2-trifluoro acetophenone derivative
CN117412966A (en) 2021-06-02 2024-01-16 Fmc公司 Condensed pyridines for combating invertebrate pests
WO2023012821A1 (en) * 2021-08-01 2023-02-09 Zenfold Sustainable Technologies Private Limited A process for the preparation of carbamoyl benzamide phenyl isoxazoline class drug/s and its intermediates
CN113651765A (en) * 2021-08-20 2021-11-16 江苏君若药业有限公司 Synthesis of afurana
CN113636919B (en) * 2021-08-23 2023-10-24 上海恩氟佳科技有限公司 Method for synthesizing 3-chloro-5-trifluoromethyl trifluoroacetophenone
CN115710185B (en) * 2021-08-23 2024-05-03 中国石油化工股份有限公司 Method for producing methylamine using metal carbide catalyst
CN115433140B (en) * 2022-11-08 2023-01-31 世华合创生物技术开发(山东)有限公司 Synthetic method of Aforana
CN116903488B (en) * 2022-11-25 2023-12-15 济南久隆医药科技有限公司 Synthesis method of aforana
CN115784858B (en) * 2022-12-21 2023-07-21 济南久隆医药科技有限公司 Preparation method of 1- (3-chloro-5- (trifluoromethyl) phenyl) -2, 2-trifluoro-ethanone
WO2024175691A1 (en) 2023-02-24 2024-08-29 Krka, D.D., Novo Mesto Process for the preparation of substituted chalcones

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879532A (en) 1974-01-18 1975-04-22 Shell Oil Co Control by isoxazoles of endoparasitic nematodes
US4129568A (en) 1977-05-12 1978-12-12 Monsanto Company 2-[3-Aryl-2-isoxazolin-5-yl]benzoates
EP0074069B1 (en) * 1981-09-03 1986-01-08 Daikin Kogyo Co., Ltd. Process for preparing chlorotrifluoromethylbenzene
GB8523126D0 (en) * 1985-09-19 1985-10-23 Ici Plc Aryl pyridones
DE3534133A1 (en) 1985-09-25 1987-04-02 Kolbenschmidt Ag LOW-MAINTENANCE SLIDING BEARING MATERIAL
EP0338686B1 (en) * 1988-04-22 1994-06-22 Zeneca Limited Pyrimidinone derivatives
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
GB9505651D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
CN1076351C (en) 1996-04-26 2001-12-19 日本曹达株式会社 Heterocyclic substituted benzene derivatives and herbicides
CA2206151A1 (en) 1996-06-06 1997-12-06 Rohm And Haas Company Benzyloxy substituted aromatics and their use as fungicides and insecticides
US5932766A (en) 1997-05-30 1999-08-03 Abbott Laboratories Process for the preparation of substituted keto-enamines
GB9816729D0 (en) * 1998-08-01 1998-09-30 Hoechst Schering Agrevo Gmbh Substituted cyclohexylaminopyrimidines
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
GB9929562D0 (en) * 1999-12-14 2000-02-09 Novartis Ag Organic compounds
JP2002005224A (en) 2000-06-16 2002-01-09 Tokai Rubber Ind Ltd Active vibration control equipment of fluid filled-system
DE10114597A1 (en) 2001-03-23 2002-10-02 Bayer Cropscience Gmbh Arylisoxazoline derivatives, process for their preparation and their use as pesticides
BR0313943A (en) 2002-08-26 2005-08-02 Nissan Chemical Ind Ltd Substituted benzanilide compound and harmful organism control agent
DE10320782A1 (en) 2003-05-09 2004-11-25 Bayer Cropscience Ag Substituted oxyarenes
US7276632B2 (en) * 2003-12-15 2007-10-02 Basf Aktiengesellschaft Method for the production of 2,3-cis-substituted 2-aryl propenals
JP2005272452A (en) 2004-02-23 2005-10-06 Nissan Chem Ind Ltd Substituted benzanilide compound and pesticide
CN1930136B (en) 2004-03-05 2012-02-08 日产化学工业株式会社 Isoxazoline-substituted benzamide compound and noxious organism control agent
MXPA06010793A (en) 2004-03-26 2006-12-19 Cytokine Pharmasciences Inc Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor.
CN1247512C (en) * 2004-07-07 2006-03-29 浙江工业大学 Process for preparing trifluoromethyl acetophenone compound
JP5051340B2 (en) 2005-06-06 2012-10-17 日産化学工業株式会社 Substituted isoxazoline compounds and pest control agents
MY146795A (en) * 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
JP4479917B2 (en) 2005-09-02 2010-06-09 日産化学工業株式会社 Isoxazoline-substituted benzamide compounds and pest control agents
ES2443690T3 (en) 2005-09-02 2014-02-20 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and harmful agent controlling agent
JP2007106756A (en) 2005-09-14 2007-04-26 Nissan Chem Ind Ltd Substituted isoxazoline compound and pesticide
EP1965645A2 (en) 2005-12-14 2008-09-10 E.I. Du Pont De Nemours And Company Isoxazolines for controlling invertebrate pests
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
US7700808B2 (en) 2005-12-26 2010-04-20 Nissan Chemical Industries, Ltd. 1-3-bis(substituted phenyl)-3-hydroxypropan-1-one or 2-propen-1-one compound, and salt thereof
TWI412322B (en) 2005-12-30 2013-10-21 Du Pont Isoxazolines for controlling invertebrate pests
DE602007006288D1 (en) 2006-03-10 2010-06-17 Nissan Chemical Ind Ltd SUBSTITUTED ISOXAZOLIN COMPOUND AND PESTICIDES
AU2007240954A1 (en) * 2006-04-20 2007-11-01 E. I. Du Pont De Nemours And Company Pyrazolines for controlling invertebrate pests
JPWO2007125984A1 (en) 2006-04-28 2009-09-10 日本農薬株式会社 Isoxazoline derivatives, pest control agents and methods of use
JP2008044880A (en) 2006-08-15 2008-02-28 Bayer Cropscience Ag Insecticidal isooxazolines
WO2008108448A1 (en) 2007-03-07 2008-09-12 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pest control agent
NZ580241A (en) 2007-04-10 2011-02-25 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
AU2008261793A1 (en) 2007-06-13 2008-12-18 E. I. Du Pont De Nemours And Company Isoxazoline insecticides
TWI430995B (en) 2007-06-26 2014-03-21 Du Pont Naphthalene isoxazoline invertebrate pest control agents
US8952175B2 (en) 2007-06-27 2015-02-10 Nissan Chemical Industries, Ltd. Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound
MX361762B (en) 2007-06-27 2018-12-17 Du Pont Animal pest control method.
TWI649303B (en) * 2007-08-17 2019-02-01 杜邦股份有限公司 Compound and method for preparing 4-acetyl-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide
TWI556741B (en) 2007-08-17 2016-11-11 英特威特國際股份有限公司 Isoxazoline compositions and their use as antiparasitics
JP2009203220A (en) 2007-09-10 2009-09-10 Nissan Chem Ind Ltd Substituted isoxazoline compound and pest control agent
US8318757B2 (en) 2007-09-10 2012-11-27 Nissan Chemical Industries, Ltd. Substituted isoxazoline compound and pest control agent
US8367584B2 (en) 2007-10-03 2013-02-05 E.I. Du Pont De Nemours And Company Naphthalene isoxazoline compounds for control of invertebrate pests
TWI583664B (en) * 2008-04-09 2017-05-21 杜邦股份有限公司 Carbonyl compound and method for preparing thereof
CN104411193A (en) 2012-06-28 2015-03-11 维珍妮国际(集团)有限公司 Brassieres, brassiere cups and methods of making same

Also Published As

Publication number Publication date
CN105566089A (en) 2016-05-11
KR101662852B1 (en) 2016-10-05
BRPI0906906B1 (en) 2017-07-25
WO2009126668A2 (en) 2009-10-15
AU2015202910A1 (en) 2015-06-18
TW201444791A (en) 2014-12-01
MX2010011014A (en) 2010-11-22
US9834523B2 (en) 2017-12-05
AU2017235974A1 (en) 2017-10-19
TW201444808A (en) 2014-12-01
CN105646215A (en) 2016-06-08
US8546618B2 (en) 2013-10-01
IL208118A (en) 2015-05-31
RU2502720C2 (en) 2013-12-27
CA3052421C (en) 2021-12-14
EP2706050B1 (en) 2016-08-31
US20160304474A1 (en) 2016-10-20
IL238438A (en) 2016-08-31
IL238437A (en) 2016-08-31
US20110009638A1 (en) 2011-01-13
EP2260016A2 (en) 2010-12-15
TW201444787A (en) 2014-12-01
IL238438A0 (en) 2015-06-30
CA2718668A1 (en) 2009-10-15
TWI518076B (en) 2016-01-21
CO6310992A2 (en) 2011-08-22
MY174828A (en) 2020-05-18
US20150210654A1 (en) 2015-07-30
IL238437A0 (en) 2015-06-30
US20160376242A9 (en) 2016-12-29
EP2706053A1 (en) 2014-03-12
AU2015202911A1 (en) 2015-06-18
TWI455919B (en) 2014-10-11
UA112324C2 (en) 2016-08-25
TW200948770A (en) 2009-12-01
KR20160118372A (en) 2016-10-11
ES2604008T3 (en) 2017-03-02
BRPI0906906A2 (en) 2015-07-21
CN105566089B (en) 2019-07-02
KR20100134101A (en) 2010-12-22
US9938248B2 (en) 2018-04-10
CA3052421A1 (en) 2009-10-15
JP2011519827A (en) 2011-07-14
PT2706053T (en) 2017-01-06
ES2554511T3 (en) 2015-12-21
AU2015202911B2 (en) 2017-02-23
ES2610830T3 (en) 2017-05-03
US20180222873A1 (en) 2018-08-09
US20170197925A1 (en) 2017-07-13
AU2015202910B2 (en) 2017-06-29
PT2706050T (en) 2016-11-29
BRPI0906906B8 (en) 2022-12-06
US9611231B2 (en) 2017-04-04
JP6162746B2 (en) 2017-07-12
CN101990530A (en) 2011-03-23
LT2706050T (en) 2016-11-10
WO2009126668A3 (en) 2010-04-08
IL208118A0 (en) 2010-12-30
US10160731B2 (en) 2018-12-25
CN101990530B (en) 2016-02-10
JP2016006037A (en) 2016-01-14
DK2260016T3 (en) 2015-12-07
US9527822B2 (en) 2016-12-27
RU2010145402A (en) 2012-05-20
US9035101B2 (en) 2015-05-19
LT2706053T (en) 2017-01-10
AU2009233858B2 (en) 2015-03-12
HUE028299T2 (en) 2016-12-28
HK1154563A1 (en) 2012-04-27
ZA201006482B (en) 2012-07-25
US20180057468A1 (en) 2018-03-01
MY160225A (en) 2017-02-28
EP2706053B1 (en) 2016-10-26
EP2260016B1 (en) 2015-09-02
PL2260016T3 (en) 2016-02-29
AU2017235974B2 (en) 2018-07-05
JP5755135B2 (en) 2015-07-29
US20140155617A1 (en) 2014-06-05
CA2954596C (en) 2019-10-01
TWI583664B (en) 2017-05-21
CA2954596A1 (en) 2009-10-15
EP2706050A1 (en) 2014-03-12
CN105646215B (en) 2020-04-14
AR071361A1 (en) 2010-06-16
CA2718668C (en) 2017-03-21
MY198064A (en) 2023-07-31

Similar Documents

Publication Publication Date Title
AU2009233858B2 (en) Method for preparing 3-trifluoromethyl chalcones
AU2008289321B2 (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CORTEVA AGRISCIENCE LLC

Free format text: FORMER OWNER(S): E. I. DU PONT DE NEMOURS AND COMPANY